---
document_datetime: 2023-09-21 18:25:40
document_pages: 89
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-3985-ii-0017-epar-assessment-report-variation_en.pdf
document_name: opdivo-h-c-3985-ii-0017-epar-assessment-report-variation_en.pdf
version: success
processing_time: 245.4250962
conversion_datetime: 2025-12-28 11:30:42.636141
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

23 March 2017 EMA/CHMP/271863/2017

## Assessment report

Invented name: OPDIVO

International non-proprietary name: nivolumab

Procedure No. EMEA/H/C/003985/II/0017

Marketing authorisation holder (MAH): Bristol-Myers Squibb Pharma EEIG

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| Table of contents                                                                                                        | ........................................................................................ 2                |
|--------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1. Background information on the procedure..............................................                                 | 6                                                                                                         |
| 1.1. Type II variation                                                                                                   | ..................................................................................................6       |
| 1.2. Steps taken for the assessment of the product                                                                       | ........................................................7                                                 |
| 2. Scientific discussion................................................................................                 | 8                                                                                                         |
| 2.1. Introduction                                                                                                        | ........................................................................................................8 |
| 2.2. Non-clinical aspects............................................................................................    | 10                                                                                                        |
| 2.2.1. Ecotoxicity/environmental risk assessment.........................................................                | 10                                                                                                        |
| 2.2.2. Discussion and conclusion on the non-clinical aspects                                                             | .......................................... 10                                                             |
| 2.3. Clinical aspects                                                                                                    | .................................................................................................. 11     |
| 2.3.1. Introduction....................................................................................................  | 11                                                                                                        |
| 2.3.2. Pharmacokinetics                                                                                                  | ............................................................................................ 11           |
| 2.3.3. Pharmacodynamics..........................................................................................        | 15                                                                                                        |
| 2.3.4. Discussion on clinical pharmacology...................................................................            | 18                                                                                                        |
| 2.3.5. Conclusions on clinical pharmacology.................................................................             | 19                                                                                                        |
| 2.4. Clinical efficacy                                                                                                   | .................................................................................................. 19     |
| 2.4.1. Dose response study(ies) .................................................................................        | 19                                                                                                        |
| 2.4.2. Main study                                                                                                        | ..................................................................................................... 20  |
| 2.4.3. Discussion on clinical efficacy............................................................................       | 52                                                                                                        |
| 2.4.4. Conclusions on the clinical efficacy                                                                              | .................................................................... 55                                   |
| 2.5. Clinical safety                                                                                                     | .................................................................................................... 56   |
| 2.5.1. Discussion on clinical safety..............................................................................       | 78                                                                                                        |
| 2.5.2. Conclusions on clinical safety ............................................................................       | 80                                                                                                        |
| 2.5.3. PSUR cycle                                                                                                        | ..................................................................................................... 80  |
| 2.6. Risk management plan                                                                                                | ....................................................................................... 80                |
| 2.7. Update of the Product information........................................................................           | 84                                                                                                        |
| 2.7.1. User consultation ............................................................................................    | 84                                                                                                        |
| 3. Benefit-Risk Balance.............................................................................                     | 84                                                                                                        |
| 3.1. Therapeutic Context                                                                                                 | ........................................................................................... 84            |
| 3.1.1. Disease or condition                                                                                              | ........................................................................................ 84               |
| 3.1.2. Available therapies and unmet medical need.......................................................                 | 85                                                                                                        |
| 3.1.3. Main clinical studies.........................................................................................    | 85                                                                                                        |
| 3.2. Favourable effects..............................................................................................    | 85                                                                                                        |
| 3.3. Uncertainty in the knowledge about the beneficial effects........................................                   | 85                                                                                                        |
| 3.4. Unfavourable effects...........................................................................................     | 86                                                                                                        |
| 3.5. Uncertainty in the knowledge about the unfavourable effects...................................                      | 86                                                                                                        |
| 3.6. Effects Table...................................................................................................... | 87                                                                                                        |
| 3.7. Benefit-risk assessment and discussion.................................................................             | 88                                                                                                        |
| 3.7.1. Importance of favourable and unfavourable effects                                                                 | .................................... 88                                                                   |
| 3.7.2. Balance of benefits and risks .......................................................................             | 88                                                                                                        |
| 3.7.3. Additional considerations on the benefit-risk balance                                                             | ................................. 88                                                                      |
| 4. Recommendations.................................................................................                      | 89                                                                                                        |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

5-FU 5-fluorouracil ADR Adverse drug reaction AE Adverse event ADA Anti-drug antibody ALT Alanine aminotransferase AST Aspartate aminotransferase BMS Bristol-Myers Squibb BOR Best overall response BSC Best supportive care Cavgss Time-averaged steady-state concentration CHMP   Committee for Medicinal Products for Human Use CI Confidence interval CL Total body clearance CMH Cochran-Mantel-Haenszel CNS Central nervous system CP Chronic phase CR Complete response CSR Clinical study report CTC-AE Common terminology criteria for adverse events DBL database lock DC discontinuation DMC Data Monitoring Committee DOR Duration of response ECOG   Eastern Cooperative Oncology Group EMA European Medicines Agency EORTC  European Organization for Research and Treatment of Cancer EU European Union ESMO   European Society for Medical Oncology FDA Food and Drug Administration FPFV First patient first visit GCP Good clinical practice GI Gastrointestinal

<div style=\"page-break-after: always\"></div>

HLGT MedDRA High-Level Group Term HNSCC Head and neck squamous cell carcinoma (also: SCCHN) HPV human papilloma virus HR hazard ratio IC investigator's choice IEC Independent Ethics Committee IMAE immune-mediated adverse event IMM immune-modulating medication IRB Institutional Review Board ITT Intent-to-treat IV Intravenous LDH Lactate dehydrogenase LLN Lower limit of normal LPLV Last patient last visit Max maximum MedDRA Medical Dictionary for Regulatory Activities Min minimum mDOR  median duration of response mOS median OS mPFS   median PFS NA not available NR not reported NSCLC  non-small cell lung cancer ORR objective response rate OS overall survival PD Progressive disease PD-1/2   programmed death receptor 1/2 PD-L1/2 programmed cell death ligand 1/2 PMBL Primary mediastinal B cell lymphoma PFS progression-free survival PK pharmacokinetics PPK population pharmacokinetics PR Partial response PS performance status

<div style=\"page-break-after: always\"></div>

PT preferred term Q2W every two weeks RCC Renal cell carcinoma RECIST Response evaluation criteria in solid tumours ROW Rest of world RSDV Reduced source data verification SAE Serious adverse event SAP Statistical analysis plan SCCHN   Squamous cell carcinoma of the head and neck SCE Summary of Clinical Efficacy SCS Summary of Clinical Safety SD Stable disease SmPC   Summary of Product Characteristics SMQ Standardized MedDRA Queries; SOC system organ class TL transformed lymphoma, TNBC   triple negative breast cancer TSH thyroid stimulating hormone TTR time to resolution ULN upper limit of normal US United States

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Bristol-Myers Squibb Pharma EEIG submitted to the European Medicines Agency on 21 June 2016 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) after platinum-based therapy in adults for OPDIVO.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, of the SmPC are updated in order to add the proposed new indication, add a warning that patients with a baseline performance score ≥ 2, untreated brain metastasis, active autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the SCCHN clinical trial and update the undesirable effect and safety information. LabellingPackage leaflet is updated in accordance.

Moreover, the updated RMP version 6.0 has been submitted.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included EMA Decisions P/0064/2014 on the agreement of a paediatric investigation plan (PIP) and CW/1/2011 on the granting of a class waiver.

At the time of submission of the application, the PIP P/0064/2014 was not yet completed as some measures were deferred.Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The applicant did not seek Scientific Advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

| Rapporteur: Aranzazu Sancho-Lopez             | Co-Rapporteur:   | Paula Boudewina van Hennik   |
|-----------------------------------------------|------------------|------------------------------|
| Timetable                                     |                  | Actual dates                 |
| Submission date                               |                  | 21 June 2016                 |
| Start of procedure:                           |                  | 16 July 2016                 |
| CHMP Rapporteur Assessment Report             |                  | 19 September 2016            |
| CHMP Co-Rapporteur Assessment Report          |                  | 6 September 2016             |
| PRAC Rapporteur Assessment Report             |                  | 16 September 2016            |
| PRAC members comments                         |                  | 21 September 2016            |
| Updated PRAC Rapporteur Assessment Report     |                  | 22 September 2016            |
| PRAC Outcome                                  |                  | 29 September 2016            |
| CHMP members comments                         |                  | 3 October 2016               |
| Updated CHMP Rapporteur(s) (Joint) Assessment | Report           | 6 October 2016               |
| Request for supplementary information (RSI)   |                  | 13 October 2016              |
| CHMP Rapporteur Assessment Report             |                  | 23 December 2016             |
| PRAC Rapporteur Assessment Report             |                  | 3 January 2017               |
| PRAC members comments                         |                  | 4 January 2017               |
| Updated PRAC Rapporteur Assessment Report     |                  | 6 January 2017               |
| PRAC Outcome                                  |                  | 12 January 2017              |
| CHMP members comments                         |                  | 16 January 2017              |
| Updated CHMP Rapporteur Assessment Report     |                  | 20 January 2017              |
| Request for supplementary information (RSI)   |                  | 26 January 2017              |
| PRAC Rapporteur Assessment Report             |                  | 24 February 2017             |
| PRAC members comments                         |                  | 1 March 2017                 |
| CHMP Rapporteur Assessment Report             |                  | 20 March 2017                |
| PRAC Outcome                                  |                  | 9 March 2017                 |
| CHMP members comments                         |                  | 13 March 2017                |
| Updated CHMP Rapporteur Assessment Report     |                  | 17 March 2017                |
| Opinion                                       |                  | 23 March 2017                |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

Nivolumab is a programmed death receptor 1 (PD-1) immune checkpoint inhibitor. The PD-1 receptor is a key regulator of T-cell activity that has been shown to control tumour-specific inhibition of T-cell responses to tumours. Engagement of the PD-1 co-inhibitory receptor on activated T cells through programmed death ligands 1 and 2 (PD-L1 and PD-L2) results in inhibition of T-cell proliferation, survival and cytokine secretion.

Opdivo is a fully human monoclonal immunoglobulin G4 (IgG4) antibody (HuMAb) that potentiates in vitro T-cell responses through dual ligand blockade of PD-L1 and PD-L2, and does not mediate antibody-dependent cell-mediated cytotoxicity (ADCC). Expression of PD-L1 and PD-L2 by malignant cells or other cells, including immune cells, allows multiple tumour types to evade immune-mediated destruction. Nivolumab potentiates T cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands.

## Problem statement

Head and neck carcinomas are the sixth most common cancer in the world, accounting for approximately 550,000 new cases and around 300,000 deaths each year 1,2,3 . In Europe, there were approximately 140,000 new cases per year with 63,500 deaths reported 4,5 . About ~90% of all head and neck cancer cancers are squamous cell carcinomas. Most SCCHN arise from the epithelial lining of the oral cavity, larynx and hypopharynx. The most important risk factors identified in SCCHN include tobacco and alcohol use, and in a subgroup of SCCHN (particularly oropharynx tumours), human papilloma virus (HPV) has been identified as a strong independent prognostic factor, with HPV positive infected tumours associated with more favourable clinical outcomes 6 .

At initial diagnosis, about a third of patients present with early stage (33%; Stage I/II), whereas the majority present with locally advanced disease (52-60%; Stage III/IV-A/IV-B). Only a small minority presents with metastatic disease initially (~10%; Stage IV-C). With standard of care treatment, the 5-year survival is 80%, 50%, and 25% for early stage, locally advanced, and metastatic disease, respectively.

Approximately 50% of the population initially treated with curative intent will either have refractory disease or will eventually develop recurrent disease. For these patients, the 1-year survival rate is 5-33% by various estimates with a median OS (mOS) of 6 to 9 months 7 . Patients with metastatic and recurrent SCCHN that is no longer amenable to local surgical/radiation therapy experience substantial morbidity and high mortality. Treatment choice is mostly determined by prior treatment, progression-free interval since last platinum-based therapy, and comorbidities.

In patients without prior platinum treatment, or with a progression-free interval of &gt; 6 months since last platinum, the current standard of care was established in 2008 with results from the EXTREME study 8 . The addition of cetuximab to platinum-based chemotherapy with 5-fluorouracil (5-FU) significantly prolonged the mOS from 7.4 months in the chemotherapy alone group to 10.1 months in the group that received

1 Siegel RL, Miller KD, Jemal A. Cancer Statistics 2016. Cancer J Clin 2016; 7-30.

2 Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet 2008;371:1695-709.

3 Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55.

4 Gatta G, Botta L, Sanchez MJ, et al. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. Eur J Cancer. 2015;51:2130.

5 Gregoire V, Lefebvre JL, Licitra L, et al. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment, and follow-up. Annals Oncol 2010; 21 (Suppl 5): v184-v186.

6 Leemans CR, Braakhuis B, Brakenhoff R. Molecular biology of head and neck cancer. Nature Reviews Cancer Vol 11 Jan 2011 7  NCCN Guidlines 2015 Head and Neck Cancers. http://oralcancerfoundation.org/treatment/pdf/head-and-neck.pdf

8 Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11):1116-1127.

<div style=\"page-break-after: always\"></div>

chemotherapy plus cetuximab. Patients whose disease progresses within 6 months of platinum-based therapy, regardless of whether it was given for locally advanced or metastatic disease, have a poor prognosis 9 . In this patient population, no OS benefit has ever been demonstrated, and thus the choice of chemotherapy is not well defined. Treatment choice is based on several factors including previous chemotherapy exposure, performance status, and comorbid conditions. In the US and the EU, recommendations include best supportive care, clinical trials, and single agents including paclitaxel, docetaxel, 5-FU, methotrexate, cetuximab, ifosfamide, bleomycin, gemcitabine, capecitabine, and vinorelbine 10 .

In Europe, no drugs have been approved for patients progressing on or after platinum based therapy. For patients not eligible for combination chemotherapy, European Society of Medical Oncology (ESMO) guidelines consider weekly methotrexate as the accepted treatment, and state that is unclear whether taxanes are useful in this context or not. The guidelines further mention that cetuximab alone has a favourable toxicity profile with activity that is comparable to methotrexate alone 5 .

Several small, single arm studies have evaluated the treatment of platinum-refractory disease with best supportive care or other therapies. In a retrospective study analysing clinical records from 151 patients with SCCHN refractory to platinum-based chemotherapy treated between 1990 and 2000 at 7 different centres around Europe, most patients (45%) received only best supportive care and had a median survival of 56 days 11 . A total of 28.5% of the patients received second-line chemotherapies, without any objective response, and a median survival of 103 days. In platinum-refractory patients treated with cetuximab and cisplatin regimen, a mOS of 4.3 months and response rate of 6% has been reported 11 .  Docetaxel monotherapy treatment of 20 patients with platinum-refractory disease with documented tumour progression during platinum-based treatment or recurrence within 6 months after platinum-based chemoradiotherapy resulted in an overall response rate of 10% (2/20) and tumour control rate of 25% (5/20) 12 . Median PFS (mPFS) and mOS were 1.7 and 4.6 months, respectively.

Table 1: Single Agents Recommended in US and EU for the Treatment of Recurrent and/or Metastatic SCCHN in the Platinum-refractory Setting

| Agent        | Date of Approval       | Indication                                                                                                                                                                                         |
|--------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cetuximab    | EU approval: Dec-2008  | In combination with RT for the treatment of locally or regionally advanced SCCHN or in combination with platinum-based chemotherapy for recurrent and/or metastatic SCCHN                          |
|              | US approval: Mar-2006  | In combinationwith RTfor the treatment of locally or regionally advanced SCCHN or monotherapy for treatment of patients with recurrent or metastatic SCCHN after failure of platinum-based therapy |
|              | US approval: Nov-2011  | In combinationwithplatinum-based therapy+5-FU for thefirst line treatment ofpatients withrecurrent locoregional disease and/or metastatic SCCHN                                                    |
| Docetaxel    | US approval: Oct-2006  | In combination with cisplatin and 5-FU for the induction treatmentofimoperable,locally advancedSCCHN                                                                                               |
|              | EU approval: Nov-2006  | In combination with cisplatin and 5-FU for the induction treatmentoflocallyadvancedSCCHN                                                                                                           |
| Methotrexate | US approval: Jan-2004  | Alone or in combination with other anti-cancer agents is the treatment of epidermoid cancers of the head and neck                                                                                  |
|              | EU approval: various a | For the treatment of head and neck cancer (not centrally authorized, national approvals only)                                                                                                      |

Abbreviations: 5-FU: 5-fluorouracil; EU: European Union, RT: radiotherapy; SCCHN: squamous cell carcinoma of the head and neck; US: United States

9 Colevas AD. Systemic therapy for metastatic or recurrent squamous cell carcinoma of the head and neck. J Natl Compr Canc Netw 2015; 13:e37-e48.

10 Mesıa R, Pastor M, Grau JJ, et al. SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013. Clin Transl Oncol 2013 Aug 27 [Epub ahead of print].

11 Herbst RS, Arquette M, Shin DM, et al., Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-87.

12 Zenda S, Onozawa Y, Boku N, et al. Single-agent Docetaxel in Patients with Platinum-refractory Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN). Jpn. J. Clin. Oncol. 2007;37(7): 477-481. (doi: 10.1093/jjco/hym059).

<div style=\"page-break-after: always\"></div>

Table 2: Clinical Efficacy of Treatments in Recurrent and/or Metastatic SCCHN

| Study/Treatment Reference   | mOS (months)           | mPFS (months)       | ORR (mDOR)          |
|-----------------------------|------------------------|---------------------|---------------------|
| Methotrexate                | NA                     | NA                  | 21%-66%             |
| Docetaxel                   | 3.9-11.3               | 1.8-2.1             | 7%-42%              |
| Platinum-refractory         | Platinum-refractory    | Platinum-refractory | Platinum-refractory |
| 10,13 Cetuximabmonotherapy  | 178 days (~5.8 months) | NA                  | 13.0% (5.8 months)  |
| Cetuximab+cisplatin 14      | 4.3                    | NA                  | 6%                  |
| Docetaxelmonotherapy 15     | 4.6                    | 1.7                 | 10%                 |
| Zalutumumab 16              | 5.3                    | 2.1                 | 5.7%                |

Abbreviations: BSC: best supportive care; mDOR: median duration of response; FU: 5-fluorouracil; mOS: median overall survival; mPFS: median progression-free survival; NA: not available; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; PT: platinum.

## The proposed indication for nivolumab in SCCHN

'Opdivo is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck after platinum-based therapy in adults.'

The final indication as adopted by the CHMP is:

'Opdivo as monotherapy is indicated for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy (see section 5.1).'

The recommended dose and schedule of nivolumab monotherapy for the SCCHN indication is 3 mg/kg administered as IV infusion over 60 minutes Q2W, which is consistent with existing approved dose and schedule of nivolumab monotherapy in adults.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

Nivolumab is a protein, which is expected to biodegrade in the environment and not be a significant risk to the environment. Thus, according to the 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00), nivolumab is exempt from preparation of an Environmental Risk Assessment as the product and excipients do not pose a significant risk to the environment.

## 2.2.2. Discussion and conclusion on the non-clinical aspects

The applicant did not submit studies for the ERA. According to the guideline, in the case of products containing proteins as active pharmaceutical ingredient(s), an ERA justifying the lack of ERA studies is acceptable.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

Table 3 Tabular overview of clinical studies

Abbreviations: BMS: Bristol-Myers Squibb, IV: intravenous, No: number, NSCLC: non-small cell lumg cancer, rate, OS: overall suvival, Q2W: every 2 weeks;

<!-- image -->

| Study Type       | Study Identifier/Report Location (Study                           | Study Objective                                                                                                                                                                                      | Study Design                                                                                  | Treatment Cohorts                                                                                                                                                                                                                                         | No.ofTreated Subjects (No. of Nivolumab- treated subjects)   | StudyPopulation                                                                                                                                                                           |
|------------------|-------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Efficacy, Safety | CA209141/ Module 5.3.5.1 (study completed, finalreport available) | To compare the OS ofnivolumab to investigator's choice therapy in subjects whohave tumor progression within 6 months of last dose of platinum therapy in the primary, recurent,or metastatic setting | Phase 3, open- labelrandomized studyof nivolumab monotherapy vs investigator's choice therapy | Randomizedin 2:1ratio to: Nivolumab-3mg/kg IV Q2W Or Investigators choice of: Cetuximab - 400 mg/m² IV once,then 250 mg/m* weekly(where approved for use as monotherapy for recurent SCCHN) Methotrexate - 40 mg/m*IV weekly Docetaxel 30 mg/m* IV weekly | 347 (236)                                                    | Adult (18years)subjects withrecurentormetastatic squamouscellcarcinomaof the head and neck (SCCHN) that has progressed on or within6monthsofthelast dose of a platinum-containing therapy |

## 2.3.2. Pharmacokinetics

The nivolumab clinical pharmacology profile has been well characterised and described in previously submitted clinical pharmacology package.

The clinical pharmacology data in this application support the proposed use of nivolumab as monotherapy for the treatment of recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) at the recommended dose and schedule of 3 mg/kg infusion over 60 minutes every 2 weeks (Q2W).

The recommended dose and schedule of nivolumab monotherapy for SCCHN is the same as that approved for melanoma, NSCLC, and RCC.

Pharmacokinetic characteristics of nivolumab as previously described for patients with solid tumours melanoma, NSCLC and RCC is summarised in Table 4.

<div style=\"page-break-after: always\"></div>

Table 4 Summary statistics of individual pharmacokinetic parameters of nivolumab in subjects with solid tumours (n= 1484)

| Parameter                       | Mean (SD)      | Geometric Mean (%CV)   | Median (Min, Max)        |
|---------------------------------|----------------|------------------------|--------------------------|
| Clearance (L/h)                 | 0.01 (0.00455) | 0.00921 (45.4)         | 0.00909 (0.00138.0.0438) |
| Volume of the Central Cmt (L)   | 4.15 (1.27)    | 3.95 (30.7)            | 4.01 (0.141,9.86)        |
| Volume of thePeripheral Cmt (L) | 3.92 (1.68)    | 3.65 (43)              | 3.68 (0.794,22.7)        |
| Volume of Distribution (L)      | 8.06 (2.35)    | 7.76 (29.1)            | 7.77 (2.49,27.6)         |
| Alpha Half-life (h)             | 41.7 (10.9)    | 40.2 (26.3)            | 40.7 (2.58,103)          |
| Beta Half-life (d)              | 28.8 (20.7)    | 26.4 (72)              | 26.3 (5.72,564)          |

Source:M:\\bmsnivolumab\\002522\\d1pk\\tablesrtfsumstat-exp.rtf

a Volume of Distribution (L) at steady-state = Volume of the Central Cmt (L) + Volume of the Peripheral Cmt (L)

SD: standard deviation; %CV: coefficient of variation expressed as a percentage; Min: minimum; Max: maximum; Cmt:compartment

Results from a nivolumab population pharmacokinetics (PPK) analysis was used to characterise the nivolumab serum concentration-time profile in subjects with SCCHN from Phase 3 Study CA209141.

## Population PK

## Model

The purpose of the current popPK analysis was to characterise the nivolumab concentration-time data in subjects with SCCHN relative to NSCLC subjects. This was achieved by assessing the effect of SCCHN tumour type as a covariate of nivolumab CL, relative to subjects with NSCLC.

The PPK analysis was performed using data from 2 Phase 1 studies (MDX1106-01, MDX1106-03), 1 Phase 2 study (CA209063) and 3 Phase 3 studies (CA209017, CA209057, and CA209141), with a total of 1035 subjects included. These studies were chosen as nivolumab PK in SCCHN and NSCLC subjects was available from these studies, as well as in which nivolumab PK was sampled intensively.

The PPK model development consisted of: 1) Base Model to re-estimate the PK parameters using a previously developed final model, and 2) Full Model to assess the tumour type effect (SCCHN vs NSCLC) on nivolumab CL. The base model was a 2-compartment model with zero order IV infusion input and first-order elimination with a combined additive and proportional residual error model. It included effects of baseline body weight, eGFR, ECOG, tumour type on CL, baseline body weight and gender on VC.

Parameter estimates from the full PPK model are provided in Table 5.

<div style=\"page-break-after: always\"></div>

Table 5: Parameter estimates of the full PPK model

| Naimeab [Units]        | Estimatec      | Standard Error (RSE%)d   | 95% Confidence Interval'   |
|------------------------|----------------|--------------------------|----------------------------|
| Fixed Effects          |                |                          |                            |
| Proportional error (-) | 0.208          | 0.00600 (2.88)           | 0.195 -0.220               |
| Additive eror (-)      | 0.286          | 0.0766 (26.8)            | 0.164-0.484                |
| CL (L/h)               | 0.00858        | 2.59E-04 (3.02)          | 0.00806-0.00915            |
| VC (L)                 | 3.78           | 0.0692 (1.83)            | 3.65 - 3.92                |
| Q (L/h)                | 0.0355         | 0.00229 (6.45)           | 0.0311- 0.0407             |
| VP (L)                 | 3.85           | 0.107 (2.78)             | 3.65 - 4.07                |
| CLBW                   | 0.665          | 0.0646 (9.71)            | 0.543 -0.794               |
| CLeGFR                 | 0.200          | 0.0527 (26.4)            | 0.0981-0.306               |
| CLECOG                 | 0.156          | 0.0316 (20.3)            | 0.0905-0.219               |
| VCBW                   | 0.756          | 0.0479 (6.34)            | 0.665 - 0.854              |
| VCSEX                  | 0.101          | 0.0226 (22.4)            | 0.0554-0.146               |
| CLSCCHN                | 0.0129         | 0.0444 (344)             | -0.0758-0.108              |
| CLOther                | 0.0615         | 0.0399 (64.9)            | -0.0182-0.140              |
| Random Effectsf        |                |                          |                            |
| CL [-]:                | 0.163 (0.404)  | 0.0138 (8.47)            | 0.132 -0.195               |
| 2 VC [-]               | 0.0573 (0.239) | 0.00580 (10.1)           | 0.0457-0.0685              |
| 2 VP [-]               | 0.216 (0.465)  | 0.0262 (12.1)            | 0.167-0.270                |
| @CL:oVC                | 0.0474 (0.490) | 0.00593 (12.5)           | 0.0359- 0.0592             |

CLOther: Effect of other types of tumor relative to NSCLC on CL.

## Analysis of Covariate Effects

The effect of categorical and continuous covariates on the typical value of the structural model parameters of CL and VC and the estimated covariate effects (and 95% confidence intervals) are presented in Figure 1.

The magnitude of effect of the tested covariates on CL, accounting for uncertainty, was within the ±20% boundaries for all covariates, except BW. The magnitude of the effect of ECOG, body weight and eGFR on CL, and the effect of gender and body weight on central volume of distribution in this SCCHN population are comparable to what was previously reported in other solid tumour populations including RCC, NSCLC and melanoma. The SCCHN tumour type was associated with a non-statistically significant increase of approximately 1% in nivolumab CL.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Analysis-Directory:/global/pkms/data/CA/209/C15/prd/ppk/final ProgramSource:Analysis-Directory/R/scripts/cov-eff-plot-fullmodel.r Source:Analysis-Directory/R/plots/full-ppk-cov-eff-plot.png

Note1:Categorical covariateeffects(95%CI) arerepresentedby opensymbols(horizontal red lines).

Note 2:Continuouscovariateeffects(95%CI) at the5th/95thpercentilesof thecovariate arerepresentedbythe endof horizontal boxes(horizontalredlines).Open/Blue areaofboxesrepresentstherangeofcovariateeffectsfromthemediantothe5th/95th percentile of the covariate.

estimate inreferencesubjectisconsidered as100%(vertical solidline)anddashedverticallinesareat80%and120%ofthis value.

Figure 1: Covariate effects on PPK model parameters (full PPK model)

## Evaluation of the Effect of Tumour Type on Nivolumab Exposure

Nivolumab exposure (measured as dose-normalized Cavgss, other exposure measurements are highly correlated with Cavgss) appears to be similar across SCCHN, NSCLC, and other solid tumour types (which include subjects with melanoma, prostate, renal, and colorectal cancer in phase 1 studies) as shown in Figure 2. SCCHN tumour type was not associated with any clinically or statistically different nivolumab CL relative to the NSCLC reference value determined in the population PK analysis.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Analysis Directory: /global/pkms/data/CA/209/C15/prd/ppk/final Program Source: Analysis Directory/R/scripts/reporting-tables-individual-exposures.r Source: Analysis Directory/R/plots/CAVGSS by Tumor Type Q2W.png The boxes represent the 25th, 50th, and 75th percentiles of the distribution. The whiskers extend from the 5th to

95th percentiles.

Figure 2: Distribution of nivolumab exposure (dose-normalised Cavgss) by tumour type

## 2.3.3. Pharmacodynamics

Exposure response analyses of efficacy were not conducted as data in subjects with SCHNN are only available from a single nivolumab dosing regimen. Previous exposure-response analyses of efficacy in RCC, lung cancer and melanoma indicated that high nivolumab Cl but not Cavgss was associated with less efficacy.

Exposure response analysis of safety were also not conducted for subjects with SCHNN, as nivolumab 3 mg/kg Q2W has been shown to be safe and well tolerated in several other tumour types and previous analyses in advanced melanoma, NSCLC, and RCC patients have shown that AE-DC/D does not increase with Cavgss produced by nivolumab doses of 1 to 10 mg/kg Q2W.

## Immunogenicity

Anti-nivolumab antibody (ADA) was analysed using the previously described assay (ICDIM 140).

## Immunogenicity Results from Study CA209141

A summary of the ADA assessments for nivolumab subjects on Study CA209141 who had evaluable ADA data at baseline and on treatment is presented in Table 6.

From 240 patients treated with nivolumab in CA209141 (SCCHN trial) only 148 (61.7%) were evaluable subjects for immunogenicity.

<div style=\"page-break-after: always\"></div>

Thirteen subjects (8.8%) were ADA positive following administration of nivolumab. No subject was considered persistent positive and one subject was neutralizing ADA positive. The highest titer value observed in ADA positive subjects was 128, which occurred in 2 subjects. Both subjects were positive for ADA only at the last sample. One subject was also neutralising antibody positive. All other ADA positive subjects had low titer values of 32 or less.

Out of all nivolumab-treated subjects who were evaluable for ADA, none experienced select AEs in the hypersensitivity/infusion reaction category.

Table 6 Summary of nivolumab antibody assessments in study CA209141-All nivolumab treated subjects and at least one positive post-baseline assessment.

|                           | Number of Subjects (%) CA209141 (N=148)   |
|---------------------------|-------------------------------------------|
| Baseline ADA Positive     | 13 (8.8)                                  |
| ADA Positive              | 13 (8.8)                                  |
| Persistent Positive       | 0                                         |
| Only Last Sample Positive | 9 (6.1)                                   |
| Other Positive            | 4 (2.7)                                   |
| a NeutralizingADAPositive | 1 (0.7)                                   |
| ADA Negative              | 135 (91.2)                                |

Source: Table 8.13.1-1 of the CA209141 CSR

## Integrated Immunogenicity Analysis for Nivolumab (Monotherapy)

A pooled analysis of nivolumab ADA assessments was performed with data available from the following BMS-sponsored studies in which ADA was assessed by the current assay (ICDIM 140 V1.00/V2.02): CA209037, CA209063, CA209066, CA209017, CA209057, CA209067 (nivolumab monotherapy arm), CA209025, CA209039, CA209205 and CA209141 (see Table 7).

Of 1734 subjects who were treated with nivolumab 3 mg/kg every 2 weeks (Q2W) and evaluable for the presence of anti-drug antibodies (ADA), 170 subjects (9.8%) were ADA positive. Of those who were ADA positive, only 2 subjects (0.1% of the total) were persistent positive, and neutralising antibodies were detected in only 10 subjects (0.6% of the total). There were no acute infusion reactions, hypersensitivity events, or new or additional AEs observed in subjects with neutralising antibodies. Neutralising antibodies were not detectable in subsequent ADA assessments in 8/10 of these subjects; one of the subjects with neutralising ADA had a subsequent assessment which was ADA positive with a lower titre and neutralising antibody positive.

<div style=\"page-break-after: always\"></div>

Table 7: Summary of nivolumab antibody assessments using method ICDIM 140 including study CA209141

| NumberofSubjects(%)      | NumberofSubjects(%)                   | NumberofSubjects(%)   | NumberofSubjects(%)     |
|--------------------------|---------------------------------------|-----------------------|-------------------------|
| StudyNumber              | Summary of PreviousStudies a (N=1586) | CA209141 (N=148)      | Pooled Summary (N=1734) |
| BaselineADAPositive      | 79 (4.98)                             | 13 (8.8)              | 92 (5.3)                |
| ADAPositive              | 157 (9.9)                             | 13 (8.8)              | 170 (9.8)               |
| Persistent b Positive    | 2 (0.1)                               | 0                     | 2(0.1)                  |
| Only Last SamplePositive | 54(3.4)                               | 9 (6.1)               | 63 (3.6)                |
| OtherPositive            | 101 (6.4)                             | 4 (2.7)               | 105 (6.1)               |
| NeutralizingADA Positive | 9 (0.6)                               | 1 (0.7)               | 10 (0.6)                |
| ADANegative              | 1429 (90.1)                           | 135 (91.2)            | 1564 (90.2)             |

Source:SeenoteaandTable8.13.1-1oftheCA209141CSR

Previous studiesincludes studiesCA209-063,-037,-066,-017,-057,-067,-025,-039,-205summarized in 17 Module2.7.2Summaryof ClinicalPharmacologyforClassicalHodgkinLymphoma

Persistentpositivesubjectdefined asa subjectwithADA-positivesamples at2ormoreconsecutivetimepoints, wherethefirstandlastADApositivesampleswereatleast16weeksapart.

## Effect of Immunogenicity on Safety

To further explore the relationship between immunogenicity and safety, an integrated assessment of the potential impact of ADA on immunogenicity-related effects was performed by summarising the select adverse events in the hypersensitivity/infusion reaction category by anti-nivolumab antibody status (positive or negative) for those subjects who were treated with nivolumab monotherapy. Data was available from studies CA209063, CA209037, CA209066, CA209017, CA209057, CA209067, CA209025, CA209039 (cHL all), CA209205 (cohorts A+B+C), and CA209141 (Table 8 ). Of the subjects evaluable for the presence of anti-nivolumab antibody, a total of 109 experienced hypersensitivity/infusion reactions. Of the 109 subjects who experienced hypersensitivity/infusion reactions, 4 were positive for anti-nivolumab antibody and 105 were negative for anti-nivolumab antibody during the study. A total of 4/180 (2.2%) anti-nivolumab antibody positive subjects experienced adverse events in the hypersensitivity/infusion reaction category.

One subject that was ADA positive (in Study CA209037) had an ADA positive status only for the last sample and experienced a Grade 1 hypersensitivity reaction after the first nivolumab dose when the ADA status was negative. One subject from Study CA209067 (monotherapy arm) had one ADA positive sample after one dose of nivolumab. This subject then continued nivolumab treatment, but ADA samples that were collected after 4 and 7 weeks of treatment were negative. This subject experienced bronchospasm prior to the last ADA sample at 7 weeks after initiation of treatment. Thus, the bronchospasm was not associated with the positive ADA status. Two subjects from Study CA209057 were ADA positive and had Grade 1-2 infusion related reactions on the same day. These subjects went on to receive additional nivolumab doses and ADA were not detectable in subsequent assessments.

<div style=\"page-break-after: always\"></div>

Table 8: Summary of hypersensitivity/infusion reactions by nivolumab anti-nivolumab antibody status across studies - all treated subjects receiving nivolumab monotherapy with anti-nivolumab antibody Positive or anti-nivolumab antibody negative

|                                                        | Number of Subjects (%)          | Number of Subjects (%)          |
|--------------------------------------------------------|---------------------------------|---------------------------------|
| Select AE Category: Hypersensitivity/Infusion Reaction | Nivolumab ADA Positive (N =180) | NivolumabADA Negative (N =1603) |
| Total Subjects with an Event                           | 4 (2.22)                        | 105 (6.55)                      |
| AnaphylacticShock                                      | 0                               | 1 (0.06)                        |
| Bronchospasm                                           | 1 (0.56)                        | 10 (0.62)                       |
| Hypersensitivity                                       | 1 (0.56)                        | 42 (2.62)                       |
| InfusionRelatedReaction                                | 2 (1.11)                        | 58 (3.62)                       |

Note: Integrated data from studies CA209063, CA209037, CA209066, CA209017, CA209057, CA209067 (monotherapy arm), CA209025, CA209039 (all cHL), CA209205 (Cohort A+B+C), and CA209141

The impact of immunogenicity on nivolumab clearance has been assessed as part of previous PPK analyses as a time-varying covariate, and was associated with a 13% to 25% increase in clearance.

## Effect of Immunogenicity on Efficacy

In previous integrated immunogenicity analyses it was demonstrated that the presence of neutralising antibodies was transient and did not recur in subsequent samples, and that there was no evidence of loss of efficacy in subjects with neutralising antibodies

## 2.3.4. Discussion on clinical pharmacology

No dose finding study was conducted for nivolumab monotherapy for treatment of HNSCC. The recommended dose and schedule of nivolumab monotherapy for treatment of HNSCC is the same as that approved for melanoma, NSCLC, and renal cell carcinoma monotherapy: 3 mg/kg IV infusion over 60 minutes Q2W. This is considered acceptable.

An updated popPK model has been developed for the evaluation of the PK in subjects with SCCHN. The popPK model has been based on the one initially developed for the characterisation of the PK in NSCLC. The same covariates as the ones included to characterise NSCLC have been considered in this new model for SCCHN: Baseline body weight, baseline ECOG, and baseline eFGR for CL and Baseline body weight and sex for VC.

One hundred seventy two (79.63%) out of 216 patients in the PK database from study CA209141 (SCCHN) were included in the popPK analysis dataset. Subjects with no serum concentrations available and subjects with PK samples that could not be associated with clinical data were excluded, which is acceptable. The estimated parameters were similar to the estimated parameters from the previous final models and remain in line with what could be expected for an IgG MoAb (CL=0.000858 L/h; VC=3.75 l; VP=3.85 L). The popPK model parameters were estimated with an acceptable precision (shrinkages are &lt;30% from Cl and VC and slightly above this threshold for VP; ETA\\_VP: 35.7%).

Overall the model showed an acceptable agreement between model predictions and observations. Having said that, pharmacokinetic data for study CA209141 is limited and sparse, thus results should be interpreted with caution.

<div style=\"page-break-after: always\"></div>

No clinically relevant differences in clearance and exposure were observed in patients with SCCHN vs. NSCLC vs. other tumours.

The absence of exposure response analysis for efficacy and safety for subjects with HNSCC has been sufficiently justified. Previous exposure-response relationships had shown that Cavgss was not a significant predictor of hazard of death after accounting for nivolumab CL. As in HNSCC, only one nivolumab dose was administered, relationships with Cavgss are confounded by nivolumab CL. Nivolumab 3 mg/kg Q2W has been shown to be safe and well tolerated in several other tumour types and previous analyses in advanced melanoma, NSCLC, and RCC patients have shown that AE-DC/D does not increase with Cavgss produced by nivolumab doses of 1 to 10 mg/kg Q2W.  No unexpected safety issues in subjects with HNSCC were observed.

From 240 patients treated with nivolumab in CA209141 (SCCHN trial) 148 (61.7%) were evaluable subjects for immunogenicity. Nivolumab has low immunogenic potential; pooled analysis of all tumour types showed that approximately 10% of subjects who were treated with nivolumab 3 mg/kg every 2 weeks (Q2W) monotherapy tested positive for treatment-emergent anti-nivolumab antibody. Of those who were anti-nivolumab antibody positive, only 2 subjects (0.1% of the total) were persistent positive, and neutralising antibodies were detected in 10 subjects (0.6% of the total). The safety profiles of persistent positive or neutralising positive subjects were no different than those in other subjects. There was no evidence of loss of efficacy in subjects with neutralising antibodies.

## 2.3.5. Conclusions on clinical pharmacology

Pharmacokinetics and immunogenicity of nivolumab have been sufficiently investigated for the extension of the indication of nivolumab 3 mg/kg every 2 weeks for treatment of SCCHN.

Overall, the popPK analysis indicated that there are no major differences in pharmacokinetics of nivolumab in HNSCC compared to other solid tumour types.

Nivolumab has low immunogenic potential. The safety profiles of persistent positive or neutralising positive subjects were no different than those in other subjects. There was no evidence of loss of efficacy in subjects with neutralizing antibodies.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

The dose of nivolumab, 3 mg/kg Q2W, was selected for CA209141 based upon collective experience of nivolumab monotherapy across multiple tumour types. The analyses of safety, efficacy, and exposure-response (E-R) data from the Phase 1 study CA209003, evaluating anti-tumour activity over a dose range of 0.1 mg/kg to 10 mg/kg Q2W in several tumour types including RCC, NSCLC, and melanoma has shown that nivolumab 3 mg/kg Q2W is active across multiple-tumour types. Clinical observations and E-R analyses of these tumour types showed that the probability of a tumour response approached a plateau for nivolumab trough concentrations achieved following administration of 3 mg/kg and 10 mg/kg Q2W. Although broadly similar, review of safety data for 10 mg/kg Q2W indicated a moderately greater incidence of Grade 3/4 drug-related adverse events leading to discontinuation. In an E-R analysis of the relationship between nivolumab exposure (Cavgss) and OS over the 1 mg/kg Q2W to 10 mg/kg Q2W dose range, which included 3 mg/kg Q2W, nivolumab Cavgss was not a significant predictor of hazard of death in melanoma, NSCLC, and RCC, indicating that, over this dose range, there is a flat E-R relationship. Based upon the totality of experience across immunogenic and non-immunogenic tumour types, 3 mg/kg Q2W was selected as the dose anticipated to achieve an appropriate balance of benefit and risk in CA209141.

<div style=\"page-break-after: always\"></div>

Nivolumab exposure (measured as dose-normalized Cavgss) at 3 mg/kg Q2W in SCCHN subjects in CA209141 appeared to be similar to that in NSCLC. SCCHN tumour type was not associated with a clinical or statistically significant difference in nivolumab clearance relative to the reference value for NSCLC as determined by population pharmacokinetic analysis.

Collectively, these results support the recommended dose of nivolumab 3 mg/kg Q2W in the treatment of recurrent or metastatic platinum-refractory SCCHN.

## 2.4.2. Main study

Study CA209141: An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)

The study consisted of 3 phases: screening, treatment, and follow-up. Tumour response was assessed by investigators according to the Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 at week 9 (±1 week) and every 6 weeks (±1 week) thereafter until disease progression. Subjects were treated until progression, unacceptable toxicity, or other protocol-defined reasons (e.g. dose delay beyond a defined time period). Treatment beyond initial investigator-assessed RECIST v1.1-defined progression was permitted for nivolumab if the subject had investigator-assessed clinical benefit and was tolerating the study drug. Subjects were followed for OS every 3 months until death, lost to follow-up, or withdrawal of study consent. An independent Data Monitoring Committee (DMC) provided oversight of safety and efficacy considerations.

<!-- image -->

a Prior cetuximab Yes = 221 (61.2%), No = 140 (38.8%)

c Docetaxel could be increased to 40 mg/m2 if tolerated per local practices

b Methotrexate could be increased to 60 mg/m2 if tolerated per local practices

Dose reductions were not permitted for nivolumab, but were permitted for investigator's choice therapies.

Abbreviations: IV = intravenous; Nivo = nivolumab; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; Q2W = every 2 weeks; SCCHN = squamous cell carcinomas of head and neck. Source: Figure 3.1-1 of the CA209141 CSR

Figure 3: Study design schematic

<div style=\"page-break-after: always\"></div>

## Methods

## Study participants

Main inclusion criteria:

a) Histologically confirmed recurrent or metastatic SCCHN (oral cavity, pharynx, larynx), stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).

b) Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

c) Documentation of p16-positive or p16-negative disease to determine human papillomavirus (HPV) status of tumour for SCCHN of the oropharynx. Note: If results are not available, then a sample (tissue on microscopic slides, tissue block or a fresh tissue biopsy in formalin) should be sent to the central laboratory for analysis.

d) Tumour progression or recurrence within 6 months of last dose of platinum therapy in the adjuvant (ie with radiation after surgery), primary (i.e., with radiation), recurrent, or metastatic setting. Clinical progression after platinum therapy is an allowable event for entry and is defined as progression of a lesion at least 10 mm in size that is amenable to caliper measurement (e.g. superficial skin lesion as per RECIST 1.1) or a lesion that has been visualised and photographically recorded with measurements and shown to have progressed.

e) Measurable disease by CT or MRI per RECIST 1.1 criteria.

f) Tumour tissue (archival or fresh biopsy specimen) must be available for PD-L1 expression analysis and other biomarker correlative studies. For subjects where a fresh biopsy is not feasible, archival tumour material must be made available. The subject must not have received systemic therapy subsequent to obtaining the archived biopsy and prior to screening. Tumour tissue must have been obtained in the metastatic setting or from an unresectable site of disease.

g) Prior curative radiation therapy must have been completed at least 4 weeks prior to study drug administration. Prior focal palliative radiotherapy must have been completed at least 2 weeks before study drug administration.

Tumour PD-L1 expression was quantitatively assessed using the Dako PD-L1 IHC 28-8 pharmDx with cut-off values of 1%.

## Main exclusion criteria

a) Active brain metastases or leptomeningeal metastases are not allowed. Subjects with brain metastases are eligible if these have been treated and there is no magnetic resonance imaging (except where contraindicated in which CT scan is acceptable) evidence of progression for at least 8 weeks after treatment is complete and within 28 days prior to first dose of study drug administration. Cases, including base of skull lesions without definitive evidence of dural or brain parenchymal involvement, should be discussed with the medical monitor. There must also be no requirement for immunosuppressive dose of systemic corticosteroids (&gt; 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration.

b) Histologically confirmed recurrent or metastatic carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary, and salivary gland or non-squamous histologies (e.g. mucosal melanoma) are not allowed.

<div style=\"page-break-after: always\"></div>

## Treatments

In subjects randomised to the nivolumab group, nivolumab 3 mg/kg was administered as a 60-minute IV infusion Q2W.

In subjects randomised to the investigator's choice group, subjects received one of the following treatments (as selected by the investigator):

- Cetuximab 400 mg/m 2  IV once, then 250 mg/m 2  weekly (where approved for use as monotherapy for recurrent SCCHN).
- Methotrexate 40 mg/m 2  IV weekly (could be increased to 60 mg/m 2  if tolerated as per local practices).
- Docetaxel 30 mg/m 2  IV weekly (could be increased to 40 mg/m 2  if tolerated as per local practices).

Dose reductions were not permitted for nivolumab but were permitted for cetuximab, methotrexate, and docetaxel.

Dose delays were permitted in both groups.

The following medications were prohibited during the study:

- Immunosuppressive agents (except to treat a drug-related adverse event).
- Systemic corticosteroids &gt; 10 mg daily prednisone equivalent (with defined exceptions).
- Any concurrent antineoplastic therapy (ie, chemotherapy, hormonal therapy, immunotherapy, radiation therapy except for palliative radiation therapy or standard or investigational agents for treatment of cancer).

Investigators may choose to resect solitary lesions in patients with unresectable or metastatic SCCHN and render the subject free of macroscopic disease. Subjects treated in this study may have lesions surgically resected only following consultation with the Medical Monitor and following the Week 21 re-staging assessments. If tumour shrinkage of the solitary lesion is noted on the Week 21 assessment, it is highly encouraged that surgical resection be delayed until subsequent scans fail to demonstrate further shrinkage. Subjects with a PR who go on to have surgical resection of remaining disease will be considered a PR.

## Objectives

## Primary

To compare OS of nivolumab to investigator's choice therapy in subjects who have tumour progression within 6 months of last dose of platinum therapy in the primary, recurrent, or metastatic setting.

## Secondary

To compare progression-free survival (PFS) of nivolumab to investigator's choice.

To compare objective response rate (ORR) of nivolumab to investigator's choice.

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints

| Objective                                                                       | Endpoint   | Endpoint Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------------------------------------------------------------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PRIMARY                                                                         | PRIMARY    | PRIMARY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| To compare OS of nivolumab to investigator's choice therapy                     | OS         | OSwas defined as the time fromrandomization to the date of death from any cause. The survival time for subjects who had not died was censored at the last known alive date. OS was censored at the date of randomization for subjects who were randomized but had no follow-up.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| SECONDARY                                                                       | SECONDARY  | SECONDARY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| To compare progression- free survival PFS of nivolumabto investigator's choice. | PFS        | Theprimary definition of PFSwas the time between the date of randomization and the first date of documented progression, as determined by the investigator (as per RECIST v1.1 criteria). Subjects who die without a reported progression were considered to have progressed on the date of their death. Subjects who did not progress or die were censored on the date of their last evaluable tumor assessment. Subjects who did not have any on-studytumor assessments anddidnot diewerecensoredon the date they were randomized. Subjects who received subsequent systemic anti-cancer therapy prior to documented progression were censored at the date of the last tumor assessment prior totheinitiation of the new therapy.The secondary definition ofPFS, alsoknown as the ITT definition, was the same as the primary definition, except there was no censoring for receipt of subsequent anti-cancer therapy prior to documented progression. |
| To compare objective response rate (ORR) of nivolumab to investigator's choice. | ORR        | ORR was defined as the proportion of randomized subjects who achieved a best response of complete response (CR) or partial response (PR) using the RECIST v1.1 criteria as per investigator assessment. To achieve a best response of CR or PR, confirmation was required. BOR was defined as the best response designation, recorded between the date of randomization and the date of progression, as assessed by the investigator per RECIST v1.1 or the date of subsequent anticancer therapy (including tumor-directedradiotherapy and tumor-directed surgery),whichever occurs first.                                                                                                                                                                                                                                                                                                                                                              |

## Sample size

Approximately 360 subjects were to be randomised. The study required at least 278 OS events (deaths) to ensure that a 2-sided, α=0.05 level, sequential log-rank test procedure with one interim look after 70% of OS events (195) had 90% power when the true OS hazard ratio of the experimental to the control arm was 0.6667. This is equivalent to demonstrating a 50% improvement in median OS in the nivolumab group relative to the investigator's choice group.

## Randomisation

After initial eligibility was established and the informed consent obtained, subjects were enrolled into the study via an IVRS. Once enrolled in the IVRS, subjects who met all eligibility criteria were randomized by IVRS in a 2:1 ratio to the nivolumab group or the investigator's choice group, with stratification by prior cetuximab treatment (yes vs no). The investigator's intended choice of therapy (cetuximab, methotrexate, or docetaxel) was entered in the IVRS for every subject prior to randomisation.

## Blinding (masking)

The study was open-label.

## Statistical methods

A hierarchical testing procedure was used for the comparisons of secondary endpoints to preserve the study-wise type I error rate at 0.05. If a statistically significant improvement in OS was demonstrated for nivolumab compared with investigator's choice, then PFS would be compared between treatment groups at the 5% level. If a statistically significant improvement in PFS was also demonstrated for nivolumab compared with investigator's choice, then ORR would be compared between treatment groups at the 5% level.

The comparisons of OS and PFS between treatment groups were carried out using log-rank tests stratified by prior cetuximab (yes, no), as reported in the IVRS. The primary comparison of response rate between arms was carried out using a Cochran-Mantel-Haenszel (CMH) test, stratified by prior cetuximab (yes, no).

<div style=\"page-break-after: always\"></div>

## Changes to the Planned Statistical Analyses

The following ad hoc exploratory analyses were added after database lock to help further characterise the study results:

- Cross tabulation of 'intended investigator choice agent' (as recorded in the IVRS) versus investigator's choice agent actually received. Prior to randomization, investigators were asked to state which of the 3 investigator choice agents they would give if the subject were randomized to the investigator's choice arm. This information, the so called 'intended investigator's choice regimen,' was recorded for all randomized subjects in the IVRS.
- Demographic and baseline disease characteristics by individual agent - nivolumab, cetuximab, methotrexate, and docetaxel.
- Efficacy of nivolumab (using all subjects randomized to the nivolumab arm) versus that of cetuximab, methotrexate, and docetaxel individually.
- Efficacy of nivolumab versus that of cetuximab, restricted to subjects whose intended investigator choice prior to randomization was cetuximab. These analyses were repeated on subjects whose intended investigator choice was docetaxel and methotrexate. These analyses were intended to remove any selection bias associated with the choice of agent when comparing nivolumab to cetuximab, methotrexate, and docetaxel.
- Efficacy of nivolumab versus that of the investigator choice group by HPV p-16 status, positive or negative.
- Efficacy of nivolumab versus investigator choice group in subsets formed by crossing PD-L1 expression (&lt; 1%, ≥ 1%) and HPV status (positive, negative).

Efficacy data presented are based on 3 different database locks:

- -18-Dec-2015 Database Lock : This lock was performed when the pre-planned number of events (deaths) was reached for the interim analysis. Analyses of demographics and other baseline characteristics, dosing, and OS were based on this lock.
- -03-Feb-2016 Database Lock : This lock was used for PD-L1 data only. Since not all PD-L1 measurements were available at time of the original lock, a lock was performed on 03-Feb-2016 to update PD-L1 measurements (survival was not updated at this time, i.e., all OS analyses by PD-L1 status are based on clinical data as of 18-Dec-2015).
- -05-May-2016 Database Lock : Tumour assessments, investigator-assessed best overall response (BOR), response and progression dates, and subsequent therapy are based on this lock.
- ORR is based on this lock and includes information up until this lock.
- PFS analyses are also based on this lock; however, since death information was not updated for this lock, and since PFS depends on both progression and death, PFS analyses were restricted to progression events (deaths or radiographic progressions) prior to the primary lock of 18-Dec-2015.

During review, updated efficacy (OS, progression-free survival [PFS], objective response rate [ORR], and duration of response [DOR]) and safety results based on the 20-Sep-2016 database lock were submitted.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

<!-- image -->

## Recruitment

The enrolment period lasted approximately 14 months (May-2014 to Jul-2015). The last subject was randomised on 28-Aug-2015, and the last patient last visit date (primary clinical cut-off) for this CSR occurred on 06-Nov-2015, providing a minimum follow-up for survival of approximately 2.3 months. A total of 55 sites in 15 countries randomised subjects. Of the 361 randomised subjects, 171 (47.4%) were in Europe, 145 (40.2%) were in North America, and 45 (12.5%) were in Rest of World.

## Conduct of the study

The original protocol for this study was dated 05-Feb-2014. As of 18-Dec-2015, 3 global amendments and 6 country-specific amendments were issued for this study. In addition, 1 administrative letter was issued for this study (22-Apr-2015) that corrected the title page of Amendment 08 to be country specific (Argentina) instead of global (all sites).

<div style=\"page-break-after: always\"></div>

Table 9: Summary of Changes to Protocol CA209141

| Document (Sites)                          | Date Summaryof Change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 01 (DE)                         | 02-Jan-2014 Based on recommendations by the German health authorities, HIV testing was added as a safety assessment at screening and a positive test for HIV was added as an exclusion criterion (3b).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Amendment 02 (FR)                         | 04-Jun-2014Based on a requestfrom theFrench competent authority, aninclusion criterion (5c, contraindications for subjects treated with methotrexate) and prohibited medications for subjects treated with methotrexate were added.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Amendment 03 (All)                        | 10-Jul-2014Table 4-1 of the protocol was updated to ensure that detailsfor investigational product were described accurately. In addition, the dose recalculation rules as a function of body weight for the nivolumab arm were clarified, and the collection schedule for PK samples was modified. Typos were removed and other details were modified to increase comprehensibility.                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Amendment 04 (JP)                         | 10-Jul-2014  Local regulatory requirements for Japanese sites were added.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| FR, DE, IT, ES, CH, NL,UK, HK,TW, and KR) | Amendment 05 (CA, 26-Nov-2014 At the end of February 2015, the source and potency of the investigational product methotrexatewas changed.Methotrexate 25mg/mL,250mg solution forinfusion used for this studywould nolonger be available.Methotrexate 25 mg/mL, 1000 mg solution for infusion was to be used instead.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Amendment 06 (JP)                         | 11-Dec-2014At the end ofFebruary 2015, the source and potency of the investigational product methotrexate was changed.Methotrexate 25mg/mL,250 mg solution for infusion used for this study would no longer be available. Methotrexate 25 mg/mL, 10o0 mg solution for infusion was to be used instead.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Amendment 07 (All)                        | 30-Jan-2015 Data external to the trial suggest that assumptions for co-primary outcomes of PFS and OS in CA209141 were underestimated for both treatment arms. Hence, the sample size was increased to target a hazard ratio that is in line with the available data.PFS was changed from a co primary endpoint to a secondary endpoint,leaving OS as the sole primary endpoint.This modification wasbased on external data whichsuggest that medianPFSis comparable in both arms. PFS was now the first secondary endpoint to be tested in the statistical hierarchy if OS was positive. The amendment also contained administrative changes and clarifications ofprocedures, concomitant treatments, and eligibility criteria.This amendment was implemented prior to the Sponsor being unblinded to the data. |
|                                           | Amendment 08 (AR) 25-Mar-2015 Based on a request from the Argentinean health authority, study drug should be permanently discontinued in case of pregnancy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Amendment 09 (All)                        | 09-Jun-2015The interim analysis was to occur 2 months after the last subject was randomized.However,becauseofafasterthanexpectedaccrualrate,itwas projected that there would be only 55% of the required number of deaths at that time. For this reason, the stopping rule was changed to *after 70% of events or 6 months after the end of accrual, whichever occurs earlier.\"The amendment also contained clarification of eligibility criteria and survival data collection.                                                                                                                                                                                                                                                                                                                                  |

Relevant protocol deviations (significant protocol deviations that were programmable and could potentially affect the interpretability of study results) were reported in 11.9% of subjects (13.3% nivolumab and 9.1% investigator's choice). The most common relevant protocol deviation at study entry was progression associated with last prior platinum regimen &gt; 6 months after last dose. Subjects with insufficient information to determine refractoriness to their prior platinum regimen were considered to be not refractory.

The most common relevant protocol deviation during the treatment period was receipt of concurrent anti-cancer therapy (other than palliative radiation to non-target lesions), affecting 3.3% of subjects in the nivolumab group and 1.7% of subjects in the investigator's choice group.

<div style=\"page-break-after: always\"></div>

Table 10: Relevant Protocol Deviations

|                                                                                              | Number of Subjects(%)    | Number of Subjects(%)         | Number of Subjects(%)   |
|----------------------------------------------------------------------------------------------|--------------------------|-------------------------------|-------------------------|
|                                                                                              | Nivolumab 3mg/kg (N=240) | Investigator's Choice (N=121) | Total (N=361)           |
| SUBJECTSWITHATLEASTONEDEVIATION                                                              | 32 (13.3)                | 11 ( 9.1)                     | 43 (11.9)               |
| ATENTRANCE                                                                                   |                          |                               |                         |
| ECOG PS > 1  (1)                                                                             | 2 (0.8)                  | 4 (3.3)                       | 6 (1.7)                 |
| DIDNOTHAVEMEASUREABLEDISEASEATBASELINE                                                       | 5 (2.1)                  | 1 (0.8)                       | 6 (1.7)                 |
| PROGRESSIONASSOCIATEDWITHLASTPRIORPLATINUM REGIMEN >6 MONTHS AFTER LAST DOSE OF PLATINUM (2) | 18 (7.5)                 | 4 ( 3.3)                      | 22 ( 6.1)               |
| ON-TREATMENTDEVIATIONS                                                                       |                          |                               |                         |
| RECEIVEDCONCURRENT ANTI-CANCER THERAPY(3)                                                    | 8 (3.3)                  | 2 (1.7)                       | 10 (2.8)                |
| SUBJECT TREATEDWITHTHEWRONG(NOTRANDOMIZEDTO) REGIMENTHROUGHOUTTHESTUDY                       | 0                        | 0                             | 0                       |

(1) There was no ECoG PS reported at baseline for subjects 29-227 and 40-364. These subjects were includedin the count.

(3) Palliative radliation to non-target lesions is not counted as a deviation.

(2) 9 subjects (1-316, 17-509, 42-443, 48-470, 58-424， 6-342, 61-257, 8-469, and 8-499) had insufficientinformation todetermine time frcmlastdoseofprior platinum toprogression. These subjects were counted as deviators.

## Baseline data

Baseline demographic and disease characteristics and tumour assessments were generally well balanced between the nivolumab and investigator's choice groups. There was a higher proportion of former/current smokers in the nivolumab group (79.6%) than in the investigator's choice group (70.2%).

Among all randomised subjects, the median age was 60.0 years and the majority of subjects were white and male. At baseline, 90.0% had Stage IV disease, 76.5% were either former or current smokers, and 66.2% had 2 or more disease sites.

Table 11: Baseline Demographic Characteristics - All Randomized Subjects

|                        | Nivolumab 3 mg/kg (N=240)   | Investigator's Choice (N=121)   | Total (N=361)   |
|------------------------|-----------------------------|---------------------------------|-----------------|
| AGE                    |                             |                                 |                 |
| N                      | 240                         | 121                             | 361             |
| MEAN                   | 59.0                        | 59.4                            | 59.1            |
| MEDIAN                 | 59.0                        | 61.0                            | 60.0            |
| MIN, MAX               | 29,83                       | 28,78                           | 28, 83          |
| STANDARDDEVIATION      | 10.15                       | 11.00                           | 10.43           |
| AGE CATEGORIZATION(&)  |                             |                                 |                 |
| Grouping 1             |                             |                                 |                 |
| <65                    | 172 (71.7)                  | 76 (62.8)                       | 248 (68.7)      |
| >=65AND<75             | 56 (23.3)                   | 39 (32.2)                       | 95 (26.3)       |
| >= 75                  | 12 (5.0)                    | 6 (5.0)                         | ( 5.0)          |
| Grouping 2             |                             |                                 | 18              |
| <65                    | 172 (71.7)                  | 76 (62.8)                       | 248 (68.7)      |
| >= 65                  | 68 (28.3)                   | 45 (37.2)                       | 113 (31.3)      |
| GENDER (%)             |                             |                                 |                 |
| MALE                   | 197 (82.1)                  | 103 (85.1)                      | 300 (83.1) 61   |
| FEMALE                 | 43 (17.9)                   | 18 (14.9)                       | (16.9)          |
| RACE (%)               |                             |                                 |                 |
| WHITE                  | 196 (81.7)                  | 104 (86.0)                      | 300 (83.1)      |
| BLACKORAFRICANAMERICAN | 10 (4.2)                    | 3 (2.5)                         | 13 (3.6)        |
| ASIAN                  | 29 (12.1)                   | 14 (11.6)                       | 43 (11.9)       |
| OTHER                  | 5 5(2.1)                    | 0                               | 5 (1.4)         |
| ETHNICITY (%)          |                             |                                 |                 |
| HISPANIC/LATINO        | 9 (3.8)                     | 4 (3.3)                         | 13 (3.6)        |
| NOT HISPANIC/LATINO    | 132 (55.0)                  | 60 (49.6)                       | 192 (53.2)      |
| NOT REFORTED           | 99 (41.3)                   | 57 (47.1)                       | 156 (43.2)      |
| REGION (%)             |                             |                                 |                 |
| NORTH AMERICA          | 101 (42.1)                  | 44 (36.4)                       | 145 (40.2) 171  |
| EUROPE                 | 109 (45.4)                  | 62 (51.2)                       | (47.4)          |
| REST OF WORLD          | 30 (12.5)                   | 15 (12.4)                       | 45 (12.5)       |

Between the 2 treatment groups, the most frequent site of the primary tumour was the oral cavity. The lymph node and lung were the most common site of disease reported outside of the head and neck.

Per protocol, and in keeping with clinical practice and guidelines, investigators were instructed to test the HPV-p16 ('HPV') status of subjects when they identified the primary site to be oropharynx. Among all randomised subjects, the proportion of subjects with HPV-positive status was balanced between the nivolumab (26.3%) and investigator's choice groups (24.0%).

<div style=\"page-break-after: always\"></div>

Table 12: Baseline Disease Characteristics and Tumour Assessments - All Randomized Subjects

|                                          | Nivolumab 3 mg/kg (N=240)   | Investigator's Choice (N=121)   | Total (N=361)                     |
|------------------------------------------|-----------------------------|---------------------------------|-----------------------------------|
| ECOG PS (%)                              |                             |                                 |                                   |
| 0                                        | (20.4)                      | 23 (19.0)                       | 72 (19.9)                         |
| 1                                        | 189 (78.8)                  | 94 (77.7)                       | 283 (78.4)                        |
| >= 2                                     | 1 (0.4)                     | 3 (2.5)                         | 4 (1.1)                           |
| NOT REFORTED                             |                             |                                 |                                   |
|                                          | (0.4)                       | 1 (0.8)                         | 2 ( 0.6)                          |
| TOBACCO USE(%)                           |                             |                                 |                                   |
| NEVER                                    | 39 (16.3)                   | 31 (25.6)                       | 70 (19.4)                         |
| FORMER/CURRENT                           | 191 (79.6)                  | 85 (70.2)                       | 276 (76.5)                        |
| UNKNOWN                                  | 10 ( 4.2)                   | 5 (4.1)                         | 15 ( 4.2)                         |
| Stage of Disease at Study Entry          |                             |                                 |                                   |
|                                          | 25 (10.4)                   | 10 (8.3)                        | 35 (9.7)                          |
| STAGE III                                |                             |                                 |                                   |
| STAGE IV                                 | 214 (89.2)                  | 111 (91.7)                      | 325  (90.0)                       |
| NOT REFORTED                             | 1 (0.4)                     | 0                               | 1 ( 0.3)                          |
| Site of Primary Tumor (a)                |                             |                                 |                                   |
| ORAL CAVITY                              | 108( (45.0)                 | 67 (55.4)                       | 175 (48.5)                        |
| PHARYNX                                  | 92 (38.3)                   | 36 (29.8)                       | 128 (35.5)                        |
| LARYNX                                   | 34 (14.2)                   | 15 (12.4)                       | 49 (13.6)                         |
|                                          |                             | 3                               | 9 (2.5)                           |
| OIHER                                    | 6( 2.5)                     | (2.5)                           |                                   |
| HFV-16 Status                            |                             |                                 |                                   |
| POSITIVE                                 | 63 (26.3)                   | 29 (24.0)                       | 92 (25.5)                         |
| NEGATIVE                                 | (20.8)                      | 36 (29.8)                       | 98 (23.8)                         |
| UNKNONN (b)                              | 50                          |                                 | 183 (50.7)                        |
|                                          | 127 (52.9)                  | 56 (46.3)                       |                                   |
| TIME FROM INITIAL DIAGNOSIS(YEARS)       |                             |                                 |                                   |
| N MEDIAN (MIN - MAX)                     | 240 2.1 (0.2-17.5)          | 121                             | 361 1.5 (0.1-19.9) 1.9 (0.1-19.9) |
| TIME FROM INITIALDIAGNOSIS(%)            |                             |                                 |                                   |
| < 1 YEAR                                 | 62 (25.8)                   | 29 (24.0)                       | 91 (25.2)                         |
| 1- < 2 YEARS                             | 55 (22.9)                   | 43 (35.5)                       | 98 (27.1)                         |
| 2- <3YEARS                               | 48 (20.0)                   | 16 (13.2)                       | 64 (17.7)                         |
| 3- <4YEARS                               | (10.8)                      | 9 (7.4)                         | 35 (9.7)                          |
| 4-<5YEARS                                | 17 (.7.1)                   | 7 (.5.8)                        | 24 (.6.6)                         |
| >= 5 YEARS                               | 32 (13.3)                   | 17 (14.0)                       | 49 (13.6)                         |
| SUBJECTS WITH AT LEAST ONE LESION (b)(&) | 239 (99.6)                  | 120 (99.2)                      | 359 (99.4)                        |
| SKIN/SOFT TISSUE                         | 41 (17.1)                   | 11 1 ( 9.1)                     |                                   |
| SITE OFLESION (c）(d)()                   | 113 (47.1)                  | 58                              | 52 (14.4) 171 (47.4)              |
| LUNG                                     |                             | (47.9)                          |                                   |
| LIVER                                    | 34 (14.2)                   | 19 (15.7)                       | 53 (14.7)                         |
| VISCERAL，OTHER                           | 1 (0.4)                     | 5 (4.1)                         | 6 (1.7)                           |
| LYMPH NODE                               | 122 (50.8)                  | 69 (57.0)                       | 191 (52.9)                        |
| ADRENAL GLAND                            | (1.3)                       | 2 (1.7)                         | 5 (1.4)                           |
| CENTRAL NERVOUS SYSTEM                   | 3 1 0.4)                    | 0                               | 1 (0.3)                           |
|                                          | 6 (3.8)                     | 6 (.5.0)                        | 15 (4.2)                          |
| MEDIASTINUM                              |                             |                                 |                                   |
| ORALCAVITY                               | 66 (27.5)                   | 32 (26.4)                       | 98 (27.1)                         |
| EFFUSION                                 | 1 (0.4)                     | 2 (1.7)                         | 3 (0.8)                           |
| SPLEEN                                   | 1 0.4)                      | 0                               | 1 (0.3)                           |
| BRAIN                                    | 2 0.8)                      | 1 (0.8)                         | 3 (0.8)                           |
| BREAST                                   | 1 （ 0.4)                    | 0                               | 1 0.3)                            |
| PELVIS                                   | 2 0.8)                      | 0                               | 2 0.6)                            |
| PERITONEUM                               | 4 (1.7) 0                   | 0                               | 4 1.1) 1 0.3)                     |
| ESOPHAGUS PANCREAS                       | 1 0.4)                      | 1 (0.8) 0                       | 1 0.3)                            |
|                                          | 0.8)                        | 3 ( 2.5)                        |                                   |
| KIINEY                                   | 2                           |                                 | 5 1.4)                            |
| PLEURA                                   | 4 1.7)                      | 1.7)                            | 6 1.7)                            |
| GASTRIC                                  | 1 0.4)                      | 0.8)                            | 2 0.6)                            |
| CHEST WALL BONEWITHSOFTTISSUECOMPONENT   | 8 3.3) 6 3.8)               | 2138 2.5) 6.6)                  | 11 3.0) 17 (4.7)                  |

<div style=\"page-break-after: always\"></div>

|                                                                        | Nivolumab 3 mg/kg (N=240)   | Investigator's Choice (N=121)   | Total (N=361)       |
|------------------------------------------------------------------------|-----------------------------|---------------------------------|---------------------|
| SITE OF IESION (c)(d)()，continued BONE，NO SOFTTISSUECOMFONENT OTHER    | 67 2.9                      | 36 (29.8) 7(5.8)                | 103 (28.5) 14 (3.9) |
| NUMBER OF DISEASE SITES Fer Subject (*)                                |                             |                                 |                     |
| 1                                                                      | 78 (32.5)                   | 42 (34.7)                       | 120 (33.2)          |
| 23                                                                     | 82 (34.2)                   | 31 (25.6)                       | 113 (31.3)          |
|                                                                        | 60 (25.0)                   | 32 (26.4)                       | 92 (25.5)           |
| 4                                                                      | 17 (7.1)                    | 10 (8.3)                        | 27 (7.5)            |
|                                                                        | 2 ( 0.8)                    | 5 ( 4.1)                        | 7(1.9)              |
| SUBJECTS WITH AT LEAST ONE TARGET LESION (&)                           | 238 (99.2)                  |                                 | 358 (99.2)          |
| SITE OF TARGET LESION (C)() SKIN/SOFT TISSUE                           | 38 (15.8)                   | 120 (99.2) 11                   | 49 (13.6)           |
| LUNG                                                                   | 95 (39.6)                   | (9.1) 48 (39.7)                 | 143 (39.6)          |
| LIVER                                                                  | 29 (12.1)                   | 17 (14.0)                       | 46 (12.7)           |
| VISCERAL，OTHER                                                         | 1 (0.4)                     | 4 (3.3)                         | 5 (1.4)             |
| LYMPH NODE                                                             | 78 (32.5)                   | 55 (45.5)                       | 133 (36.8)          |
| ADRENALGLAND                                                           | 0                           | 1 (0.8)                         | 1 (0.3)             |
| CENTRALNERVOUSSYSTEM                                                   | 1 (0.4)                     | 0                               | 1 0.3)              |
| MEDIASTINUM                                                            | 7 (2.9)                     | 6 ( 5.0)                        | 13 (3.6)            |
| ORAL CAVITY                                                            | 64 (26.7)                   | 30 (24.8)                       | 94 (26.0)           |
| SPLEEN                                                                 | 1 (0.4)                     | 0                               | 1 (0.3)             |
| BREAST                                                                 | 1 (0.4)                     | 0                               | 1 0.3)              |
| PELVIS                                                                 | 2 0.8)                      | 0                               | 2 0.6)              |
| PERITONEUM                                                             | 3 (1.3)                     | 0                               | 3 0.8)              |
| ESOPHAGUS                                                              | 0                           | 1 (0.8)                         | 1 0.3)              |
| PANCREAS                                                               | 1 (0.4)                     | 0                               | 1 0.3)              |
| KIINEY                                                                 | 0                           | 2 (1.7)                         | 2 (0.6)             |
| PLEURA                                                                 | 4 1.7)                      | 2 1.7)                          | 6 (1.7)             |
| GASTRIC                                                                | 1 0.4)                      | 1 (0.8)                         | 2 (0.6)             |
| CHEST WALL                                                             | 7 (2.9)                     | 2 1.7)                          | 9 ( 2.5)            |
| BONE WITH SOFT TISSUE COMPONENT                                        | 8 (3.3)                     | 4 (3.3)                         | 12 (3.3) 86 (23.8)  |
| OTHER                                                                  | 60(25.0)                    | 26 (21.5)                       | 358                 |
| SUM OF REFERENCE DIAMETERS OF TARGET LESIONS (MM) N MEDIAN (MIN - MAX) | 238 72.0 (11-490)           | 120 66.0 (10-198)               | 70.0 (10-490)       |

a Each was not subcategorized to capture a more precise primary tumor site (eg, oropharymx) (b) Baseline unkmown' Hpy status included 180 subjects who were not tested (per protocol, HFV status testing was only required for patients with oropharyngeal cisease), 2 subjects whose sanyple was coilected after baseline, andl 1 nivolumab subject who was tested for HPv, but hada non-evaluabletestresult.

(d) Inclucles both target and non-target lesions.

C Subjects may have lesions at more than one site.

Table 13: Summary of Tumour Specimen Acquisition and Characteristics and Frequencies of PD-L1 Expression at Baseline - All Randomized Subjects

|                                                                             | Nivolumab bx/Eu g N = 240   | Nivolumab bx/Eu g N = 240   | Investigator's Choice N = 121   | TOTAL N = 361     | TOTAL N = 361   |
|-----------------------------------------------------------------------------|-----------------------------|-----------------------------|---------------------------------|-------------------|-----------------|
| SUBJECTSWITH TUMORTISSUESAMPLE OOLIECTEDATBASELINE                          |                             | 213 (88.8)                  | 114 (94.2)                      | 327 (90.6)        |                 |
| SITE OF COLIECTION (b)                                                      |                             |                             |                                 |                   |                 |
| PRIMARY                                                                     |                             | 66 (31.0)                   | 31 (27.2)                       | 97 (29.7)         |                 |
| METASTASIS                                                                  |                             | 107 (50.2)                  | 63 (55.3)                       | 170 (52.0) (18.3) |                 |
| NOT REFORTED                                                                |                             | 40 (18.8)                   | 20 (17.5)                       | 60                |                 |
| OTHER                                                                       | 0                           |                             | 0                               | 0                 |                 |
| SUBJECTS WITH QUANTIFIABLE PD-L1 EXPRESSION AT BASELINE (C)                 |                             | 161 (67.1)                  | 99 (81.8)                       | 260 (72.0)        |                 |
|                                                                             |                             | 88/161 (54.7)               | 61/99 (61.6)                    | 149/260 (57.3)    |                 |
| SUBJECTS WITH BASELINE PD-L1 EXFRESSION< 1&                                 | 73/161                      | (45.3)                      | 38/99 (38.4)                    | 111/260 (42.7)    |                 |
| SUBJECTSWITHBASELINEPD-L1EXFRESSION>=5&                                     | 54/161                      | (33.5)                      | 43/99 (43.4)                    | 97/260 (37.3)     |                 |
| SUBJECTSWITHBASELINEPD-L1EXPRESSION<5                                       | 107/161                     | (66.5)                      | 56/99 (56.6)                    | 163/260 (62.7)    |                 |
| SUBJECTSWITHBASELINEPD-L1EXPRESSION>=10&                                    | 43/161                      | (26.7)                      | 34/99 (34.3)                    | 77/260 (29.6)     |                 |
| SUBJECTS WITH BASELINEPD-L1EXFRESSION< 10&                                  | 118/161                     | (73.3)                      | 65/99 (65.7)                    | 183/260 (70.4)    |                 |
| SUBJECTSWITHOUTPD-L1QUANTIFIABLEATBASELINE                                  |                             | 79 (32.9)                   | 22 (18.2)                       | 101 (28.0)        |                 |
| SUBJECTS WITHOUT TUMORTISSUE SAMPLE(al)                                     |                             | 25 (10.4)                   | 7 (5.8)                         | 32 (8.9)          |                 |
| SUBJECTSWITHTUMORTISSUESAMPIEOOLIECTED AFTER BASELINE ONLY (a2)             |                             | 2 (0.8)                     | 0                               | 2 (0.6)           |                 |
| SUBJECTS WITH INDETERMINATE PD-L1 EXPRESSION AT BASELINE (a3)(d)            |                             | 0                           | 0                               | 0                 |                 |
| SUBJECIS WITH PD-L1 EXPRESSION AT BASELINE NOT EVALUABLE (a4) (e) 52 (21.7) |                             |                             | 15 (12.4)                       | 67 (18.6)         |                 |

(al)+(a2)+(a3)+(a4) : Subjects without quantifiable tumor PD-Ll expression at baseline.

(c) Subjects with at least one tumor sample collected at baseline, with number viable tumor cells &gt;=l00 and

(b） Percentages are based on subjects with tumor tissue sample coilected at baseline.

(cl) Indeterminate=tumorcellmembranestaininghamperedforreasonsattributed tothebiologyofthetumor e neithercquantifiablenorincetenminate).

<div style=\"page-break-after: always\"></div>

Table 14: Prior Cancer Therapy Summary - All Randomized Subjects

|                                                                | Number of Subjects (%)                              | Number of Subjects (%)        | Number of Subjects (%)   |
|----------------------------------------------------------------|-----------------------------------------------------|-------------------------------|--------------------------|
|                                                                | Nivolumab 3 mg/kg (N=240)                           | Investigator's Choice (N=121) | Total (N=361)            |
| NUMBER OF LINES OF PRIOR SYSTEMIC CANCER THERAPY               |                                                     |                               |                          |
| 12                                                             | 106 (44.2)                                          | 58 (47.9)                     | 164 (45.4)               |
|                                                                | 80 (33.3)                                           | 45 (37.2)                     | 125 (34.6)               |
| 3                                                              | 54 (22.5)                                           | 18 (14.9)                     | 72 (19.9)                |
| NUMBEROFLINESOFPRIORSYSTEMICCANCER THERAPYFORMETASTATICDISEASE |                                                     |                               |                          |
| 0 (a)                                                          | 128 (53.3)                                          | 62 (51.2)                     | 190 (52.6)               |
| 1                                                              | 74 (30.8)                                           | 37 (30.6)                     | 111 (30.7)               |
| 2                                                              | 27 (11.3)                                           | 13 (10.7)                     | 40 (11.1)                |
| 3                                                              | 11 (4.6)                                            | 9 (7.4)                       | 20 (5.5)                 |
| PRIORSYSTEMIC THERAPY REGIMENSETTING                           |                                                     |                               |                          |
| ADJUVANT                                                       | 37 (15.4)                                           | 21 (17.4)                     | 58 (16.1)                |
| NEO-ADJUVANT                                                   | 17 (7.1)                                            | 16 (13.2)                     | 33 (9.1)                 |
| PRIMARY                                                        | 173 (72.1)                                          | 83 (68.6)                     | 256 (70.9)               |
|                                                                | 112                                                 | 59 (48.8)                     |                          |
| METASTATIC DISEASE                                             | (46.7)                                              |                               | 171 (47.4)               |
| TYPE OF PRIOR SYSTEMIC THERAPY RECEIVED (b)                    |                                                     |                               |                          |
| ANYPRIORSYSTEMICTHERAPY                                        | 240 (100.0)                                         | 121 (100.0)                   | 361 (100.0)              |
| PRIOR PLATINUM BASED THERAPY                                   | 240 (100.0)                                         | 121(100.0)                    | 361 (100.0)              |
| PRIORMONOCLONAL ANTIBODIES                                     | 153 (63.8)                                          | 73 (60.3)                     | 226 (62.6)               |
| PRIOR FOLIC ACID ANAIOGUE                                      | 7 (2.9)                                             | 3 (2.5)                       | 10 (2.8)                 |
|                                                                | 23 (9.6)                                            |                               |                          |
| PRIOR TAXANES OTHERSYSTEMICCANCERTHERAPY-EXPERIMENTALDRUGS     | 131 (54.6)                                          | 62 (51.2)                     | 193 (53.5)               |
| OTHERSYSTEMICCANCER THERAPY-APPROVED                           | 140 (58.3)                                          | 13 (10.7) 69 (57.0)           | 36 (10.0) 209 (57.9)     |
| BESTRESPONSETOMOSTRECENTPRIORSYSTEMICTHERAPYREGIMEN            | BESTRESPONSETOMOSTRECENTPRIORSYSTEMICTHERAPYREGIMEN |                               |                          |
| CR OR FR                                                       | 44 (18.3)                                           | 19 9(15.7)                    | 63 3 (17.5)              |
| SD                                                             | 47 (19.6)                                           | 37 (30.6)                     | 84 (23.3)                |
| PD                                                             | 112 (46.7)                                          | 48 (39.7)                     | 160 (44.3)               |
| UNKNOWN/NOT REFORTED                                           | 37 (15.4)                                           | 17 (14.0)                     | 54 (15.0)                |
| MOSTRECENTPRIORPLATINUMTHERAPY                                 |                                                     |                               |                          |
| CARBOPLATIN                                                    | 123 (51.3)                                          | 61 (50.4)                     | 184 (51.0)               |
| CISPLATIN                                                      | 115 (47.9)                                          | 60 (49.6)                     | 175 (48.5)               |
| NEDAPLATIN                                                     | 1 (0.4)                                             | 0                             | 1 (0.3)                  |
| PLATINUMCOMPOUND                                               | 1 (0.4)                                             | 0                             | (0.3)                    |
| BESTRESPONSETOMOSTRECENTPRIORPLATINUM-CONTAININGREGIMEN        |                                                     |                               |                          |
| CR OR ER                                                       | 54 (22.5)                                           | 24 (19.8)                     | 78 (21.6)                |
| SD                                                             | 48 (20.0)                                           | 30 (24.8)                     | 78 (21.6)                |
| PD                                                             | 100 (41.7)                                          | 46 (38.0)                     | 146 (40.4)               |
| UNKNOWN/NOT REPORTED                                           | 38 (15.8)                                           | 21 (17.4)                     | 59 (16.3)                |
|                                                                | 67                                                  | 40                            |                          |
| >4- <= 6 MONTHS                                                |                                                     |                               |                          |
| <=2MONTHS                                                      | 119 (49.6)                                          | 57 (47.1)                     | 176 (48.8)               |
| >2-<=4 MONTHS                                                  | (27.9)                                              | (33.1)                        | 107 (29.6)               |
|                                                                | 36 (15.0)                                           | 20 (16.5)                     | 56 (15.5)                |
| >6-<=8MONTHS                                                   | 6 (2.5)                                             | 2 (1.7)                       | 8 (2.2)                  |
| >8MONTHS                                                       | 4 1.7)                                              | 1 (0.8)                       | 5 (1.4)                  |
| UNKNOWN/NOT REFORTED                                           | 8 (3.3)                                             | 1 ( 0.8)                      | 9 (2.5)                  |
| PRIOR SURGERY RELATED TO CANCER                                |                                                     |                               |                          |
| YES                                                            | 207 (86.3)                                          | 109 (90.1)                    | 316 (87.5)               |
| NO                                                             | 33 (13.8)                                           | 12 (9.9)                      | 45 (12.5)                |
| PRIORRADIOTHERAPY                                              |                                                     |                               |                          |
| YES                                                            | 216 (90.0)                                          | 114 (94.2)                    | 330 (91.4)               |
| NO                                                             | 24 10.0                                             | 5.8)                          | 31 (8.6)                 |

(a) The percentage of patients with O prior therapies for metastatic disease cannot necessarily be interpreted as the percentage of first-line patients in this stucy, as some patients may have received first-line therapy for non-metastatic clisease, which was not amenable to surgery and/or prior platinum therapy.

(b) Some subjects may have been treated with more than 1l type of therapy.

<div style=\"page-break-after: always\"></div>

Table 15: Subsequent Cancer Therapy Summary - All Randomized Subjects

|                                                               | Number of Subjects (%)    | Number of Subjects (%)        |
|---------------------------------------------------------------|---------------------------|-------------------------------|
|                                                               | Nivolumab 3 mg/kg (N=240) | Investigator's Choice (N=121) |
| SUBJECTS WITH ANY SUBSEQUENT THERAPY (%)(1)                   | 84 (35.0)                 | 46 (38.0)                     |
| SUBJECTS WHO RECEIVED SUBSEQUENT RADIOIHERAPY (&)             | 29 (12.1)                 | 12 (9.9)                      |
| SUBJECTS WHORECEIVEDSUBSEQUENTSURGERY()                       | 1 (0.4)                   | 2 (1.7)                       |
| SUBJECTS WHORECEIVEDSUBSEQUENTSYSTEMICTHERAPY(&)              | 71 (29.6)                 | 39 (32.2)                     |
| FOLICACIDANALOGUE METHOTREXATE                                |                           | 5.8) 5.8)                     |
| IMMUNOTHERAPY                                                 |                           | 6 7.4)                        |
| PEMBROLIZUMAB URELUMAB                                        | 1 0.4 4 (1.7)             | 6.6) 1 (0.8)                  |
| MONOCIONALANTIBODIES BEVACIZUMAB                              | 26 (10.8)                 | 0                             |
| CETUXIMAB                                                     | 1 0.4) 23                 | 11 (9.1)                      |
|                                                               | 12.6                      | 10 8.3)                       |
| NIVOLUMAB                                                     | 2 0.8)                    | 1 0.8)                        |
|                                                               | 20 (8.3)                  | 16 (13.2)                     |
| OIHERSYSTEMIC CANCERTHERAPY-APPROVED AFATINIB                 | 0                         |                               |
| ANTINEOPLASTIC                                                | 03 1.3)                   | 1 0.8) 15 0.8)                |
| CAPECITABINE FLUOROURACIL                                     |                           | 4.1) 8                        |
| GEMCITABINE                                                   | 4 1.7) 0.4)               | 6.6)                          |
|                                                               |                           | 1.7)                          |
| GIMER/TEGFUR/OIERA                                            | 7 2.9)                    | 21 0.8)                       |
| HYDROXYUREA MITOMYCIN                                         | 1 0.4)                    |                               |
| OLAPARIB                                                      | 0.4) 1                    | (0.8) 0                       |
| TEGAFUR                                                       | 0.4) 2 (0.8)              | 0                             |
| TEMSIROLIMUS                                                  | 0 0.4)                    | 1 (0.8)                       |
| TEGFUR/URACIL                                                 |                           |                               |
|                                                               | 0.8)                      |                               |
| VINORELBINE                                                   |                           | 0                             |
| OTHERSYSTEMICCANCERTHERAPY-EXPERIMENTALDRUGS ABBV 221 AZD6738 | 9 3.8) 1 0.4) 2 0.8)      | 2 (1.7) 0 0 0                 |
| BAY 16443 BKM120 BUPARLISIB                                   | 2 0.8) 1 0.4) 1           | 0.4) 0 0 0                    |
| FICLATUZUMAB                                                  |                           | 0                             |
| BUPARLISIB/PLACEBO                                            |                           | 1                             |
|                                                               | 0.4)                      |                               |
| GSK200980                                                     | 0.4)                      |                               |
|                                                               | 0.4) 0.4)                 | (0.8) 0                       |
| INVESTIGATIONAL ANTINEOPLASTIC DRUG MEDI0562                  |                           | 0                             |
| MIN0128                                                       | 0.4) 0.4)                 | 0                             |
| MN1117                                                        | 0.4)                      | 0:0                           |
| MIN4924                                                       | 110                       | 1                             |
| MSB0010718C                                                   |                           | (0.8)                         |
| PLATINUM-BASED 0CHEMOTHERAPY                                  | 12 5.0)                   | 9 7.4)                        |
| CARBOPLATIN                                                   | 3.8) 1.3)                 | 6 5.0) 3 2.5)                 |
| CISPLATIN                                                     |                           |                               |
| TAXANES DOCETAXEL                                             | 28 (11.7) 10 4.2)         | 10 8.3) 3.3)                  |
|                                                               | 19                        | 6 (5.0)                       |
| UNASSIGNED                                                    |                           | 0.8)                          |
|                                                               |                           | (0.8)                         |
|                                                               | 0.4)                      |                               |
| UNASSIGNED                                                    |                           |                               |
|                                                               | 0.4)                      |                               |
| 4                                                             |                           |                               |
|                                                               | PACLITAXEL                |                               |
|                                                               |                           | 7.9)                          |

defined as non-study anticancer therapy started on or after first dosing date (randcmization date if subject never treatedl).

Based on 05-May-2016 catabase lock.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

The all-randomised population was the primary population used for the primary efficacy analysis and the all-treated population was the primary population for safety analyses.

Table 16: Analysis Populations

| Population                                                                                                                                           | Nivolumab Group N   | Investigator's ChoiceGroup N   | Total N   |
|------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|--------------------------------|-----------|
| Enrolledsubjects:All subjectswhosignedanICFand were registered into the IVRS. This is the population for pre-treatment disposition.                  | NA                  | NA                             | 506       |
| Randomizedsubjects:All enrolled subjectswhowererandomized This is the population for baseline demographics and efficacy analyses.                    | 240                 | 121                            | 361       |
| Treated subjects: All randomized subjects who received at least one dose of study drug. This is the population for the safety and dosing evaluation. | 236                 | 111                            | 347       |
| Biomarker subjects:Allrandomized subjects with available biomarkerdata.                                                                              |                     |                                |           |
| Allrandomized subjects with quantifiablePD-Llexpression at baseline:Seedefinitionsof baselineandquantifiablePD-L1 expression in Table 3.5.1-1.       | 161                 | 99                             | 260       |
| Immunogenicity(ADAevaluable)subjects:Allnivolumab-treated subjects with baseline and at least 1 post-baseline assessment for ADA                     | 148                 | NA                             | 148       |

Source:Table S.2.5(enrolled),Table S.2.6 (randomized),Table S.2.7(treated),Table S.10.2 (PD-L1 quantifiable) and Table S.7.10a (immunogenicity).

## Outcomes and estimation

## Primary endpoint: Overall survival

In all randomised subjects, nivolumab demonstrated superior OS compared with investigator's choice therapy (HR = 0.70 [97.73% CI: 0.51, 0.96]; stratified log-rank test p-value = 0.0101. Median OS was higher in the nivolumab group than the investigator's choice group (7.49 vs 5.06 months).

At the cut-off date of 6 November 2015, median follow-up for OS (time between randomisation date and last known date alive or death) was 5.3 months (range: 0.0 to 16.8 months) in the nivolumab group and 4.6 months (range: 0.0 to 15.2 months) in the investigator's choice group.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Theboundary for statistical significancerequires the p-value to be less than 0.0227

Hazard ratio computed using a stratified Coxproportional hazards model and the p-value is from a stratified log-rank test.

Figure 4: Kaplan-Meier Overall Survival Plot - All Randomized Subjects (cut-off 18 December 2015)

The minimum follow-up for survival for all randomised subjects in the updated analysis was approximately 11.4 months. As of the 20-Sep-2016 database lock, 16 (6.8%) subjects in the nivolumab group and 1 (0.9%) subject in the investigator's choice group were continuing on study therapy.

<div style=\"page-break-after: always\"></div>

Figure 5: Kaplan-Meier Overall Survival Plot- All Randomised Subjects- CA209141 (Cut-off 20 Sep 2016)

<!-- image -->

Table 17: Status of censored subjects, OS primary analysis. All Randomised Subjects.

Status of Censored Subjects, Os Primary Analysis AllRandcmized Subjects

|                                 | Number of Subjects (%)    | Number of Subjects (%)        |
|---------------------------------|---------------------------|-------------------------------|
|                                 | Nivolumab 3 mg/kg (N=240) | Investigator's Choice (N=121) |
| NUMBER OF DEATHS (%)            | 133 (55.4)                | 85 (70.2)                     |
| NUMBER OF SUBJECTS CENSORED(%)  | 107 (44.6)                | 36 (29.8)                     |
| STATUS OF CENSORED SUBJECIS (%) |                           |                               |
| STILLON-TREAIMENT               | 41 (17.1)                 |                               |
| NOT PROGRESSED                  | 35 (14.6)                 | ( 2.5)                        |
| PROGRESSED (1)                  | 6 (2.5)                   | 0                             |
| INEOLIOW-UP                     | 55 (22.9)                 | 29 (24.0)                     |
| OFF STUDY                       | 4.6)                      | (3.3)                         |
| SUBJECTWITHDREW CONSENT         | .1                        | 2.5)                          |
| LOST TOFOLLOW-UP                |                           | ( 0.8)                        |
| OIHER                           |                           | 43100                         |
| NOT REPORTED                    |                           |                               |

<div style=\"page-break-after: always\"></div>

Table 18: Overall Survival Rates - All Randomized Subjects - CA209141 (Cut-off 20 Sep 2016)

| Suurvival Rate (95% CI)   | Nivolumab 3 mg/kg (N=240)   | Imvestigator's Choice (N=121)   |
|---------------------------|-----------------------------|---------------------------------|
| 3-MONTH                   | 71.3 (65.1, 76.6)           | 74.2 (65.4，81.1)                |
| 6-MONTH                   | 56.5 (49.9, 62.5)           | 43.0 (34.0，51.7)                |
| 9-MONTH                   | 42.3 (35.9,48.5)            | 27.5 (19.8, 35.8)               |
| 12-MONTH                  | 34.0  (28.0,40.1)           | 19.7 (13.0, 27.3)               |
| 18-MONTH                  | 21.5 (16.2, 27.4)           | 8.3 (3.6, 15.7)                 |
| 24-MONIH                  | 15.8 (10.3, 22.3)           | NA.                             |

BasedonKaplan-MeierEstimates.

Source: Table 6.1-1 of Acldlenclum 01 to the CA209141 Final CSR

## Sensitivity analyses

Table 19: OS Sensitivity Analyses - All Randomized Subjects

|                                                                                              | Nivolumab3mg/kg (N=240)         | Investigator's Choice (N=121)   | HR(1) (958CI）    |   P-Value (2) |
|----------------------------------------------------------------------------------------------|---------------------------------|---------------------------------|------------------|---------------|
| UnstratifiedAnalysis: EVENTS/#SUBJECTS（) MEDIANOS(MONTHS)(95CI)                              | 133/240 (55.4) 7.49 (5.49-9.10) | 85/121 (70.2) 5.06 (4.04-6.05)  | 0.69 (0.53-0.91) |        0.0078 |
| AnalysisBasedlonSubjectswithNoRelevant Deviations: EVENTS/#SUBJECTS() MEDIANOS(MONIHS)(9SCI) | 116/208 (55.8) 7.49(5.39-9.26)  | 76/110(69.1) 5.06 (4.04-6.28)   | 0.71 (0.53-0.94) |        0.018  |

In a multivariate analysis of OS, the treatment effect when adjusted for HPV-p16 status, baseline ECOG PS, and prior chemotherapy for metastatic disease was consistent with the primary OS analysis. ECOG PS was a significant prognostic variable for OS.

Table 20: Overall survival, multivariate Analysis - All randomised subjects

<!-- image -->

|                                               | HR (2) (95%CI)                       | P-Value (2)   |
|-----------------------------------------------|--------------------------------------|---------------|
| TREATMENT NIVO.VSINV.CHOICE(1)                | 0.71 (0.53 - 0.93)                   | 0.0144        |
| HPV-16STATUSBYP-16TESTING POSITIVEVSNEGATIVE  | 0.92 (0.62 -1.36) 1.06 (0.76 - 1.48) | 0.6780 0.7462 |
| UNKNONNVSNEGATIVE ECOG PS 0 VS >=1            | 0.51 (0.35 - 0.75)                   | 0.000675      |
| PRIORCHEMOTHERAPYFORMETASTATICDISEASE NOVSYES | 0.88                                 | 0.3925        |

(0.66 - 1.17)

- (1) Effect of treatment adjusted for HPV-16 status, baseline ECOG, prior chemotherapy for metastatic disease.
- (2) P-values and HRs from multivariate Cox Model stratified by prior treatment with cetuximab (yes, no) as entered into the IVRS.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Symbols represent censored observations.

Hazardratiois based on unstratified Cox proportional hazards model with regimen -Nivolumab,Cetuximab, Methotrexate or Docetaxel -as the sole covariate.

Figure 6: Kaplan-Meier Overall Survival Plot by Agent (Nivolumab, Cetuximab, Methotrexate, or Docetaxel) All randomized subjects (cut-off 18 December 2015)

<!-- image -->

Symbolsrepresentcensoredobservations

Hazardratiois based on unstratified Cox proportional hazards modelwith regimen -Nivolumab,Cetuximab,

Methotrexate orDocetaxel-as the sole covariate.

Figure 7: Kaplan-Meier Overall Survival Plot by Agent (Nivolumab, Cetuximab, Methotrexate, or Docetaxel) All randomized subjects (data cut-off: 20 September 2016)

<div style=\"page-break-after: always\"></div>

Per protocol, investigators were to indicate their choice of therapy (cetuximab, methotrexate, or docetaxel) for each patient prior to randomisation.

## Secondary endpoints:

- Progression free survival (PFS)

<!-- image -->

NIVOvs.INV Choice-hazard ratio95%:0.89 (0.70,1.13),pvalue:0.3236 Symbolsrepresentcensoredobservations

Hazard ratio computed using a stratified Coxproportional hazards model and thep-value is froma stratified log-rank test.

Figure 8: Kaplan-Meier Plot of Progression-free Survival (Primary Definition, cut-off 18 December 2015) All Randomized Subjects

<div style=\"page-break-after: always\"></div>

Updated PFS results (20-Sep-2016 database lock) were consistent with those reported in the CA209141 Final CSR.

<!-- image -->

Nivolumab 3 mg/kg (events : 204/240),median and 95% Cl: 2.04 (1.91,2.14)

Investigator's Choice (events : 104/121), median and 95% Cl: 2.33 (1.97,3.12)

NVO vs. INV Choice -hazard ratio 95%: 0.87 (0.69, 1.11), pvalue:0.2597

Symbolsrepresentcensoredobservations

Figure 9: Kaplan-Meier Plot of Progression-free Survival (Primary Definition) -All Randomized Subjects

Table 21: Reason for censoring PFS, primary definition - All randomised subjects

|                                                                                                   | Numbear of Subjects (3)   | Numbear of Subjects (3)    |
|---------------------------------------------------------------------------------------------------|---------------------------|----------------------------|
|                                                                                                   | Nivolumab 3 mg/kg (N=240) | Investigator's Cmoics 121) |
| NUMEER OE EVENTS (G)                                                                              | 190 (79.2)                | 103 (85.1)                 |
| TYFECEEVENT(5) EROERESSICN (I) DEATH                                                              | 139 (57.9) 51 (21.3)      | 71 (58.7) 32 (26.4)        |
| NUMBEROESUBJDCTSCENSORED(S)                                                                       | 50 (20.8)                 | 18 (14.9)                  |
| CONSOREDONDATEOERANDOMIZATION                                                                     | 7 (2.9)                   | 1 (0.8)                    |
| NOBASSLINETUMORASSESSMENTANDNOIEATH（2) NOVER TREATED OTHER                                        | (0.4) 0.4)                | 1 (0.8) (0.8)              |
| NOCN-STUDYTUMCRASSESSMENTANDNOIEATH(2) NEVER TREATED OTHER                                        | 6 (2.5) 2 0.8) 1.7)       | 0:00                       |
| CONSOREDCNDHTEO OELASTTUMCRASSESSONTCN-STUEY CR LAST ASSESSMENTFRICRTOSURSDQUDNTANTI-CANCERTHDRAP | 43 (17.9)                 | 17 (14.0)                  |
| RDLEIVEDSUBSDQUDNTANTICANCERTHERAPY(3) STILL CN-TR2AIMONT INEOLION-UP                             | T (5.8) 24 (10.0)         | 10 (8.3) 8.3) 3.3)         |
|                                                                                                   | 1 (0.4)                   | 2 (1.7)                    |
| SUBJDCT WITHIREN CONSENT LOST TO EOMION-UP OTHER NOT RERORTED                                     | OHOO (0.4）                | NOOO (1.7)                 |

A pre-specified sensitivity analysis was performed for PFS in which there was no censoring for systemic anti-cancer therapy prior to a progression event.

<div style=\"page-break-after: always\"></div>

## · ORR

Table 22: Best Overall Response - All Randomized Subjects

|                                            | Number of Subjects (%)    | Number of Subjects (%)        |
|--------------------------------------------|---------------------------|-------------------------------|
|                                            | Nivolumab 3 mg/kg (N=240) | Investigator's Choice (N=121) |
| BESTOVERALLRESFONSE:                       |                           |                               |
| COMPIETE RESFONSE (CR)                     | 6 (2.5)                   | 1 (0.8)                       |
| PARTIAL RESFONSE (PR)                      | 26 (10.8)                 | 6 (5.0)                       |
| STABIE DISEASE (SD)                        | 55 (22.9)                 | 43 (35.5)                     |
| PROGRESSIVE DISEASE (PD)                   | 100 (41.7)                | 42 (34.7)                     |
| UNABIE TODETERMINE(UTD)                    | 53                        | 29 (24.0)                     |
| NEVERTREATED                               | 4                         | 8 (6.6)                       |
| WRONGCANCERDIAGNOSIS                       | 0                         | 0                             |
| DEATHPRIORTODISEASEASSESSMENT              | 30 (12.5)                 | 11 9.1)                       |
| EARLYDISCONTINUATIONDUETOTOXICITY          | 2 (0.8)                   | 1 (0.8)                       |
| OTHER                                      | 15 (6.3)                  | 8 (6.6)                       |
| NOT REFORTED                               | 2 (0.8)                   | 1 (0.8)                       |
| OBJECTIVE RESFONSE RATE (1,2) (95CI)       | 32/240 (13.3) (9.3, 18.3) | 7/121 (5.8) (2.4, 11.6)       |
|                                            | 7.55                      |                               |
| DIFFERENCE OF OBJECTIVE RESFONSE RATES (3) |                           |                               |
|                                            | (1.55, 13.56)             |                               |
| (95% CI)                                   |                           |                               |
|                                            | 2.49                      |                               |
| CMHESTIMATE OFCOMMONODDS RATIO(4,5)        |                           |                               |
| (95%CI)                                    |                           |                               |
|                                            | (1.07, 5.82)              |                               |

(3) Stratum acljusted cifference in response rates (Nivolumab Investigator's Choice) based on the Cochran-Mantel-Haenszel (CMH) method of weighting.

(2） Confidence interval ccmputed using the Clopper andl Fearson method.

(4) Stratified by Prior Cetuximab (yes,no) as recorded in the IvRs.

(5) Methocl.

Includesdatareporteduntil05-May-2016.

In the updated analysis (20-Sep-2016 database lock), the investigator-assessed confirmed ORR (using RECIST v1.1) was unchanged from what was reported in the Final CSR: 13.3% for nivolumab and 5.8% for investigator's choice.

- Time to response (exploratory endpoint)

<!-- image -->

Table 23: Time to Objective Response - All Randomized Subjects with Response

|                         | Nivolumab3mg/kg (N=32)   | Investigator's Choice (N=7)   |
|-------------------------|--------------------------|-------------------------------|
| TIMETORESPONSE (MONTHS) |                          |                               |
| NUMBERRESPONLERS        | 32                       |                               |
| MEAN                    | 3.0                      | 2.4                           |
| MEDIAN                  | 2.1                      | 2.0                           |
| MIN,MAX                 | 1.8,7.4                  | 1.9,4.6                       |
| Q1,Q3                   | 1.9,3.6                  | 2.0，2.3                       |
| STANDARDDEVIATION       | 1.55                     | 0.99                          |

Incluclescatareportedluntil05-May-2016

In the updated analysis (20-Sep-2016 database lock), median TTR was unchanged from what was reported in the CA209141 Final CSR: 2.1 months in the nivolumab group and 2.0 months in the investigator's choice group.

<div style=\"page-break-after: always\"></div>

- Duration of the response
- (a)s Symbol + indicates a censored value.
- (b) Median computed using Kaplan-Meier method.

Table 24: Time to Response and Duration of Response - All Responders

<!-- image -->

|                               | Nivolumab_3 mg/kg (N=32)   | Investigator's Choice (N=7)   |
|-------------------------------|----------------------------|-------------------------------|
| TIMETORESPONSE (MONTHS)       |                            |                               |
| NUMBERRESFONDERS              | 32                         | 7                             |
| MEAN                          | 3.0                        | 2.4                           |
| MEDIAN                        | 2.1                        | 2.0                           |
| MIN, MAX                      | 1.8, 7.4                   | 1.9,4.6                       |
| Q1,Q3                         | 1.9,3.6                    | 2.0, 2.3                      |
| STANDARDDEVIATION             | 1.55                       | 66'0                          |
| DURATION OF RESPONSE (MONTHS) |                            |                               |
| MIN, MAX (a)                  | 2.8,20.3+                  | 1.5+，8.5+                     |
| MEDIAN (95% CI)(b)            | 9.7 (5.6, NR)              | 4.0(2.9,NR)                   |
| 01,03                         | 5.6, NR                    | 3.0,NR                        |
| N EVENT/N RESP (*)            | 16/32 (50.0)               | 3/7 (42.9)                    |

At the time of the 20-Sep-2016 database lock, 16/32 (50.0%) subjects in the nivolumab group and 4/7 (57.1%) subjects investigator's choice group had an ongoing response (as of the last available tumour assessment).

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

- Efficacy outcomes  in Subpopulations

<!-- image -->

HRisnotcomputed for subsets（except age,race,region,andgender)with 20orfewer subjectsin total（across treatmentgroups).HRsarecomputedusingunstratified CoxProportionalHazardsmodelswithtreatmentasthesole covariate.

Figure 10: Forest Plot of Treatment Effect on Overall Survival in Baseline Subgroups - All Randomised Subjects - CA209141 (20-Sep-2016 Database Lock)

<div style=\"page-break-after: always\"></div>

Figure 11: Forest Plot of Treatment Effect on PFS in Baseline Subgroups - All Randomised Subjects CA209141 (20-Sep-2016 Database Lock)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 12: Forest Plot of Treatment Effect on ORR in Baseline Subgroups - All Randomised Subjects CA209141 (20-Sep-2016 Database Lock)

<!-- image -->

|                                                                                                | N                                                   | Nivolumab3 mg/kg                                    | Nivolumab3 mg/kg                                               | Investigator's Choice                               | Investigator's Choice                                                   |                                                                       |                                                                       |                                                     |
|------------------------------------------------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|----------------------------------------------------------------|-----------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------|
|                                                                                                | O ecls) (Exaci95%C1) ORR (Exact95%C1) ORR 985% Egio | O ecls) (Exaci95%C1) ORR (Exact95%C1) ORR 985% Egio | O ecls) (Exaci95%C1) ORR (Exact95%C1) ORR 985% Egio            | O ecls) (Exaci95%C1) ORR (Exact95%C1) ORR 985% Egio | O ecls) (Exaci95%C1) ORR (Exact95%C1) ORR 985% Egio                     | O ecls) (Exaci95%C1) ORR (Exact95%C1) ORR 985% Egio                   | O ecls) (Exaci95%C1) ORR (Exact95%C1) ORR 985% Egio                   | O ecls) (Exaci95%C1) ORR (Exact95%C1) ORR 985% Egio |
| Overall                                                                                        | 361                                                 | 32/240                                              | 13.3 (9.3-18.3)                                                | 7/121                                               | 5.8 (2.4-11.6)                                                          | 2.51 (1.07, 5.86)                                                     | 2.51 (1.07, 5.86)                                                     |                                                     |
| Age categorization 65                                                                          | 248                                                 | 22/172                                              | 12.8 (8.2-18.7)                                                | 5/76                                                | 6.6 (2.2-14.7)                                                          | 2.08 (0.76,5.73)                                                      | 2.08 (0.76,5.73)                                                      |                                                     |
| >=65 AND<75 >=75                                                                               |                                                     |                                                     | 8.3(0.2-38.5) 16.1(7.6-28.3)                                   |                                                     | 5.1(0.6-17.3) 0.0(0.0-45.9)                                             | 3.54 (0.72,17.40)                                                     | 3.54 (0.72,17.40)                                                     |                                                     |
| Gender Male Female                                                                             | 300 61                                              | 28/197 4/43                                         | 14.2 (9.7-19.9) 9.3 (2.6-22.1)                                 | 6/103 1/18                                          | 5.8 (2.2-12.2) 5.6 (0.1-27.3)                                           | 2.68 (1.07,6.70) 1.74 (0.18, 16.78)                                   | 2.68 (1.07,6.70) 1.74 (0.18, 16.78)                                   |                                                     |
| Race White Black                                                                               | 300 13 43 5                                         | 22/196 1/10 9/29 0/5                                | 11.2 (7.2-16.5) 10.0 (0.3-44.5) 31.0(15.3-50.8) 0.0 (0.0-52.2) | 7/104 0/3 0/14 00                                   | 6.7 (2.7-13.4) 0.0(0.0-70.8) 0.0 (0.0-23.2) NR (NR-NR)                  | 1.75 (0.72, 4.25)                                                     | 1.75 (0.72, 4.25)                                                     |                                                     |
| Asian Other Region NorthAmerica EU ROW ECOGperfomance status                                   | 145 171 45                                          | 14/101 11/109 7/30                                  | 13.9 (7.8-22.2) 10.1 (5.1-17.3) 23.3(9.9-42.3)                 | 0/44 6/62 1/ 15                                     | 0.0(0.0-8.0) 9.7 (3.6-19.9) 6.7 (0.2-31.9)                              | 1.05 (0.37,2.99) 4.26(0.47,38.38)                                     | 1.05 (0.37,2.99) 4.26(0.47,38.38)                                     |                                                     |
| 0 >= 1 Not Reported PriorCetuimabUse (StratificationFactor) Yes                                | 72 287 2                                            | 6/49 26/190 0/1                                     | 12.2(4.6-24.8) 13.7 (9.1-19.4) 0.0 (0.0-97.5)                  | 0/23 7/97 0/1                                       | 0.0 (0.0-14.8) 7.2(3.0-14.3) 0.0 (0.0-97.5)                             | 2.04 (0.85, 4.88) 1.69 (0.59,4.80)                                    | 2.04 (0.85, 4.88) 1.69 (0.59,4.80)                                    |                                                     |
| No Intendedinvestigator'schoice therapyfromIVRS                                                | 221 140                                             | 16/147 16/93                                        | 10.9 (6.4-17.1) 17.2 (10.2-26.4)                               | 5/74 247                                            | 6.8 (2.2-15.1) 4.3(0.5-14.5)                                            | 4.68(1.03. 21.28)                                                     | 4.68(1.03. 21.28)                                                     |                                                     |
| Methotrexate Docetaxel IV                                                                      | 171 142 35                                          | 14/119 10/63                                        | 15.9 (7.9-27.3) 8.0(2.2-19.2)                                  | 1/10                                                | 0.0-103 NR(NR-NR) 2.0-11.4) 3.4 (0.1-17.8) 11.1(3.1-26.1) 0.0(0.0.97.5) | 6.80(0.87,53.15) 1.51 (0.54, 4.21) 5.28(0.64,43.40) 0.70 (0.16, 2.99) | 6.80(0.87,53.15) 1.51 (0.54, 4.21) 5.28(0.64,43.40) 0.70 (0.16, 2.99) |                                                     |
| HPV-16status NotReported Positive                                                              | 180                                                 | 0/                                                  | 0.0 (0.0-97.5) 8.9-18.                                         | 0/0 6/111 1/29 4/36 1                               | 3.6(0.4-12.5) 3.2(0.1-16.7) 7.1(2.6-14.7)                               | 4.46 (1.00,19.93) 7.74 (0.91, 65.71) 1.89 (0.74,4.81)                 | 4.46 (1.00,19.93) 7.74 (0.91, 65.71) 1.89 (0.74,4.81)                 |                                                     |
| Negative Not Reported Unknown                                                                  | 283                                                 | 4/50 0/2 18/125                                     | 0.00.0.842 14.4(8.8-21.8)                                      | 2/55 1/31                                           | 5.5 62-11.3)                                                            |                                                                       |                                                                       |                                                     |
| Tobaccouse Never CurrentFomer NotReported Priorsurgery Yes                                     | 70 276                                              | 8/39 24/191 0/10 200/2                              | 20.5 (9.3-36.5) 12.6(8.2-18.1) 0.0 (0.0-30.8) 13.2 6.4-11.4)   | 6/85 0/5                                            | 0.0(0.0-52.2)                                                           |                                                                       |                                                                       |                                                     |
| Pnor radiotherapy No Yes No                                                                    | 30                                                  |                                                     | 183910621862                                                   | 6/114                                               | 5.3(2.0-11.1)                                                           | 2.8 (1.14 7-29)                                                       | 2.8 (1.14 7-29)                                                       |                                                     |
| Bestresponsetothemost recentregimen                                                            |                                                     |                                                     |                                                                | 1/7                                                 | 14.3 (0.4-57.9)                                                         | 3.41(0.39.29.82)                                                      | 3.41(0.39.29.82)                                                      |                                                     |
| Responder Non-responder UnknownlNot Reported                                                   |                                                     |                                                     |                                                                | 1/17                                                | 5.3(0.1-26.0) 5.9(0.1-28.7) 5.9(1.9-13.2                                | 2.84 (1.05, 7.69)                                                     | 2.84 (1.05, 7.69)                                                     |                                                     |
| Time frominitial disease diagnosis to randomization <1year >=1year Site ofPrimary Tumor Larynx | 91. 270 49                                          | 9 7/62 25/178                                       |                                                                | 5/92                                                | 13.3 (1.7-40.5) 1.5 (0.0-8.0)                                           | 11.48 (1.49, 88.71)                                                   | 11.48 (1.49, 88.71)                                                   |                                                     |
| Oral cavity Pharynx                                                                            |                                                     | 3/34                                                | 8.8(1.9-23.7) 14.8 (8.7-22.9) 12.0 (6.1-20.4)                  | 2/15 1/67 4/36                                      | 11.1 (3.1-26.1) 0.0 (0.0-70.8)                                          | 1.09 (0.32, 3.66)                                                     | 1.09 (0.32, 3.66)                                                     |                                                     |
| Other Number of prior lines of systemic therapy                                                | 175 128 9                                           | 16/108 11/ 92 2/6                                   | 33.3 (4.3-77.7)                                                | 0/3                                                 |                                                                         |                                                                       |                                                                       |                                                     |
|                                                                                                |                                                     | 12/106 13/80                                        | 11.3 (6.0-18.9)                                                | 5/58 1/45                                           | 8.6 (2.9-19.0) 2.2(0.1-11.8) 5.6 (0.1-27.3)                             | 8.54(1.08,67.60) 2.53 (0.29, 22.12)                                   | 8.54(1.08,67.60) 2.53 (0.29, 22.12)                                   |                                                     |
| 1 2 >=3                                                                                        | 164 125 72                                          | 7/54                                                |                                                                | 1/18                                                |                                                                         | 2.07 (0.66,6.48) 4.98(0.61,40.94)                                     | 2.07 (0.66,6.48) 4.98(0.61,40.94)                                     |                                                     |
| Number of lines of prior chemotherapy in the metastatic setting 0                              | 111 40                                              | 9/74 6/27                                           | 22.2 (8.6-42.3) 9.1 (0.2-41.3)                                 | 4/62 1/37 1/13                                      | 2.7 (0.1-14.2) 7.7 (0.2-36.0)                                           | 3.43 (0.37,31.97) 0.80 (0.04,14.89)                                   | 3.43 (0.37,31.97) 0.80 (0.04,14.89)                                   |                                                     |
| 1                                                                                              | 20                                                  | 1/11                                                |                                                                | 1/9                                                 | 11.1 (0.3-48.2)                                                         |                                                                       |                                                                       |                                                     |
| 2 >=3                                                                                          |                                                     |                                                     |                                                                |                                                     |                                                                         |                                                                       |                                                                       |                                                     |
|                                                                                                |                                                     |                                                     |                                                                |                                                     |                                                                         | 2                                                                     | 2                                                                     |                                                     |
|                                                                                                |                                                     |                                                     |                                                                |                                                     |                                                                         | 0.5 16 32                                                             | 0.5 16 32                                                             |                                                     |
|                                                                                                |                                                     |                                                     |                                                                |                                                     |                                                                         | 0.25                                                                  | 0.25                                                                  |                                                     |
|                                                                                                |                                                     |                                                     |                                                                | 2/29                                                |                                                                         |                                                                       |                                                                       |                                                     |
|                                                                                                |                                                     |                                                     |                                                                | 1/19 5/85                                           |                                                                         |                                                                       |                                                                       |                                                     |
|                                                                                                |                                                     |                                                     |                                                                | 6/109                                               |                                                                         | 0.0625 0.125                                                          | 0.0625 0.125                                                          |                                                     |
|                                                                                                |                                                     |                                                     |                                                                | 1/12                                                |                                                                         |                                                                       |                                                                       |                                                     |
|                                                                                                |                                                     |                                                     | 12.2 (5.7-21.8)                                                |                                                     |                                                                         |                                                                       |                                                                       |                                                     |
|                                                                                                |                                                     |                                                     | 16.3 (8.9-26.2) 13.0 (5.4-24.9) 12.5 (7.3-19.5)                |                                                     |                                                                         |                                                                       |                                                                       |                                                     |
|                                                                                                |                                                     |                                                     |                                                                |                                                     | 6.5 (1.8-15.7)                                                          |                                                                       |                                                                       |                                                     |
|                                                                                                |                                                     |                                                     |                                                                |                                                     |                                                                         | 2.50(0.27,23.23) 30(0.83.6.37) 1.72 (0.33, 8.84) 0.63 (0.09, 4.22)    |                                                                       |                                                     |
|                                                                                                | 190 16/128                                          |                                                     |                                                                |                                                     |                                                                         |                                                                       |                                                                       |                                                     |
|                                                                                                | 316                                                 |                                                     | 11.3 (4.7-21.9) 14.0 (9.3-20.0)                                |                                                     | 6.9 (0.8-22.8) 5.4 (1.8-12.2)                                           | 1.35 (0.45, 4.05)                                                     | 1.35 (0.45, 4.05)                                                     |                                                     |

- PD-L1 expression

<div style=\"page-break-after: always\"></div>

<!-- image -->

HRscomputedusingunstratifiedCoxproportional hazardsmodelwithtreatmentgroupasthesolecovariate

Figure 13: Forest Plot of OS Hazard Ratios by Baseline tumour PD-L1 Expression - All Randomized Subjects - CA209141 (20-Sep-2016 Database Lock)

<!-- image -->

NIVOvs.INVChoice-hazardratio(95%CI):0.53(0.37,0.77)

NVOvs.INVChoice-hazardratio(95%CI):0.83(0.54,1.29)

Statistical modelfor hazardratio:Coxproportional hazards model with treatment as thesolecovariate. Symbolsrepresentcensoredobservations.

Figure 14: Kaplan-Meier Plot of OS by Baseline tumour PD-L1 Expression (1% Expression Level) - All Randomized Subjects with Quantifiable PD-L1 Expression at Baseline - CA209141 (20-Sep-2016 Database Lock)

PD-L1 expression on tumour cells and tumour-associated immune cells (TAICs) was analysed on baseline samples  and  assessed  for  association  with  clinical  outcome  (OS,  PFS  and  ORR)  using  data  from  the 20-Sep-2016 database lock. These were exploratory post-hoc analysis using a non-validated assay.

PD-L1+ TAIC abundance in the tumour microenvironment were qualitatively assessed, and characterised as 'abundant' and 'rare' based on pathologist assessments. Amongst 254 subjects analysed, TAICs were detected in all but 1 patient, and 98% of the subjects had TAIC PD-L1 expression.

<div style=\"page-break-after: always\"></div>

PD-L1+ TAIC location in the tumour microenvironment were qualitatively assessed and defined based on pathological assessment as:

- Intra-tumoural defined as being within the tumour
- Intra-peritumoural defined as being within the tumour and surrounding stroma
- Peritumoural defined as being outside the tumour in the tumour stromal only

Table 25: Efficacy in subjects with &lt;1 % tumour PD-L1 expression by abundance or location of TAICs

|                                                                 | MedianOS,Months HR (95% C1)   | MedianOS,Months HR (95% C1)   | MedianPFS,Months HR (95% C1)   | MedianPFS,Months HR (95% C1)   | ORR, % (95% CI)   | ORR, % (95% CI)   |
|-----------------------------------------------------------------|-------------------------------|-------------------------------|--------------------------------|--------------------------------|-------------------|-------------------|
|                                                                 | Nivo                          | IC                            | Nivo                           | IC                             | Nivo              | IC                |
| PD-L1<1%.PD-L1+TAIC Abundant (43 Nivo,25 IC)                    | 11.73                         | 6.51                          | 2.10                           | 2.73                           | 18.6              | 12.0              |
| PD-L1<1%.PD-L1+TAIC Abundant (43 Nivo,25 IC)                    | 0.67 (0.38, 1.18)             | 0.67 (0.38, 1.18)             | 0.96 (0.55, 1.67)              | 0.96 (0.55, 1.67)              | (8.4, 33.4)       | (2.5, 31.2)       |
| PD-L1<1%. PD-L1+ TAIC Rare (27 Nivo, 10 IC)                     | 3.71                          | 4.85                          | 1.84                           | 2.12                           | 3.7               | 10.0              |
| PD-L1<1%. PD-L1+ TAIC Rare (27 Nivo, 10 IC)                     | 1.09 (0.50, 2.36)             | 1.09 (0.50, 2.36)             | 1.91 (0.84, 4.36)              | 1.91 (0.84, 4.36)              | (<0.1, 19.0)      | (0.3, 44.5)       |
| PD-L1<1%,Intra/Intra- peritumoural PD-L1+TAICs (44 Nivo, 27 IC) | 9.07                          | 5.09                          | 2.07                           | 2.63                           | 18.2              | 11.1              |
| PD-L1<1%,Intra/Intra- peritumoural PD-L1+TAICs (44 Nivo, 27 IC) | 0.65 (0.38, 1.13)             | 0.65 (0.38, 1.13)             | 1.03 (0.61, 1.74)              | 1.03 (0.61, 1.74)              | (8.2, 32.7)       | (2.4, 29.2)       |
| PD-L1<1%.PeritumouralPD-L1 TAICs (22 Nivo, 7IC)                 | 4.27                          | 6.47                          | 2.04                           | 1.84                           | 4.5               | 14.3              |
| PD-L1<1%.PeritumouralPD-L1 TAICs (22 Nivo, 7IC)                 | 1.16 (0.46, 2.94)             | 1.16 (0.46, 2.94)             | 1.58 (0.57, 4.34)              | 1.58 (0.57, 4.34)              | (0.1, 22.8)       | (0.4, 57.9)       |

OSandPFSwereestimatedusingKaplan-Meiermethod

HRis nivolumab overIC.

ConfidenceintervalforORRcalculatedusingtheClopper-Pearsonmethod.

Source:Table AR-RSI24(ORR,TAIC abundance),TableAR-RSI25(ORR,TAIC1ocation),Figure AR-RSI20(OS,TAIC abundance),Figure AR-RSI21(PFS, TAICabundance),FigureAR-RSI22(OS,TAIC1ocation).FigureAR-RSI23(PFS,TAIClocation)are allinAnnex 2.

## TumourPD-L1&lt;1%+AbundantPD-L1+TAICs

Source: Figure AR-RSI20 (OS, TAIC abundance) in Amnex 2

## TumourPD-L1&lt;1%+RarePD-L1+TAICs

Figure 15: Kaplan-Meier plots of OS in tumour PD-L1 &lt;1% and PD-L1+ TAIC abundance subset

<!-- image -->

<div style=\"page-break-after: always\"></div>

TumourPD-L1&lt;1%+Intra/intra-peritumouralPD-L1+TAICs

Source:FigureAR-RSI22(OS.TAIClocation)inAnnex2

TumourPD-L1&lt;1%+PeritumouralPD-L1+TAICs

Figure 16: Kaplan-Meier plots of OS in tumour PD-L1 &lt;1% and PD-L1+ TAIC location subset

<!-- image -->

Table 26: Efficacy in subjects with ≥ 1 % tumour PD-L1 expression by abundance or location of TAICs

|                                                                | Median OS,Months HR (95%CI)   | Median OS,Months HR (95%CI)   | MedianPFS,Months HR (95% C1)   | MedianPFS,Months HR (95% C1)   | ORR, % (95% CI)   | ORR, % (95% CI)   |
|----------------------------------------------------------------|-------------------------------|-------------------------------|--------------------------------|--------------------------------|-------------------|-------------------|
|                                                                | Nivo                          | IC                            | Nivo                           | IC                             | Nivo              | IC                |
| PD-L1≥1%.PD-L1+TAIC Abundant (61 Nivo,47 IC)                   | 9.10                          | 4.60                          | 3.19                           | 1.97                           | 19.7              | 0                 |
| PD-L1≥1%.PD-L1+TAIC Abundant (61 Nivo,47 IC)                   | 0.43 (0.28,0.67)              | 0.43 (0.28,0.67)              | 0.48 (0.31, 0.75)              | 0.48 (0.31, 0.75)              | (10.6, 31.8)      | (0, 7.5)          |
| PD-L1≥1%,PD-L1+TAICRare (27 Nivo, 14 IC)                       | 6.67                          | 4.93                          | 1.99                           | 2.04                           | 11.1              | 7.1               |
| PD-L1≥1%,PD-L1+TAICRare (27 Nivo, 14 IC)                       | 0.89 (0.44, 1.80)             | 0.89 (0.44, 1.80)             | 0.93 (0.46, 1.88)              | 0.93 (0.46, 1.88)              | (2.4, 29.2)       | (0.2,33.9)        |
| PD-L1≥1%,Intra/Intra- peritumouralPD-L1+TAICs (61 Nivo, 41 IC) | 8.67                          | 4.60                          | 2.14                           | 2.33                           | 14.8              | 2.4               |
| PD-L1≥1%,Intra/Intra- peritumouralPD-L1+TAICs (61 Nivo, 41 IC) | 0.44 (0.28. 0.69)             | 0.44 (0.28. 0.69)             | 0.64 (0.41, 1.01)              | 0.64 (0.41, 1.01)              | (7.0, 26.2)       | (<0.1, 12.9)      |
| PD-L1≥1%,PeritumouralPD-L1 TAICs (25 Nivo, 18 IC)              | 7.79                          | 4.34                          | 2.09                           | 1.89                           | 16.0              | 0                 |
| PD-L1≥1%,PeritumouralPD-L1 TAICs (25 Nivo, 18 IC)              | 0.69 (0.35, 1.36)             | 0.69 (0.35, 1.36)             | 0.45 (0.22,0.90)               | 0.45 (0.22,0.90)               | (4.5, 36.1)       | (0, 18.5)         |

OSandPFSwereestimatedusingKaplan-Meiermethod.

HRisnivolumaboverIC

ConfidenceintervalforORRcalculatedusingtheClopper-Pearsonmethod.

Source:TableAR-RSI24(ORR,TAICabundance),TableAR-RSI25(ORR,TAIC1ocation),FigureAR-RSI20(OS,TAIC abundance),FigureAR-RSI21(PFS, TAICabundance),FigureAR-RSI22(OS,TAIC location),andFigureAR-RSI23(PFS,TAIC location)are all inAmnex 2.

<div style=\"page-break-after: always\"></div>

Figure 17: Kaplan-Meier plots of OS in tumour PD-L1 ≥ 1% and PD-L1+ TAIC abundance subset

<!-- image -->

TumourPD-L1≥1%+Intra/intra-peritumouralPD-L1+TAICs

Source:FigureAR-RSI22(OS,TAIC 1ocation)inAnnex 2

Figure 18: Kaplan-Meier plots of OS in tumour PD-L1 ≥ 1% and PD-L1+ TAIC location subset

<!-- image -->

## · HPV Status

HPV testing (determined by p16 immunohistochemistry [IHC]) was only required for subjects with an oropharyngeal (OPSCC) primary location, since HPV does not play a clinically relevant role in non-oropharyngeal SCCHN (non-OPSCC).

TumourPD-L1≥1%+PeritumouralPD-L1+TAICs

<div style=\"page-break-after: always\"></div>

The OS HR for nivolumab versus investigator's choice therapy was lower for HPV-positive subjects (0.56 [95% CI: 0.32, 0.99]) than HPV-negative subjects (0.73 [95% CI: 0.42, 1.25). Confidence intervals were wide due to the small sample size. In subjects with HPV-positive status, the OS Kaplan-Meier curves separated early in favour of nivolumab. In subjects with HPV-negative status, OS Kaplan-Meier curves separated after 4 months in favour of nivolumab.

## Updated analyses of efficacy by p16 status (p16-positive, p16-negative, or 'unknown' p16 status)

As per protocol guidance, p16 testing by p16 IHC assay was only required for subjects where investigators identified the primary site of the tumour as oropharyngeal. Among all randomized subjects, p16 status was available for 184 (51.0%) subjects (118 nivolumab and 66 investigator's choice [IC]). Of these 184 subjects, 92 were p16-positive (63 nivolumab and 29 IC) and 92 were p16-negative (55 nivolumab and 37 IC).

<!-- image -->

Symbols represent censored observations.

Hazard ratio is based on unstratified Coxproportional hazardmodel.

ProgramSource:/gbs/prod/clin/programs/ca/209/141/csrfa01/rpt/adhoc/20161011\\_t1ProgramName:rg-ef-os-pfs-hpv-v01.sas

## Figure 19: Kaplan-Meier plots of OS by p16 status

- Efficacy by both baseline PD-L1 expression and HPV status

Post hoc exploratory analyses of OS were done by the combination of baseline PD-L1 expression ( ≥ 1%, &lt; 1%) and HPV status (positive or negative).

Table 27: Cross Tabulation of Baseline HPV Status (Positive, Negative) by Baseline PD-L1 Status (≥ 1%, &lt; 1%) - All Randomized Subjects with Known HPV Status and Quantifiable PD-L1 Expression

<!-- image -->

|                                                                                                                    | Number of Subjects(&)(1)                                                                                           | Number of Subjects(&)(1)                                                                                           | Number of Subjects(&)(1)                                                                                           |
|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
|                                                                                                                    | >=18                                                                                                               | BaselinePD-L1 <18                                                                                                  | Total                                                                                                              |
| BaselineHPVStatus                                                                                                  |                                                                                                                    |                                                                                                                    |                                                                                                                    |
| FOSITIVE                                                                                                           | 37 (28.5)                                                                                                          | 34 (26.2)                                                                                                          | 71 (54.6)                                                                                                          |
| NEGATIVE                                                                                                           | 33 (25.4)                                                                                                          | 26 (20.0)                                                                                                          | 59 (45.4)                                                                                                          |
| Total                                                                                                              | 70 (53.8)                                                                                                          | 60 (46.2)                                                                                                          | 130 (100.0)                                                                                                        |
| Odldls ratioand95CI for ocllsratio(2): 0.86(0.43，1.72)                                                             | Odldls ratioand95CI for ocllsratio(2): 0.86(0.43，1.72)                                                             | Odldls ratioand95CI for ocllsratio(2): 0.86(0.43，1.72)                                                             | Odldls ratioand95CI for ocllsratio(2): 0.86(0.43，1.72)                                                             |
| (1) (2) oddls of PD-L1 >= 1& to < 1& in the HPV positive group to odls PD-L1 >=1% to <1% in the HPV negative group | (1) (2) oddls of PD-L1 >= 1& to < 1& in the HPV positive group to odls PD-L1 >=1% to <1% in the HPV negative group | (1) (2) oddls of PD-L1 >= 1& to < 1& in the HPV positive group to odls PD-L1 >=1% to <1% in the HPV negative group | (1) (2) oddls of PD-L1 >= 1& to < 1& in the HPV positive group to odls PD-L1 >=1% to <1% in the HPV negative group |

<div style=\"page-break-after: always\"></div>

The OS HRs (nivolumab to investigator's choice) in the subgroups suggest that each biomarker is potentially predictive on its own, and are as follows:

- PD-L1 ≥ 1%, HPV positive: 0.50 (95% CI: 0.21, 1.19)

- PD-L1 ≥ 1%, HPV negative: 0.44 (95% CI: 0.18, 1.10)

- PD-L1 &lt; 1%, HPV positive: 0.55 (95% CI: 0.22, 1.39)

- PD-L1 &lt; 1%, HPV negative: 0.82 (95% CI: 0.31, 2.19)

## Updated analysis of efficacy by both baseline PD-L1 expression and p16 status

Table 28: Efficacy by tumour PD-L1 expression and p16 status

|                                      | MedianOS,Months HR (95% CI)   | MedianOS,Months HR (95% CI)   | MedianPFS,Months HR (95% CI)   | MedianPFS,Months HR (95% CI)   | ORR, % (95% CI)   | ORR, % (95% CI)   |
|--------------------------------------|-------------------------------|-------------------------------|--------------------------------|--------------------------------|-------------------|-------------------|
|                                      | Nivo                          | IC                            | Nivo                           | IC                             | Nivo              | IC                |
| PD-L1≥1%, p16+ (23 Nivo, 14 IC)      | 9.10                          | 3.88                          | 3.29                           | 1.97                           | 17.4              | 7.1               |
| PD-L1≥1%, p16+ (23 Nivo, 14 IC)      | 0.56 (0.25, 1.25)             | 0.56 (0.25, 1.25)             | 0.54 (0.25, 1.19)              | 0.54 (0.25, 1.19)              | (5,38.8)          | (0.2, 33.9)       |
| PD-L1≥1%,p16- (19 Nivo, 16 IC)       | 9.56                          | 6.37                          | 3.15                           | 3.22                           | 26.3              | 0                 |
| PD-L1≥1%,p16- (19 Nivo, 16 IC)       | 0.43 (0.20, 0.93)             | 0.43 (0.20, 0.93)             | 0.60 (0.28, 1.29)              | 0.60 (0.28, 1.29)              | (9.1, 51.2)       | (<0.1, 20.6)      |
| PD-L1≥1%,p16 Unknown (46 Nivo, 31 IC | 5.65                          | 4.70                          | 2.10                           | 1.91                           | 13.0              | 0                 |
| PD-L1≥1%,p16 Unknown (46 Nivo, 31 IC | 0.59 (0.36, 0.97)             | 0.59 (0.36, 0.97)             | 0.56 (0.34, 0.95)              | 0.56 (0.34, 0.95)              | (4.9, 26.3)       | (<0.1, 11.2)      |
| PD-L1<1%, p16+ (24 Nivo, 10 IC)      | 9.10,                         | 6.39                          | 1.94                           | 2.22                           | 16.7              | 0                 |
| PD-L1<1%, p16+ (24 Nivo, 10 IC)      | 0.55 (0.25, 1.22)             | 0.55 (0.25, 1.22)             | 0.84 (0.38, 1.82)              | 0.84 (0.38, 1.82)              | (4.7, 37.4)       | (<0.1, 30.8)      |
| PD-L1<1%, p16- (17 Nivo, 13 IC)      | 13.0                          | 6.47                          | 2.20                           | 3.15                           | 11.8              | 15.4              |
| PD-L1<1%, p16- (17 Nivo, 13 IC)      | 0.53 (0.22, 1.27)             | 0.53 (0.22, 1.27)             | 1.29 (0.61, 2.74)              | 1.29 (0.61, 2.74)              | (1.5, 36.4)       | (1.9, 45.4)       |
| PD-L1<1%, p16 Unknown                | 4.86                          | 4.60                          | 1.91                           | 2.00                           | 9.4               | 13.3              |
| PD-L1<1%, p16 Unknown                | 1.43 (0.72,2.88)              | 1.43 (0.72,2.88)              | 1.48 (0.73, 3.00)              | 1.48 (0.73, 3.00)              | (2, 25)           | (1.7, 40.5)       |

HR (unstratified) is nivolumab over IC.

Confidence intervals for ORR were computed using the Clopper and Pearson method.

Source: Figure S.10.105 (OS), Figure Rap Q5.6 (PFS), and Appendix 16 (ORR) in Annex 3

## Summary of main study

The following table summarises the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 29: Summary of Efficacy for trial CA209141

| Title: An Open Label, Randomised Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's choice in Recurrent or Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck (HNSCC)   | Title: An Open Label, Randomised Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's choice in Recurrent or Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck (HNSCC)   | Title: An Open Label, Randomised Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's choice in Recurrent or Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck (HNSCC)   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                               | CA209141                                                                                                                                                                                                       | CA209141                                                                                                                                                                                                       |
| Design                                                                                                                                                                                                         | Phase 3, randomised open-label study Nivolumab versus investigator's choice (cetuximab, methotrexate, or docetaxel) randomised in 2:1 ratio and stratified according to prior cetuximab treatment (yes/no).    | Phase 3, randomised open-label study Nivolumab versus investigator's choice (cetuximab, methotrexate, or docetaxel) randomised in 2:1 ratio and stratified according to prior cetuximab treatment (yes/no).    |
|                                                                                                                                                                                                                | Duration of main phase:                                                                                                                                                                                        | FPFV: 29-May-2014 LPLV for primary endpoint: 06-Nov-2015                                                                                                                                                       |
| Hypothesis                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                    | Superiority                                                                                                                                                                                                    |
| Treatment groups                                                                                                                                                                                               | Nivolumab (n=240)                                                                                                                                                                                              | Nivolumab 3 mg/kg as 60min IV infusion Q2W; no dose increases or reductions were allowed                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                           | Investigator's choice (n=121)                                                                                                                      | Investigator's choice (n=121)                                                                                                                      | One of following single agents as selected by investigator; dose reductions were allowed - Cetuximab 400 mg/m 2 once, then 250 mg/m 2 weekly (where approved for use as single agent for recurrent HNSCC) - Methotrexate 40 mg/m 2 IV weekly, increased to 60 mg/m 2 if tolerated and as per local practices - Docetaxel 30 mg/m 2 IV weekly, increased to 40 2                                                                                    |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions | Primary endpoint                                                                                                                                   | OS                                                                                                                                                 | Time from randomisation to the date of death from any cause. The survival time for subjects who had not died was censored at the last known date alive. OS was censored at the date of randomisation for subjects who were randomised but had no follow-up.                                                                                                                                                                                        |
| Endpoints and definitions | Secondary endpoint                                                                                                                                 | PFS                                                                                                                                                | Primary definition PFS: Time between date of randomisation and first date of documented progression, as determined by investigator (as per RECIST v1.1 criteria). Secondary definition PFS: Also known as ITT definition, was same as primary definition, except there was no censoring for receipt of subsequent anticancer therapy prior to documented progression.                                                                              |
| Endpoints and definitions | Secondary endpoint                                                                                                                                 | ORR                                                                                                                                                | Proportion of randomised subjects who achieved best response of CR or PR using RECIST v1.1 criteria as per investigator assessment. To achieve a best response of CR or PR, confirmation was required. BOR was defined as confirmed best response designation, recorded between date of randomisation and date of progression, as assessed by the investigator per RECIST v1.1 or date of subsequent anticancer therapy, whichever occurred first. |
| Endpoints and definitions | Key exploratory endpoint                                                                                                                           | TTR                                                                                                                                                | Time from randomisation to date of first response (CR or PR), as assessed by investigator. TTR was evaluated for responders only.                                                                                                                                                                                                                                                                                                                  |
| Endpoints and definitions | Key exploratory endpoint                                                                                                                           | Associat ion baseline PD-L1 expressi on and efficacy                                                                                               | PD-L1 expression at baseline was defined based on PD-L1 IHC 28-8 pharmDx assay. Subjects with quantifiable PD-L1 expression at baseline had at least 1 tumour sample collected at baseline and ≥ 100 viable tumour cells. PD-L1 non-quantifiable subjects had no quantifiable PD-L1 expression at baseline (including subjects without available tumour samples). PD-L1 was analysed at predefined expression levels of 1%, 5%, and 10% PD-L1      |
| Database lock             | 18-Dec-2015 clinical database lock (last patient last visit, 06-Nov-2015), 03-Feb-2016 PD-L1 database lock, and 05-May-2016 tumour assessments and | 18-Dec-2015 clinical database lock (last patient last visit, 06-Nov-2015), 03-Feb-2016 PD-L1 database lock, and 05-May-2016 tumour assessments and | 18-Dec-2015 clinical database lock (last patient last visit, 06-Nov-2015), 03-Feb-2016 PD-L1 database lock, and 05-May-2016 tumour assessments and                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Analysis population and time point description   | All randomised subjects On 18-Dec-2015, the clinical database was locked for the planned formal interim analysis of OS. On 26-Jan-2016, the independentDMC reviewed these interim data, and confirmed the pre-specified boundary for OS had been crossed (nominal   | All randomised subjects On 18-Dec-2015, the clinical database was locked for the planned formal interim analysis of OS. On 26-Jan-2016, the independentDMC reviewed these interim data, and confirmed the pre-specified boundary for OS had been crossed (nominal   | All randomised subjects On 18-Dec-2015, the clinical database was locked for the planned formal interim analysis of OS. On 26-Jan-2016, the independentDMC reviewed these interim data, and confirmed the pre-specified boundary for OS had been crossed (nominal   | All randomised subjects On 18-Dec-2015, the clinical database was locked for the planned formal interim analysis of OS. On 26-Jan-2016, the independentDMC reviewed these interim data, and confirmed the pre-specified boundary for OS had been crossed (nominal   | All randomised subjects On 18-Dec-2015, the clinical database was locked for the planned formal interim analysis of OS. On 26-Jan-2016, the independentDMC reviewed these interim data, and confirmed the pre-specified boundary for OS had been crossed (nominal   | All randomised subjects On 18-Dec-2015, the clinical database was locked for the planned formal interim analysis of OS. On 26-Jan-2016, the independentDMC reviewed these interim data, and confirmed the pre-specified boundary for OS had been crossed (nominal   |
|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability  | Treatment group                                                                                                                                                                                                                                                     | Nivolumab                                                                                                                                                                                                                                                           | Investigator's choice                                                                                                                                                                                                                                               | Investigator's choice                                                                                                                                                                                                                                               | Investigator's choice                                                                                                                                                                                                                                               | Investigator's choice                                                                                                                                                                                                                                               |
|                                                  | Number of subjects                                                                                                                                                                                                                                                  | 240                                                                                                                                                                                                                                                                 | 121                                                                                                                                                                                                                                                                 | 121                                                                                                                                                                                                                                                                 | 121                                                                                                                                                                                                                                                                 | 121                                                                                                                                                                                                                                                                 |
|                                                  | OS median, months (95% CI) Rate at 6 months %, (95%CI)                                                                                                                                                                                                              | 7.72 (5.68-8.77) 56.5 (49.9-62.5)                                                                                                                                                                                                                                   | 5.06 (4.04-6.24) 43.0 (34.0-51.7)                                                                                                                                                                                                                                   | 5.06 (4.04-6.24) 43.0 (34.0-51.7)                                                                                                                                                                                                                                   | 5.06 (4.04-6.24) 43.0 (34.0-51.7)                                                                                                                                                                                                                                   | 5.06 (4.04-6.24) 43.0 (34.0-51.7)                                                                                                                                                                                                                                   |
|                                                  | PFS prim. median, months (95% CI) Rate at 6 months %, (95%CI)                                                                                                                                                                                                       | 2.04 (1.91-2.14) 21.0 (15.9-26.6)                                                                                                                                                                                                                                   | 2.33 (1.97-3.12) 11.1 (5.9-18.3)                                                                                                                                                                                                                                    | 2.33 (1.97-3.12) 11.1 (5.9-18.3)                                                                                                                                                                                                                                    | 2.33 (1.97-3.12) 11.1 (5.9-18.3)                                                                                                                                                                                                                                    | 2.33 (1.97-3.12) 11.1 (5.9-18.3)                                                                                                                                                                                                                                    |
|                                                  | PFS sec. median, months (95%CI)                                                                                                                                                                                                                                     | 2.04 (1.91-2.14)                                                                                                                                                                                                                                                    | 2.46 (1.97-3.15)                                                                                                                                                                                                                                                    | 2.46 (1.97-3.15)                                                                                                                                                                                                                                                    | 2.46 (1.97-3.15)                                                                                                                                                                                                                                                    | 2.46 (1.97-3.15)                                                                                                                                                                                                                                                    |
|                                                  | (95%CI) BOR% CR PR SD PD NA                                                                                                                                                                                                                                         | (9.3-18.3) 2.5 10.8 22.9 41.7                                                                                                                                                                                                                                       | (2.4-11.6) 0.8 5.0                                                                                                                                                                                                                                                  | (2.4-11.6) 0.8 5.0                                                                                                                                                                                                                                                  | (2.4-11.6) 0.8 5.0                                                                                                                                                                                                                                                  | (2.4-11.6) 0.8 5.0                                                                                                                                                                                                                                                  |
|                                                  |                                                                                                                                                                                                                                                                     | 22.1                                                                                                                                                                                                                                                                | 35.5 34.7 24.0                                                                                                                                                                                                                                                      | 35.5 34.7 24.0                                                                                                                                                                                                                                                      | 35.5 34.7 24.0                                                                                                                                                                                                                                                      | 35.5 34.7 24.0                                                                                                                                                                                                                                                      |
|                                                  | TTR median, months (min, max)                                                                                                                                                                                                                                       | 2.1 (1.8-7.4) 8.1 (n=88) (6.5-9.5) 6.1 (n=73) (4.4-12.7)                                                                                                                                                                                                            | 4.7 (n=61) (3.8-6.2) 5.5 (n=38) (3.7-8.5) 5.8 (n=22)                                                                                                                                                                                                                | 4.7 (n=61) (3.8-6.2) 5.5 (n=38) (3.7-8.5) 5.8 (n=22)                                                                                                                                                                                                                | 4.7 (n=61) (3.8-6.2) 5.5 (n=38) (3.7-8.5) 5.8 (n=22)                                                                                                                                                                                                                | 4.7 (n=61) (3.8-6.2) 5.5 (n=38) (3.7-8.5) 5.8 (n=22)                                                                                                                                                                                                                |
| Effect estimate per                              | OS                                                                                                                                                                                                                                                                  | Comparison groups                                                                                                                                                                                                                                                   | Nivolumab vs. IC                                                                                                                                                                                                                                                    | Nivolumab vs. IC                                                                                                                                                                                                                                                    | Nivolumab vs. IC                                                                                                                                                                                                                                                    | Nivolumab vs. IC                                                                                                                                                                                                                                                    |
|                                                  | PFS Primary definition                                                                                                                                                                                                                                              | Comparison groups                                                                                                                                                                                                                                                   | Nivolumab vs. IC                                                                                                                                                                                                                                                    | Nivolumab vs. IC                                                                                                                                                                                                                                                    | Nivolumab vs. IC                                                                                                                                                                                                                                                    | Nivolumab vs. IC                                                                                                                                                                                                                                                    |
|                                                  |                                                                                                                                                                                                                                                                     | p-value stratified                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                  |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     | 0.2597                                                                                                                                                                                                                                                              | 0.2597                                                                                                                                                                                                                                                              | 0.2597                                                                                                                                                                                                                                                              | 0.2597                                                                                                                                                                                                                                                              |
|                                                  |                                                                                                                                                                                                                                                                     | log-rank test                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                  |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     | 0.87                                                                                                                                                                                                                                                                | 0.87                                                                                                                                                                                                                                                                | 0.87                                                                                                                                                                                                                                                                | 0.87                                                                                                                                                                                                                                                                |
|                                                  | OS median by PD-L1 expression, months (95%CI) ≥1%                                                                                                                                                                                                                   | 95%CI p-value stratified 95%CI                                                                                                                                                                                                                                      | 0.69-1.11                                                                                                                                                                                                                                                           | 0.69-1.11                                                                                                                                                                                                                                                           | 0.69-1.11                                                                                                                                                                                                                                                           | 0.69-1.11                                                                                                                                                                                                                                                           |
|                                                  |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     | (3.6-8.9)                                                                                                                                                                                                                                                           | (3.6-8.9)                                                                                                                                                                                                                                                           | (3.6-8.9)                                                                                                                                                                                                                                                           | (3.6-8.9)                                                                                                                                                                                                                                                           |
|                                                  | <1%                                                                                                                                                                                                                                                                 | 7.8 (n=79)                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                  | Non-quantifiable                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                  |                                                                                                                                                                                                                                                                     | (3.8-9.7)                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| comparison                                       |                                                                                                                                                                                                                                                                     | HR                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                  |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     | 0.0048                                                                                                                                                                                                                                                              | 0.0048                                                                                                                                                                                                                                                              | 0.0048                                                                                                                                                                                                                                                              | 0.0048                                                                                                                                                                                                                                                              |
|                                                  |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     | 0.71 0.55-0.90                                                                                                                                                                                                                                                      | 0.71 0.55-0.90                                                                                                                                                                                                                                                      | 0.71 0.55-0.90                                                                                                                                                                                                                                                      | 0.71 0.55-0.90                                                                                                                                                                                                                                                      |
|                                                  |                                                                                                                                                                                                                                                                     | HR                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                  |                                                                                                                                                                                                                                                                     | log-rank test                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| PFS Secondary              | Comparison groups                | Nivolumab vs. IC   |
|----------------------------|----------------------------------|--------------------|
| PFS Secondary              | HR                               | 0.91               |
| PFS Secondary              | 95%CI                            | 0.73-1.15          |
| PFS Secondary              | p-value stratified log-rank test | 0.4208             |
| ORR                        | Comparison groups                | Nivolumab vs. IC   |
| ORR                        | OR estimate                      | 2.49               |
| ORR                        | 95%CI                            | 1.07-5.82          |
| ORR                        | p-value CMH test                 | Not available      |
| OS by PD-L1 expression ≥1% | Comparison groups                | Nivolumab vs. IC   |
| OS by PD-L1 expression ≥1% | Unstratified HR                  | 0.55               |
| OS by PD-L1 expression ≥1% | 95%CI                            | 0.37-0.77          |
| OS by PD-L1 expression ≥1% | p-value                          | Not available      |
|                            | Unstratified HR                  | 0.83               |
|                            | 95%CI                            | 0.54-1.29          |
|                            | p-value                          | Not available      |
| Non-quantifiable           | Unstratified HR                  | 0.90               |
| Non-quantifiable           | 95%CI                            | 0.53-1.52          |
| Non-quantifiable           | p-value                          | Not available      |

## Clinical studies in special populations

Special populations - Elderly patients

In the pivotal study, 95 patients aged ≥65 - &lt;75 years were included (56 were treated with nivolumab, 93 with IC). In this age group, OS HR was 0.93 [95% CI: 0.56, 1.54]. A very small number of patients aged ≥75 years of age was enrolled, namely 12 in the nivolumab group and 6 in the control group and there were no subjects treated with nivolumab ≥85 years of age.

## Special populations - Paediatric patients

The therapeutic indication currently applied for, treatment of oropharyngeal, laryngeal or nasal epithelial carcinoma (excluding nasopharyngeal carcinoma or lymphoepithelioma), is one of the conditions currently listed in the consolidated EMA decision on class waivers, adopted on 19 December 2011 (CW/1/2011). In addition, a PIP for nivolumab in the condition of \"treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue)\" was approved on 7 March 2014 (EMA Decision P/0064/2014).

## Supportive study(ies)

N/A

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

Efficacy data to support the proposed indication in SCCHN is based on data derived from 361 randomised subjects (240 nivolumab and 121 investigator's choice) in the single pivotal trial, CA209141. This was an open label, randomised phase 3 clinical trial of nivolumab vs therapy of investigator's choice in the recurrent or metastatic platinum-refractory setting.

The inclusion/exclusion criteria were aimed to recruit patients (mildly symptomatic as ECOG is 0-1) with recurrent or metastatic oropharynx (except salivary gland) SCCHN, who have failed prior platinum therapy

<div style=\"page-break-after: always\"></div>

(platinum resistant). This platinum regimen could have been part of induction, adjuvant or metastatic scheme.

SCCHN originating from paranasal sinuses and nasopharynx are usually excluded from trials, which is also applicable here. Nasopharynx carcinoma seems to have the highest likelihood to metastasize to distant size.

In subjects randomised to the investigator's choice group, subjects received one of the following treatments (as selected by the investigator): cetuximab, methotrexate, or docetaxel. Both methotrexate and weekly docetaxel have been used in several studies for recurrent/metastatic head and neck cancer. Cetuximab has also shown some responses in second line. The use of three different options as comparator adds uncertainty to the analysis, however from a clinical perspective, only response rates have been reported with these treatments without increase in survival.

Subjects were randomized 2:1 (nivolumab:investigator's choice) and stratified according to prior cetuximab treatment (yes/no). The 2:1 ratio is accepted given the lack of relevant survival benefit associated to the comparators and the previous results with immunotherapy. The stratification by prior use of cetuximab is agreed however the stratification by HPV status (+ or -) would have been desirable as well.

Given the open-label nature of the study, ORR and PFS data might be biased in view of the investigator-based response assessment.

506 patients were enrolled, 361 randomized (240 nivolumab, 121 investigators' choice), and 347 treated (236 nivolumab, 111 investigator's choice). It should be noted the percentage of subjects not treated in the investigator's choice (8.3%) of them 5% were due to 'subject withdrew consent', which probably reflects the open label design of the study.

There are more subjects continuing in the treatment period in the nivolumab arm (17.4% vs 2.7%). Among the main reasons for not continuing in the treatment period, disease progression and toxicity are the most frequent. Both of them higher in the comparator arm, which could imply a better efficacy and tolerability of nivolumab.

Baseline demographic characteristics are evenly balanced between both groups except for patients between 65 and 75 years and &lt; 65. The disease characteristics indicate a mildly symptomatic population (78% ECOG 1), former or current smoker (76%) with stage IV at study entry (90%) and oral cavity or pharynx as primary tumours. Both groups are overall balanced in the sites of lesions, with lung, lymph node and oral cavity as most frequent. All subjects have been previously treated with platinum. Overall, the subjects recruited into the study represent a platinum refractory population in stage IV with prior surgery and radiotherapy.

Patients had a much poorer prognosis (with ~20% of the patients deceased after 2 months), than would be expected from the inclusion criteria (ECOG PS of 0 or 1). Moreover, 40.4% of subjects had disease progression as their best response to their most recent prior platinum-based regimen, indicating that the enrolled patient population had a very poor prognosis. It is therefore plausible, that there was insufficient time for nivolumab to achieve clinical effect in a subset of patients with such poor prognosis. However, an analysis provided by the Applicant demonstrated that, overall, patients with progressive disease within 2 months on their prior treatment regimen do have clinical benefit from treatment with nivolumab compared to treatment with Investigator's Choice Therapy and this is consistent with the OS analysis in the overall study population.

## Efficacy data and additional analyses

On 18 December 2015, the clinical database was locked for the planned formal interim analysis of OS as specified in the protocol. On 26 January 2016, with 55.4% of events in the nivolumab arm, there was a gain in the life expectancy of almost 2.5 months (in terms of medians of OS; HR = 0.70 [97.73% CI: 0.51, 0.96]; stratified log-rank test p-value = 0.0101). According to the profile of the curves, the benefit in OS takes approximately 3 months to become apparent. The magnitude of the difference in survival is around 15%

<div style=\"page-break-after: always\"></div>

between groups (OS rates at 6, 9 and 12 months). Results from the two sensitivity analyses carried out (unstratified analysis and analysis based on subjects with no relevant deviations) are consistent with the main one. Furthermore, a multivariate analysis adjusted for HPV-p16 status, baseline ECOG PS, and prior chemotherapy for metastatic disease, showed a similar result. When split according to individual investigator's choice therapies, the advantage of nivolumab is retained versus cetuximab (HR 0.54; 95% CI: 0.30, 0.98) and methotrexate (HR 0.60; 95% CI: 0.41, 0.86). However, for docetaxel, even though nivolumab seems superior from the point of 4 months forward, due to likely lack of power to find differences and the crossover of the curves, no statistical conclusion can be drawn (HR 0.84; 95% CI 0.58, 1.23). When focusing on docetaxel comparison, a pattern of higher deaths associated to nivolumab is observed. The curve of nivolumab is clearly below docetaxel's one in the first 4 months. This fact recalls the same effect seen in melanoma and lung. The Applicant performed only univariate analyses to investigate factors that were associated with better 3-months survival for docetaxel instead of nivolumab and which suggest that with PS1, &lt; 3 lines of therapy (especially 2), fast PD (&lt;=4 months), no CR on previous therapy, former/current smokers have a better probability to survive 3 months with docetaxel. Analyses using the updated database (20-Sep-2016 database lock) were conducted to better characterise the subgroup of subjects who died within first 3 months and to explore factors which might be associated with higher risk of early death. During the first 3 months of therapy, there was a higher percentage of patients who died in the nivolumab group vs docetaxel arm (28.3% vs 18.5% of the whole number of nivolumab and docetaxel treated patients respectively). The delay in the onset of action of nivolumab along with some prognostic factors appears the most plausible explanation. Likewise in NSCLC and melanoma, ECOG performance status, fast progressive disease and high tumour burden seem to be an important factor to consider when it comes to starting a nivolumab treatment.

Cross-over from nivolumab to an investigator's choice therapy and from investigator's choice to a regimen with an anti PD-L1 component was limited (20.9 and 7.4%, respectively) and the OS advantage is still in favour of nivolumab, so the impact of cross-over on OS is limited. Subjects in the nivolumab group received more often taxanes, and subjects in the investigator's group were more often treated with an anti-PD-1 targeted agent. The primary endpoint OS is not expected to be impacted to a relevant extent by the use of subsequent anticancer therapies as frequencies were similar in both groups.

In the updated analysis (20-Sep-2016 database lock) nivolumab continued to demonstrate statistically significant and clinically meaningful improvement in OS versus investigator's choice therapy (HR= 0.71 [95% CI: 0.55, 0.90]; stratified log-rank test p-value = 0.0048), with survival rates of 34.0% and 21.5% at 12 and 18 months, respectively. The HR for OS of nivolumab versus individual investigator's choice therapies was 0.49 (95% CI: 0.29, 0.84) for cetuximab, 0.57 (95% CI: 0.41, 0.78) for methotrexate, and 0.92 (95% CI: 0.66, 1.29) for docetaxel.

Regarding the secondary endpoints, no statistically significant difference in terms of PFS was found between nivolumab and control group, even though from the 5th month forward there seem to be some benefit. This lack of positive results in PFS has been previously observed in other clinical developments with nivolumab (renal and non-squamous NSCLC), highlighting the discrepancy between PFS and OS.

ORR results offer better outcomes, with a significant difference in favour of nivolumab (13% vs 6% for the nivolumab and control group respectively) but with only 6 complete responders. Median time to objective response was 2 months.

Results in the various subgroups were not significantly dissimilar to the overall population. In the European population, neither OS (HR 0.91 95%CI 0.62, 1.33) nor ORR (10.1% vs 9.7%) show a clear benefit for nivolumab and even in terms of PFS the control group offers better results (HR 1.27 95%CI 0.90, 1.78). Even though some imbalances in prognostic factors (time from prior platinum to progression, gender and HPV status) could partially explain this absence of benefit, no firm conclusions can be drawn. In a worst-case scenario, nivolumab would offer similar efficacy to docetaxel, though with a priori better safety profile.

<div style=\"page-break-after: always\"></div>

Analyses provided by the MAH demonstrate that activity of nivolumab relative to investigator's choice therapy (ICT) is markedly less in patients with low tumour PD-L1 expression (&lt;1%) compared to patients with higher tumour PD-L1 expression (≥1%). However, after several analyses in order to explore the link between PD-L1 expression on tumour cells and tumour-associated immune cells (TAICs) and response to treatment with nivolumab in head and neck squamous cell carcinoma (HNSCC), the subgroup of patients which has intratumoural PD-L1 expressing TAIC appears to have greater benefit from treatment with nivolumab than from treatment with investigator's choice therapy (ICT) while the subgroup of patients with low tumour cell PD-L1 expression (&lt;1%) without intratumoural PD-L1 expressing TAIC appears not to have greater benefit from nivolumab compared to ICT. A less pronounced, but a similar pattern is observed in the group of patients with high tumour cell PD-L1 expression (≥1%), with the number and the localisation of the PD-L1 positive TAIC appearing to be associated with response to nivolumab. It should, however, be acknowledged that the investigated subgroups are small, and in combination with technical challenges, definitive conclusions cannot yet be drawn from this analysis. In order to further investigate the relationship between clinical outcomes to nivolumab and PD-L1 expression in immune cells and other biomarkers (PD-L2, mutational load), a biomarker investigation has been included as post authorisation measure (see Annex II).

In the updated analysis of efficacy by both baseline PD-L1 expression and p16 status, in all subgroups nivolumab treatment had numerically better efficacy than IC treatment, except for PD-L1&lt;1% and p16 unknown (HR 1.41 [95% CI 0.72- 2.88]). Since the confidence interval encompasses 1 and it concerns a small sample size, no conclusion can be drawn on these data. With the addition of 6 p16-negative patients and the updated analyses, the HR for the PD-L1 &lt;1% and p16-negative patients decreased from 0.82 to 0.53, which is reassuring.

Finally, HPV status revealed a different pattern of efficacy in those patients HPV negative (HR 0.73 [95% CI: 0.42, 1.25]) vs HPV positive (HR 0.56 [95% CI: 0.32, 0.99]) with a different profile of the curves. Nevertheless in the updated analysis hazard ratios for OS favour nivolumab treatment compared to investigator's choice for p16-positive, p16-negative, and unknown p16 status, ie. OS benefit was observed regardless of HPV status (HPV-positive: HR = 0.63; 95% CI: 0.38, 1.04, HPV-negative: HR = 0.64; 95% CI: 0.40, 1.03, and HPV-unknown: HR = 0.78; 95% CI: 0.55, 1.10), as reported in the Product Information.

## 2.4.4. Conclusions on the clinical efficacy

Nivolumab showed an improvement in overall survival compared to the best investigator choice in the overall population in the single pivotal study. However, the overall survival, PFS and ORR data show that this added efficacy versus the standard of care might be limited or even not present in certain subgroups (see section 5.1 of the SmPC).

The CHMP considers the following measures necessary to address issues related to efficacy:

The MAH should further investigate in study CA209141, the association between improved clinical outcomes to nivolumab and the presence of:

-Higher mutational load, and as feasible, PD L1 tumour associated immune cell (TAIC) expression (30 September 2017)

- -PD-L2 expression (31 March 2018)
- -High inflamed phenotype (30 September 2018)

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## Introduction

Safety  was  assessed  based  on  the  data  from  Study  CA209141  supporting  the  use  of  nivolumab (BMS-936558) at the proposed dose and schedule of 3 mg/kg administered as an IV infusion over 1 hour every 2 weeks (Q2W) for the treatment of patients with recurrent or metastatic SCCHN.

Of the 361 subjects randomized (240 to nivolumab, 121 to investigator's choice therapy), 347 (96.1%) were treated (236 with nivolumab, 111 with investigator's choice therapy). Safety analyses were conducted in all treated subjects who received at least one dose of study drug. Safety presentations of AEs, SAEs, AEs leading to discontinuation, select AEs, and laboratory abnormalities are based on all treated subjects using a safety window of 30 days after last dose.

The primary clinical database lock was 18-Dec-2015. The CA209141 Final CSR was updated with safety data following  the  20-Sep-2016  database  lock.  This  updated  analysis  represents  a  minimum  follow-up  for survival of 11.4 months. The assessment of longer-term safety was based on frequency of deaths, as well as all-causality and drug-related AEs, SAEs, AEs leading to discontinuation of study drug, and selected AEs.

There were a higher proportion of former/current smokers in the nivolumab group (79.6%) than the in investigator's choice group (71.1%). The only stratification factor in the randomisation was prior cetuximab (yes/no; IVRS source).

In CA209141, the incidence rates of AEs leading to discontinuation, drug-related AEs, and drug-related SAEs, reported within 100 days of last dose were consistent with those reported within 30 days of the last dose.

## Patient exposure

As  of  the  clinical  database  lock  date  (20-Sep-2016),  the  majority  (82.2%)  of  treated  subjects  in  the nivolumab group received ≥ 90% of the planned dose intensity, which was similar to the frequency for cetuximab (84.6%), and higher than for docetaxel (67.3%) and methotrexate (50.0%) (Table 30). The lower  proportion  of  subjects  receiving ≥ 90%  of  the  planned  dose  intensity  in  the  docetaxel  and methotrexate  groups  is  consistent  with  the  protocol,  which  allowed  dose  reductions  of  cetuximab, methotrexate, and docetaxel, but not nivolumab. The median duration of nivolumab therapy was similar to that of the investigator's choice therapy; see Table 30 (by individual investigator's choice agent).

<div style=\"page-break-after: always\"></div>

Table 30: Cumulative Dose and Relative Dose Intensity Summary - All Treated Subjects in CA209141 (20-Sep-2016 database lock)

|                                                                            | Nivolumab (N=236) Nivolumab 3 mg/kg (N=236)   | Investigator's Choice (N=111)   | Investigator's Choice (N=111)   | Investigator's Choice (N=111)   |
|----------------------------------------------------------------------------|-----------------------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                                                            | Nivolumab (N=236) Nivolumab 3 mg/kg (N=236)   | Cetximab (N=13)                 | Methotrexate (N=46)             | Docetaxel (N=52)                |
| NUMBEROFDOSESRECEIVED MEAN (SD) MEDIAN (MIN - MAX)                         | 9.4( (10.53) 5.0 (1 - 51)                     | 10.5 (7.61) 8.0 (3 - 32)        | (5.22)                          | 11.1 (8.32) 9.0 (1 -38)         |
| DURATICN OFTHERAPY(1) MEDIAN Q1, Q3 MN, MAX (2)                            | 1.9 1.0, 4.9 0,24*                            | 1.6                             | 1.6 0.5, 3.0 .2.0               | 2.0 1.4, 3.3 6, 12*             |
| CUMULATIVE DOSE (3) MEAN (SD) MEDIAN (MIN - MAX)                           | 号:1 (814156)                                  | 2246:3 (8239 -73232)            | 292: (295:2925)                 | 376:3 (886-91534)               |
| RELATIVE DOSEINIENSITY  (%) >110% 90% to < 110% 70%to< 5.06 50%to<70% <50% | (82.2) (14.8) 5                               | (62:7) (76. (15.4)              | (50.0) 28. 45 (10. 9 1          | 520 5 19 (11 9                  |
| MISSING                                                                    |                                               |                                 |                                 | 610                             |

(1)The first quartile (Ql)， the meclian, cnd the third quartile (Q3)， are cumputed using a Kaplan-Veier estimate of the chuation of 3) ）Dose\\_units are mg/m2 for investigator's choice of chemotherapeutic agent, andl mg/kg for nivolumeb.

Souroe: Table S.4.1

As of the 20-Sep-2016 database lock, 16 (6.8%) subjects in the nivolumab group and 1 (0.9%) subject in investigator's choice group were continuing in the treatment period. Most subjects received all doses of study  medication  without  an  infusion  interruption,  infusion  rate  reduction,  or  dose  delay.  Most  of  the subjects in the investigator's choice group did not require a dose reduction or escalation; dose reductions or escalations were not permitted with nivolumab treatment. In the investigator's choice group, 0%, 4.3%, and 5.8% of subjects had a dose escalation of cetuximab, methotrexate, or docetaxel, respectively.

Among treated subjects in the nivolumab group, the majority (55.9%; 132/236) were exposed to nivolumab for  less  than  3  months;  44.1%  (104/236)  of  nivolumab-treated  subjects  were  exposed  for  3  or  more months, with 25.0% (59/236) and 11.4% (27/236) exposed for ≥ 6 or ≥ 12 months, respectively. The median duration of nivolumab therapy in CA209141 was 1.9 months.

In SCCHN, the mean number of doses received and cumulative dose was lower than RCC, melanoma, and NSCLC; a high proportion of subjects received ≥ 90% of the relative dose intensity, similar to the other tumour types; median duration of therapy was similar to NSCLC and shorter than RCC and melanoma; a similar proportion of subjects were still being treated with nivolumab at the time of database lock compared with RCC and NSCLC; total exposure to nivolumab monotherapy was shorter than in other tumour types.

<div style=\"page-break-after: always\"></div>

Table 31: Cumulative Dose and Relative Dose Intensity, Duration of Study Therapy, and Total Exposure to Nivolumab Monotherapy Across Tumour Types - All Treated Subjects

|                                                                 | SOCHN N=236                       | ROC N=406                                          | Melanoma N=787                                     | NSCIC N=535                                        |
|-----------------------------------------------------------------|-----------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| NUMEEROE DOSES RECEIVED                                         |                                   |                                                    |                                                    |                                                    |
| MEAN(SD)                                                        | 7.6(6.71)                         | 19.2(16.25)                                        | 15.4(10.99)                                        | 12.0(12.49)                                        |
| MEDIAN(MMN-MAX)                                                 | 5.0(1-34)                         | 12.0(1-65)                                         | 12.0(1-45)                                         | 6.0(1-52)                                          |
| CUMILATIVE IOSE (MG/KG)                                         | CUMILATIVE IOSE (MG/KG)           | CUMILATIVE IOSE (MG/KG)                            | CUMILATIVE IOSE (MG/KG)                            | CUMILATIVE IOSE (MG/KG)                            |
| MEAN(SD) MEDIAN(MMN-MAX)                                        | 22.8(20.15) 15.0(3-102)           | 57.72(49.025) 36.03(0.5-195.1)                     | 46.20（33.144) 36.00(3.0-135.0)                     | 36.05(37.388) 18.04(1.4-156.0)                     |
| RETATIVEDOSEINTENSITY                                           | RETATIVEDOSEINTENSITY             | RETATIVEDOSEINTENSITY                              | RETATIVEDOSEINTENSITY                              | RETATIVEDOSEINTENSITY                              |
| >110号 90810<110% 70%10<90%                                      | 0 195 (82.6) 35 (14.8)            | 3 0.7) 330 (81.3) 9 （15.8） 8 2.0) 1 0.2)           | 0.4) 681 (86.5) 88 (11.2) 13 1.7 2 0.3)            | 0 447 (83.6) 75 (14.0) 11 2.1) 2 0.4)              |
| 508TO<70号                                                       | 2.1                               |                                                    |                                                    |                                                    |
| <50%                                                            |                                   |                                                    |                                                    |                                                    |
|                                                                 | (0.4)                             |                                                    |                                                    |                                                    |
| DURATION OETHERAPY(MONTHS) MEDIAN（95号CI）（B) NOEETRT/NTREATED（号) | 0,16+ 1.9.(1.6,2.3) 195/236(82.6) | 0.03,29.60+ 5.536(5.060,6.932) 339/406（83.5) 328.3 | 0.03,20.30+ 5.815(5.092,6.669) 499/787(63.4) 500.2 | 0.03,23.95+ 2.727(2.300,3.023) 456/535(85.2) 277.8 |
| TOTAL EXPOSURE(P-Y)                                             | 79.0                              |                                                    |                                                    |                                                    |

Nivolumeb monotherapy treatwent groups frcm the following studies are included in the disease categories:sochN: CA209141; ROC:CA209025;Me1anCma:CA209037,CA209066,CA209067;N5CIC:CA209063,CA209017,CA209057.

(A)Symbol+indicates a censored value.

P-Y=person-years of exposure.

(B)Medlian oonputed usingKaplan-Meier method.

Soumoe:refer to Table 6.1-1 and Figure 6.1-1 of the CA209141 Final CsRfor SOcHN data.

<div style=\"page-break-after: always\"></div>

## Adverse events

## All-causality AEs

Table 32: Summary of Safety Results Based on 20-Sep-2016 Database lock - All Treated Subjects in CA209141

<!-- image -->

|                                                                                                    | Nurber ()Subjects                           |                        |                            |                         |                        |                             |
|----------------------------------------------------------------------------------------------------|---------------------------------------------|------------------------|----------------------------|-------------------------|------------------------|-----------------------------|
|                                                                                                    | Nivoluweb3mg/kg(N=236)                      |                        | Imvestigator'sCmoioe(=l11) |                         |                        |                             |
| DEATHS                                                                                             |                                             |                        | 1676 (96                   |                         |                        |                             |
| WITHNN30 DAYSOEIAST DOSE                                                                           |                                             |                        | (18                        |                         |                        |                             |
| WITHIN 100 LAYS OELAST DOSE DLETO (e)                                                              | 109 2                                       |                        | (52                        |                         |                        |                             |
|                                                                                                    | Ninber (e) Subjects                         |                        |                            |                         |                        |                             |
|                                                                                                    | Nivolumeb3mg/kg@=236)                       |                        | Irvestigator'sChoioeQ=ll1) |                         |                        |                             |
|                                                                                                    | Any Gaade                                   | Grade3-4               | Any Grade                  | Gde3-4                  |                        |                             |
| ALL-CAISALITYSARS                                                                                  | 132 (55.9)                                  | 80(33.9)               | 65 (58.6)                  | 45 (40.5)               |                        |                             |
| IRUG-RELAIRDSARe                                                                                   | 17 (7.2)                                    | 13(5.5)                | 17 (15.3)                  | 12 (10.8)               |                        |                             |
| ALL-CAISALITYARSIRADINGTODC IROG-RETATRDARSIEADNNGTODC                                             | 5 123:83                                    | 3715-7 73.0            | 25 (23:8)                  | 13 74:3 6               |                        |                             |
| ALL-CAUSALITYAEe Most FreguentAEs                                                                  |                                             | group)                 | （98.2)                     |                         |                        |                             |
|                                                                                                    |                                             |                        | 109                        | 69                      |                        |                             |
|                                                                                                    | 232(98.3)                                   | 113(47.9)              |                            |                         |                        |                             |
| (21 .2) (20.3)                                                                                     | 20sofAnyGdeineitherteatment 50 97 (28-4) 48 | 4 6. 4                 | 333 37 (33.3) (30. 6 20:7  | (62.2) T 0.9) 6.3) 9.01 | NAISEA EATTCLE ANAEMIA |                             |
| DLARRHOEA ASTHDNA                                                                                  | 46 19.5) 2号 188B                            | 35                     | (35.1 强                    | 18 10.6                 |                        | MALTENNTNEOELASMBROGRESSION |
| DRUG-RELATRDARS                                                                                    |                                             |                        | 88 (79.3)                  |                         |                        |                             |
|                                                                                                    |                                             | 36(15.3)               | goup)                      |                         |                        |                             |
|                                                                                                    | 146                                         |                        |                            |                         |                        |                             |
|                                                                                                    |                                             |                        |                            | 40(36.0)                |                        |                             |
| MostFrequentDtug-relatedAEs15ofAryGrad (15. 7)                                                     | 6(61.9) in                                  | either thaatment (2.1) | 0                          | 33 9                    | FATTGLE                |                             |
|                                                                                                    | 29                                          | 6:83                   | 88 28:9 7j 195 17. (15.3)  | 4) 8                    | NAISEA                 |                             |
| MUDOGALINELAMTATION                                                                                | 4 1.7)                                      |                        | 15 (13.5)                  | 1.8)                    |                        |                             |
| ENDOORINE                                                                                          | 49 (20.6)                                   |                        |                            |                         |                        |                             |
|                                                                                                    | 3 1.3)                                      |                        | 4                          |                         |                        |                             |
| ALL-CAUGALTTYSXTBCTARS,BYCAIEGIRY                                                                  |                                             |                        | (14.4)                     | 0330121 0.9)            |                        |                             |
| PUNOERY RONRL SKTN                                                                                 |                                             | HMr4OOO                | 1.8)                       |                         |                        |                             |
| HYEERSONSITIVITY/DREUSIONREACTIONS                                                                 |                                             |                        |                            |                         |                        |                             |
| ENUORINE                                                                                           |                                             |                        |                            |                         |                        |                             |
| DRUG-RELATRDSRIROTAES,BYCATEGIRY                                                                   |                                             |                        |                            |                         |                        |                             |
|                                                                                                    | 2 77 18-8                                   |                        | 3359                       | 0.9)                    |                        |                             |
| HOATIC PUMONDRY RONeL                                                                              | 3 40 (16.9)                                 | ANNOOO 88              | 8 (12.                     |                         |                        |                             |
| SRIN                                                                                               | 1.3                                         |                        |                            | 0.9) 1.8)               |                        |                             |
| HYHERSENSTTIVITY/INEUSIONREACTIONS                                                                 |                                             |                        |                            |                         |                        |                             |
|                                                                                                    | 3                                           |                        |                            |                         |                        |                             |
|                                                                                                    |                                             |                        | 2                          |                         |                        |                             |
|                                                                                                    | (1.3)                                       |                        |                            |                         |                        |                             |
| MedLRA versicn 19.0;CTC versicn 4.0. All events are within 30 days of the last dose of study drug, |                                             |                        |                            |                         |                        |                             |
| inless ctherwise inricated.                                                                        |                                             |                        |                            |                         |                        |                             |
|                                                                                                    |                                             |                        | (1.8)                      |                         |                        |                             |
| GASTRODNTESTINAL                                                                                   |                                             |                        |                            |                         |                        |                             |
|                                                                                                    |                                             |                        |                            | 1.8 8)                  |                        |                             |
|                                                                                                    |                                             |                        |                            | （0.9)                   |                        |                             |
|                                                                                                    | GASTROINIESTDNAL HOPAMC                     |                        |                            | 2:3                     |                        |                             |
| (12 31                                                                                             |                                             |                        | C 5.                       |                         |                        |                             |
|                                                                                                    |                                             |                        |                            |                         | ANAEMTA                | ASTHDNLA                    |

in the imvestigator's choice group (Grade Spneurcnia)were assessed asrelated to stucy chugScuuce: Table S.6.58 （deaths）, Table S.6.62（a11 caLusality SAEs),Tahle S.6.64 4(dzug-related SAES) Table S.6.87 （all causality Aes lesding to DO), Table S.6.89 （dug-related PEs 1eading to DC) Table S.6.3(ell causalityAEs),TebleS.6.5(chrug-related AEs), Table S.6.12 （ell causality select AES), Tabie S.6.16 (all ceueality endbcrine select AEs),TableS.6.14 （drug-velated select AEs）, Table S.6.18 （dug-related endbcrine select AEs).

<div style=\"page-break-after: always\"></div>

## Drug-related AEs

Table 33: Drug-related AEs by Worst CTC Grade Reported in ≥ 5% of Treated Subjects in CA209141 (20-Sep-2016 database lock)

|                                                         | Nivolumeb3mg/kg N-236   | Nivolumeb3mg/kg N-236   | Nivolumeb3mg/kg N-236   | Iwetigstor's sogop N=111   | Iwetigstor's sogop N=111   | Iwetigstor's sogop N=111   |
|---------------------------------------------------------|-------------------------|-------------------------|-------------------------|----------------------------|----------------------------|----------------------------|
| Syeton Organ Clauc (o) Preferred Ten (0)                | ky Grae                 | Ge3-4                   | Grade5                  | Aay Goadk                  | Go3-4                      | Grade5                     |
| TOLAL SUBJECTS WITH AN EVENT                            | 146 (61.9)              | 36(15.3)                |                         | 88(79.3)                   | 40(36.0)                   | 1(0.9)                     |
| GENETALDISORLERSANDADMDNISTRATTONSTTE CONIITIORS        | 61 (25.6)               | 6(2.5)                  | 口                       | 50(45.0)                   | 9(6.1)                     | 口                          |
| FATTGLE ASTHENTA PUOSALDELAMATTON                       | 59T (15.7)              | 2.1)                    |                         | 859 (16-0)                 | :83 1 7                    |                            |
| SIRODNMESTDDLDISORDERS SROMRTITIS                       |                         | (1.7) (0.4) (0.4)       |                         | 63282 1                    | C 2.7)                     |                            |
| SINAND SLBLUIZNEOUS TISSLEDTSORIERS DRY SOON ALOEECTA   |                         |                         |                         | (28 .8)                    | UOHOO (4.5) (0.9)          |                            |
| METABOLISM AND MUARITION DTBORIERS TELREAGED AFRENITE   | 39 88:3                 | (4.2）                   |                         |                            | （4.5)                      |                            |
| DNESTTG-TTCNS                                           | 35 213                  | 31 2 1:3                |                         | (12.6)                     | (3.6)                      | 00                         |
| ENUOCRDEDTSORIERS HYPORHYROTDISM                        | 88                      | 10 (0.4)                |                         | 0.9) (60                   | 00                         |                            |
| ELOODAND LIMEHEIVICSYSTEM DISORLERS ANGDMTA NETIROPENLA | 920 7:13                |                         |                         | 9 (8.1)                    | （7.2)                      |                            |
| NERUOIS SYSTEMDISCRLERS NEUROBAEHYFERIRHERAL            | 3.8) 0.4)               | 1（0.4)                  |                         | 7 (15.3) 7 6.3)            | HO (0.9）                   |                            |

ChC Veroion4.0

MedlRA Versicn

19.0

Tneludesevente xeported between first doseand 30 days after last dbse ofstudy therapy.

Source:

Table

When incidence rates were exposure-adjusted, the AE rate was lower in the nivolumab group than in the investigator's choice group (2101.0 vs. 3783.9 incidence rate per 100 person years).

## Adverse Events in CA209141 and Across Pooled Monotherapy Studies

Safety  data  from  nivolumab  3  mg/kg  Q2W  monotherapy  were  pooled  across  tumour  types  (renal  cell carcinoma  [RCC,  CA209025],  melanoma  [CA209037,  CA209066,  and  CA209067],  non-small  cell  lung cancer [NSCLC, CA209063, CA209017, and CA209057]), and SCCHN (CA209141).

Exposure-adjusted AE incidence rates (events per 100 person-years of exposure) were 1607.0 in SCCHN and 1648.7, 1747.5, and 1795.6 in RCC, melanoma, and NSCLC, respectively.

No new safety concerns with nivolumab monotherapy treatment were identified in SCCHN (CA209141, 18-Dec-2015 database lock). An update of safety (20-Sep- 2016 database lock) in CA209141 Final CSR confirms that no new safety concerns with nivolumab monotherapy in SCCHN were identified (Table 34).

<div style=\"page-break-after: always\"></div>

Table 34: Adverse Events and Reactions with Nivolumab Monotherapy in Clinical Trials using Re-mapped Terms

|                                                                  | SOCHNCA209141 N=236                                              | SOCHNCA209141 N=236                                              | AllNivo MonoinclulingCA209141 N=2227                             | AllNivo MonoinclulingCA209141 N=2227                             |
|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| PreferredTerm (t)                                                | Any Grade                                                        | Grade3-4                                                         | Ary Grade                                                        | Grade3-4                                                         |
| TOTALSUBJECTSWTIHANEVENT (RECARDLESSOFCAUSALTTY)                 | 229(97.0)                                                        | 97(41.1)                                                         | 2163(97.1)                                                       | 955(42.9)                                                        |
| FATIGE                                                           | 85 (36.0)                                                        | 13 5.5)                                                          | 1076(48.3）                                                       | 89 4.0)                                                          |
| MUSOULOSKELETALPAIN                                              | 44 18.6)                                                         | 2.5)                                                             | 726(32.6)                                                        | 74 3.3)                                                          |
| HE00O                                                            | 42 17.8)                                                         | 0.4)                                                             | 558 （25.1)                                                       | 7 0.3)                                                           |
| NAUSEA                                                           | 45 19.1)                                                         | 0.4)                                                             | 535 (24.0)                                                       | 18 0.8)                                                          |
| RASH                                                             | 29 12.3)                                                         | 61102                                                            | 512 (23.0)                                                       | 1.1)                                                             |
| DIARRHOEA                                                        | 35 (14.8)                                                        | 0.8)                                                             | 501 （22.5）                                                       | 243 1.6)                                                         |
| DYSPNOEA                                                         | 35(14.8)                                                         | 13 5.5)                                                          | 458 （20.6)                                                       | 67 3.0)                                                          |
| TOTAL SUBJECTSWITHAN EVENT (DRUG-RELATED)                        | 139(58.9)                                                        | 31(13.1)                                                         | 1617(72.6)                                                       | 316(14.2)                                                        |
| Most Frequent (>10 in any grade in the pool across tumour types) | Most Frequent (>10 in any grade in the pool across tumour types) | Most Frequent (>10 in any grade in the pool across tumour types) | Most Frequent (>10 in any grade in the pool across tumour types) | Most Frequent (>10 in any grade in the pool across tumour types) |
| FATIGE                                                           | 42 (17.8)                                                        | 6（2.5)                                                           | 674(30.3）                                                        | 36(1.6)                                                          |
| RASH                                                             | 25 (10.6)                                                        | 000                                                              | 380(17.1)                                                        | 19 0.9)                                                          |
| NAUGEA                                                           | 20 8.5)                                                          |                                                                  | 278(12.5)                                                        | 3 0.1)                                                           |
| FRURITUS                                                         | 17 7.2)                                                          |                                                                  | 276(12.4)                                                        | 2 <0.1)                                                          |
| DIARRHOEA                                                        | 16 6.8)                                                          |                                                                  | 274 4(12.3)                                                      | 21 0.9)                                                          |

MedDRA Version:18.1,CIC Version4.0

Monotherapy Pooledgroup consistsofnivolumab monotherapy Lreatment group from studies CA209063,CA209017,cA209057,CA209037, CA209066,CA209067,CA209025,CA209039（cHLsubjects),CA209205,andCA20914.

Inclices eventsreported between firstdose and30cays after last dose of study therapy.

Grade3-4byworstCiCgrade.

Somepreferred terms arere-mapped orceleted based on BMSmedicalreview.

Table 35: Summary of Safety of Nivolumab Monotherapy across tumour types - All Treated Subjects

|                                                                 | SOCHN N=236                                                     | RCC N=406                                                       | Melanoma N=787                                                  | JEOSN N=535                                                     |
|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| NUMBEROF SUBJECTSWHODIED(8)                                     | 132 （55.9)                                                      | 181(44.6)                                                       | 251(31.9)                                                       | 339(63.4)                                                       |
| WITHIN 30 DAYS                                                  | 50(21.2)                                                        | 19(4.7)                                                         | 57(7.2)                                                         | 66(12.3)                                                        |
| WITHIN 100 DAYS                                                 | 103(43.6)                                                       | 56(13.8)                                                        | 151(19.2)                                                       | 181(33.8)                                                       |
| STUDY IRUG TOXICITY                                             | 2(0.8)                                                          | 0                                                               | 0.1)                                                            | 2 0.4)                                                          |
| AEs,all grades                                                  | 229 (97.0)                                                      | 397 7（97.8)                                                     | 768(97.6)                                                       | 524(97.9)                                                       |
| AEs,Grade 3-4                                                   | 97 41.1)                                                        | 216（53.2)                                                       | 319 （40.5)                                                      | 244 （45.6)                                                      |
| MOSTERDQUENILYREFORIEDAEs208ofsubjects,allgrades)               | MOSTERDQUENILYREFORIEDAEs208ofsubjects,allgrades)               | MOSTERDQUENILYREFORIEDAEs208ofsubjects,allgrades)               | MOSTERDQUENILYREFORIEDAEs208ofsubjects,allgrades)               | MOSTERDQUENILYREFORIEDAEs208ofsubjects,allgrades)               |
| FATIGUE                                                         | 62 (26.3)                                                       | 195 (48.0)                                                      | 328 (41.7)                                                      | 189 (35.3）                                                      |
| NAUSEA                                                          | 19.1)                                                           | 115 28.3)                                                       | 213 27.1)                                                       | 13                                                              |
| TECREASEDAPFETITE                                               | 18.6)                                                           | 93 22.9)                                                        | 132 16.8)                                                       |                                                                 |
| CONSTIPATION                                                    | 15.3)                                                           | 92 22:7)                                                        | 155 19.7)                                                       | 111 20.7)                                                       |
| DIARRHOEA                                                       | 14.8)                                                           | 96 23.6)                                                        | 223 28.3)                                                       | 86 16.1)                                                        |
| COUGH                                                           | 13.6)                                                           | 128 31.5)                                                       | 148 18.8)                                                       | 154 28.8)                                                       |
| DYSENOEA                                                        | 13.6)                                                           | 药 23.2)                                                         | 102 13.0)                                                       | 157 29.3)                                                       |
| ERURITUS                                                        | 8.5)                                                            | 75 18.5)                                                        | 182 23.1)                                                       | 56 10.5)                                                        |
| RASH                                                            | 20 8.5)                                                         | 64 15.8)                                                        | 176 22.4)                                                       | 09 11.2)                                                        |
| BACK PAIN                                                       | 14 5.9)                                                         | 87 21.4)                                                        | 104 （13.2）                                                      | 60 11.2)                                                        |
| DRUG-REIATFDAEs,allgrades                                       | 139(58.9)                                                       | 319(78.6)                                                       | 609(77.4)                                                       | 362(67.7)                                                       |
| IRUG-RETATED AEs,Grade3-4                                       | 31(13.1)                                                        | 76(18.7)                                                        | 108(13.7)                                                       | 59 (11.0)                                                       |
| MOSTERDQUENILYREPORIEDDRUG-RETATEDAES (108ofsubjects,allgrades) | MOSTERDQUENILYREPORIEDDRUG-RETATEDAES (108ofsubjects,allgrades) | MOSTERDQUENILYREPORIEDDRUG-RETATEDAES (108ofsubjects,allgrades) | MOSTERDQUENILYREPORIEDDRUG-RETATEDAES (108ofsubjects,allgrades) | MOSTERDQUENILYREPORIEDDRUG-RETATEDAES (108ofsubjects,allgrades) |
| FATIGUE                                                         | 33(14.0)                                                        | 134 33.0)                                                       | 230(29.2）                                                       | 105 (19.6)                                                      |
| NAUSEA                                                          | 20 8.5)                                                         | 57 14.0)                                                        | 108 (13.7)                                                      | 12.0)                                                           |
| RASH                                                            | 18 7.6)                                                         | 41 10.1)                                                        | 133 16.9)                                                       | 9259 8.4)                                                       |
| ERURITUS                                                        | 7.2)                                                            | 57 14.0)                                                        | 145 18.4)                                                       | 6.4)                                                            |
| TECREASED APFETITE                                              | 7.2)                                                            | 48 11.8)                                                        | 63 8.0)                                                         | 12.3)                                                           |
| DIARRHOEA                                                       | 16 6.8)                                                         | 50 12.3)                                                        | 135 17.2)                                                       | 44 8.2)                                                         |
| ASTHENIA                                                        | 10 4.2)                                                         | 18 4.4)                                                         | 59 7.5)                                                         | 56 (10.5)                                                       |
| ALL SAES，allgrades                                              | 127(53.8)                                                       | 194(47.8)                                                       | 319(40.5)                                                       | 263(49.2)                                                       |
| DROG-REIATFD SAES,allgrades                                     | 16(6.8)                                                         | 47(11.6)                                                        | 64(8.1)                                                         | 42(7.9)                                                         |
| ALLAESIFADINGTODC，allgrades                                     | 51(21.6)                                                        | 72(17.7)                                                        | 91(11.6)                                                        | 99（18.5)                                                        |
| DRUG-RELATFDAESIFADINGTODC,allgrades                            | 9(3.8)                                                          | 31 (7.6)                                                        | 41(5.2)                                                         | 32(6.0)                                                         |

MedIRA Version: 18.1 （SOcHN) and 18.0 (ROC, melanoma and NsCIC);CICversion 4.0;Unless stated otherwise,includes events reported between first dose and 30 days after last dose of study therapy.

Nivolumab monotherapy treatnent grouos from the following stuclies are included in the disease categories: socHN: CA209141; ROC:CA209025;Me1anCma:CA209037,CA209066,CA209067;N5CIC:CA209063,CA209017,CA209057.

Source:refer to Table 8.1-1,Table S.6.l,and Table S.6.5oftheCA209141 Final CSRfor SOcHN data.

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Serious Adverse Events (SAEs)

Table 36: Summary of SEAs by Worst CTC Grade (Any Grade, Grade 3-4, Grade 5) with 1% Cutoff - All Treated Subjects in CA209141 (20-Sep-2016 database lock)

|                                                                 | Nivolumab 3 mg/kg N=236   | Nivolumab 3 mg/kg N=236   | Nivolumab 3 mg/kg N=236   | Investigator's Choioe N=111   | Investigator's Choioe N=111   | Investigator's Choioe N=111   |
|-----------------------------------------------------------------|---------------------------|---------------------------|---------------------------|-------------------------------|-------------------------------|-------------------------------|
| System Orgen Class (3) Preferred Tem (%)                        | Any Grade                 | Gracie 3-4                | Grade 5                   | Any Grade                     | Grace 3-4                     | Grade 5                       |
| TOTALSUBJECTSWITHANEVENT                                        | 132 (55.9)                | 80 (33.9)                 | 40 (16.9)                 | 65 (58.6)                     | 45 (40.5)                     | 15 (13.5)                     |
| NEOPLASMS BENIGN, MALIGNANTAND                                  | 50 (21.2)                 | 14 ( 5.9)                 | 36 (15.3)                 | 25 (22.5)                     | 10 ( 9.0)                     | 13 (11.7)                     |
| UNSFECIFIED(INCL CYSIS AND FOLYPS) MALIGNANTNEOPLASMPROGRESSION | 46 (19.5)                 | 11 (4.7)                  | 35 (14.8)                 | 23  (20.7)                    | 10 (9.0)                      | 13 (11.7)                     |
| TUMOUR PAIN                                                     | 1 (0.4)                   | 1 (0.4)                   | 0                         | 2 (1.8)                       | 0                             | 0                             |
| INFECTIONSANDINFESTATIONS                                       | 68 (16.5)                 | (13.1)                    | 0                         | (18.9)                        | 17 (15.3)                     | 1 0.9)                        |
| PNEUMONIA                                                       | 4. 7                      | 3.8)                      |                           | 1.8)                          | (0.9)                         | (0.9)                         |
| RESPIRATORYTRACTINFECTION                                       | 2. 1)                     | 1.3)                      | 0                         | 0.91                          |                               | 10:0:0:0:00                   |
| SEPSIS                                                          |                           | 2.11                      | 0                         |                               |                               |                               |
| LUNG INFECTION                                                  | 1. 7                      | 1.3)                      |                           | 2:3                           | ( 2:3)                        |                               |
| URINARYTRACTINFECTION                                           | 1.7)                      | ( 1.3)                    | 0:00                      |                               |                               |                               |
| TEVICE RELATED INFECTION                                        | 1.3)                      | ( 0.4)                    |                           | (3:3                          |                               |                               |
| RESPIRATORY,THORACICANDMEDIASTINAL                              | 36 (15.3)                 | 33 (14.0)                 | 0                         |                               | 11 ( 9.9)                     | 0                             |
| DISORDERS                                                       |                           |                           |                           | 12 (10.8)                     |                               |                               |
| DYSPNOEA                                                        | 83583 8                   |                           | 0000:0                    | 1:83                          | (9:8                          |                               |
| FNEUMONIAASPIRATION                                             |                           |                           |                           |                               |                               |                               |
| RESPIRATORYFAILURE                                              | 78                        | 7)                        |                           |                               |                               |                               |
| PIEURALEFFUSION                                                 |                           |                           |                           | 2.71                          | 2.71                          | 0:0:00:0                      |
| RESPIRATORYDISIRESS                                             | 98421                     | 98421 0.4)                |                           | 12032 1.8)                    | 12032 1.8)                    |                               |
| METABOLISMANDNUIRITIONDISORDERS                                 | 8.1)                      | 6.8)                      |                           | 2.7)                          | 2.7)                          |                               |
| DECREASEDAPPETITE                                               | 7                         | 6                         |                           | 8.3                           | 0.9)                          |                               |
| DEHYDRATION                                                     | 3)                        |                           |                           | 3111                          | 3111 0.9)                     |                               |
| HYFERCAICAEMIA                                                  | 1.3)                      | 0.8)                      | 000:0                     | 0.9)                          | 0.9)                          | 0:0:0:0                       |
| GASTROINTESTINAL DISORDERS                                      | 2221                      |                           | 0000                      | 0) 87                         | 7132 囍                        |                               |
| ABDOMMNAL PAIN                                                  |                           |                           |                           |                               |                               | 0000                          |
| DYSEHAGIA                                                       |                           | 0.8)                      |                           |                               |                               |                               |
| DIARRHOEA                                                       | 0.4)                      | 0-20                      |                           | 2.7)                          | 1.8)                          |                               |
| GENERALDISORDERS AND AIMMNISTRATION SITE CONDITIONS             | 11 （4.7)                  | 6(2.5)                    | 0                         | 12 (10.8)                     | 7 (6.3)                       | 0                             |
| PYREXTA                                                         | C 1.3)                    | (0.4)                     | 0                         | 3.6)                          | （ 2.7)                        |                               |
| ASTHENIA                                                        | 3110 0.4)                 | 1-0 (0.4)                 |                           | 18                            | 11 16.0                       |                               |
| MALAISE                                                         | 7 （3.0)                   |                           | o0                        | 4.5)                          | (6:0                          | 000                           |
| NERVOUS SYSTEM DISORDERS                                        |                           | 5 (2.1)                   | 1（0.4）                    |                               | 3.6)                          |                               |
| DIZZINESS                                                       | 0                         | 0                         | 0                         | 1.8)                          | 0.9)                          | 0                             |
| BLOOD AND LYMPHATICSYSTEM DISORDERS                             |                           | 0                         |                           | 2.7) 1.8)                     | 32 2.7) （ 1.8)                |                               |
| ANAEMIA                                                         | 0                         |                           | 0                         |                               |                               |                               |

MscDRA Version: 19.0

CTC Version 4.0 Incluces events reported between first dose and 30days after last dose of stucdy therapy.

DataSources:AnAE,ADTM

Table 37: Drug-related SAEs by Worst CTC Grade Reported in at least 2 subjects - All Treated SubjectsCA209141 (20-Sep-2016 database lock)

| SystemOrganClass ($) Preferred Tenm (%)          | Nivolumab 3 mg/kg N236   | Nivolumab 3 mg/kg N236   | Nivolumab 3 mg/kg N236   | Investigator'sChoice N=111   | Investigator'sChoice N=111   | Investigator'sChoice N=111   |
|--------------------------------------------------|--------------------------|--------------------------|--------------------------|------------------------------|------------------------------|------------------------------|
| SystemOrganClass ($) Preferred Tenm (%)          | Any Grade                | Grade 3-4                | Grade 5                  | Any Grade                    | Grade3-4                     | Grade5                       |
| TOTALSUBJECTSWITHANEVENT                         | 17 (7.2)                 | 13 ( 5.5)                | 0                        | 17 (15.3)                    | 12 (10.8)                    | 1 ( 0.9)                     |
| RESPIRATORY,THORACICANDMEDIASTINAL DISORDERS     | 6 (2.5)                  | 5 (2.1)                  | 0                        | 1 ( 0.9)                     | 1 (0.9)                      | 0                            |
| PNEUMONITIS                                      | 2 (0.8)                  | 2 (0.8)                  | 0                        | 0                            | 0                            | 0                            |
| GENERALDISORDERSANDAIMINISTRATIONSITE CONDITIONS | 1 (0.4)                  | 0                        | 0                        | 4 ( 3.6)                     | 3 (2.7)                      | 0                            |
| MALAISE                                          | 0                        |                          | 0                        | 2 (1.8)                      | 1 (0.9)                      |                              |
| PYREXIA                                          | 0                        | 0                        | 0                        | 2( 1.8)                      | 2(1.8)                       | 00                           |
| INFECTIONSANDINEESTATIONS PNEUMONIA              | 10 (0.4)                 | 10 (0.4)                 | 00                       | 211:8                        | 118:3                        | 118:3                        |
| BLOODANDLYMPHATICSYSTEMDISORDERS ANAEMIA         | 0:0                      | 0                        | 0:0                      | 213:3                        | 211:3                        | 0:0                          |
| GASTROINIESTINALDISORDERS DIARRHOEA              | 0 0                      | 0 0                      | 0:0                      | 4 ( 3.6) 2 ( 1.8)            | 2 (1.8) 1 ( 0.9)             | 0:0                          |

MecDRA Version: 19.0

CIC Version 4.0

Includes events reported betheen first cose and 30 days after last dose of stucdy therapy.

Source:TableS.6.64

<div style=\"page-break-after: always\"></div>

## Deaths

Table 38: Summary of Deaths - All Treated Subjects in CA209141 (20-Sep-2016 database lock)

|                                                                                       | Nivolumab 3mg/kg                                                                      | Iivestigator's Choioe (=111)                                                          | Total (N347)                                                                          |
|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| NUMEER OE SUBJECTS WHO DIED (5)                                                       | 183(77.5)                                                                             | 96(86.5)                                                                              | 279(80.4)                                                                             |
| FRIMARY REASON FOR DEATH ()                                                           | FRIMARY REASON FOR DEATH ()                                                           | FRIMARY REASON FOR DEATH ()                                                           | FRIMARY REASON FOR DEATH ()                                                           |
| DISFASE                                                                               | 151 (64.0)                                                                            | 87 (78.4)                                                                             | 238 (68.6)                                                                            |
| STUDY DRUGTOXICITY（a)                                                                 | 2 (0.8)                                                                               | 12 C 0.9)                                                                             | 3 (6'0)                                                                               |
| UNKINONN                                                                              | 14 5.9)                                                                               | C 1.8)                                                                                | 16 (4.6)                                                                              |
| OTHER                                                                                 | 16 (6.8)                                                                              | 6 5.4)                                                                                | 22 (6.3)                                                                              |
| NUBER OE SUBJECTS WHO DTED                                                            | NUBER OE SUBJECTS WHO DTED                                                            | NUBER OE SUBJECTS WHO DTED                                                            | NUBER OE SUBJECTS WHO DTED                                                            |
| WITHIN 30 DAYS OF LASTDOSE （O)                                                        | 52(22.0)                                                                              | 21(18.9)                                                                              | 73(21.0)                                                                              |
| FRIMARY REASON EOR DEATH (O）                                                          | FRIMARY REASON EOR DEATH (O）                                                          | FRIMARY REASON EOR DEATH (O）                                                          | FRIMARY REASON EOR DEATH (O）                                                          |
| DISEASE                                                                               | 40 (16.9)                                                                             | 19 17                                                                                 | 59 (17.0)                                                                             |
| STUDYDRUG TOXICITY                                                                    | 1 （0.4)                                                                               | 1 0                                                                                   | 21 0.6)                                                                               |
| UNKINONN                                                                              | 1 0.4)                                                                                |                                                                                       | 0.3)                                                                                  |
| OTHER                                                                                 | 10 4.2)                                                                               | 1 0.9)                                                                                | 11 3.2)                                                                               |
| NUMBEROE SUBJECTS WHO DIED WITHIN1OO DAYSCEIAST DOSE(O) 109(46.2) 58 (52.3) 167(48.1) | NUMBEROE SUBJECTS WHO DIED WITHIN1OO DAYSCEIAST DOSE(O) 109(46.2) 58 (52.3) 167(48.1) | NUMBEROE SUBJECTS WHO DIED WITHIN1OO DAYSCEIAST DOSE(O) 109(46.2) 58 (52.3) 167(48.1) | NUMBEROE SUBJECTS WHO DIED WITHIN1OO DAYSCEIAST DOSE(O) 109(46.2) 58 (52.3) 167(48.1) |
| FRIMARYREASON FOR DEATH (S) DISEASE                                                   | 89 (37.7)                                                                             | 53 (47.7)                                                                             | 142 (40.9)                                                                            |
| STUDY DRUG TOXICITY                                                                   | 2 (0.8)                                                                               | 1 (0.9)                                                                               | 3 （0.9)                                                                               |
| UNKINONN                                                                              | 3 1.3)                                                                                | 0                                                                                     | 3 0.9)                                                                                |
| OTHER                                                                                 | 15 6.4)                                                                               | 4 3.6)                                                                                | 19 5.5)                                                                               |

Scurce: Teble S.6.58

drug-

As of the 20-Sep-2016 database lock, two deaths in the nivolumab group (grade 3 pneumonitis and grade 5 hypercalcemia) were assessed as study drug-related, versus one death in the investigator's choice group (docetaxel, grade 5 pneumonia).

## Select adverse events / adverse events of special interest

The  majority  of  select  AEs  reported  were  Grade  1-2,  and  most  were  considered  drug-related  by  the investigator. The most frequently reported any-grade drug-related select AE categories with nivolumab treatment were skin (16.9%), endocrine (9.3%), and gastrointestinal (8.5%).

## Endocrine Events

The endocrine select AE category included the following subcategories: adrenal disorders, diabetes, pituitary disorders, and thyroid disorders.

Two Grade 3-4 events (hypophysitis and secondary adrenocortical insufficiency) were reported, both in the same subject, and 1 event (hypophysitis) led to permanent discontinuation of nivolumab. This event was ongoing at the time of database lock.

<div style=\"page-break-after: always\"></div>

Table 39: Summary of Drug-related Endocrine Select Adverse Events Reported Up to 30 days After Last Dose - All Treated Subjects - CA209141 (20-Sep-2016 database lock)

|                                           | Nivolumab 3 mg/kg N=236   | Nivolumab 3 mg/kg N=236   | Nivolumab 3 mg/kg N=236   | Iivestigator's Choice N=-111   | Iivestigator's Choice N=-111   | Iivestigator's Choice N=-111   |
|-------------------------------------------|---------------------------|---------------------------|---------------------------|--------------------------------|--------------------------------|--------------------------------|
| Subcategory(%) PreferredTerm (%)          | Any Grade                 | Grade3-4                  | Grade5                    | Any Grade                      | Grade3-4                       | Grade5                         |
| TOTALSUBJECTSWITHANEVENT                  | 22(9.3)                   | 1(0.4)                    | 0                         | 1(0.9)                         | 0                              | 0                              |
| THYROID DISORDER                          | 8.9)                      | 000                       | 00                        | 11O                            | 000                            | 00                             |
| HYEOTHYROIDISM                            | 5.9)                      |                           |                           | 8:3                            |                                |                                |
| BLOODTHYROIDSTIMULATING HORMONE INCREASED | 3 3(1.3)                  |                           |                           |                                |                                | 0                              |
| HYPERTHYROIDISM                           | 321 (1.3)                 | 000                       | 0                         |                                |                                | 0:00                           |
| THYROIDITIS                               | 0.8)                      |                           |                           |                                | 00                             |                                |
| THYROIDFUNCTIONTESTABNORMAL               | 0.4)                      |                           | 00                        | 000                            |                                |                                |
| PITUITARYDISORDER                         | 21 (0.8)                  | 1 0.4)                    | 000                       |                                |                                |                                |
| HYPOEHYSTTIS                              | (0.4)                     | 1 (0.4)                   |                           |                                |                                |                                |
| HYPOPITUITARISM                           | 1(0.4)                    | 10                        |                           | 000                            | 00:0                           | 000                            |
| ADRENALDISORIER                           | 1(9.4)                    |                           | 0:0                       | 00                             |                                |                                |
| SECONDARYADRENOOORTICAL INSUEFICTENCY     | 1 (8.3)                   | ( 8:4)                    |                           |                                | 0                              | 0                              |

MedIRA Version: 19.0

CTC Version 4.0

Source:Table S.6.18

o  e e

## Gastrointestinal Events

As of the 20-Sep-2016 database lock for CA209141, gastrointestinal select AEs (all-causality, any grade) were reported in 43 subjects (18.2%) in the nivolumab group and 26 subjects (23.4%) in the investigator's choice group.

In the nivolumab group, 20 subjects (8.5%) had GI select AEs that were considered to be drug-related by the investigator (Table 40). In the nivolumab group, all drug-related events were diarrhoea and all were Grade 1-2 except for 1 Grade 3 event; 1 Grade 1-2 events led to permanent discontinuation of nivolumab.

Table 40: Summary of Drug-related Gastrointestinal Select Adverse Events Reported Up to 30 days After Last Dose - All Treated Subjects - CA209141 (20-Sep-2016 database lock)

|                          | Nivolumab 3 mg/kg N=236   | Nivolumab 3 mg/kg N=236   | Nivolumab 3 mg/kg N=236   | Investigator'sChoice N=111   | Investigator'sChoice N=111   | Investigator'sChoice N=111   |
|--------------------------|---------------------------|---------------------------|---------------------------|------------------------------|------------------------------|------------------------------|
| Preferred Term (%)       | Any Grade                 | Grade3-4                  | Grade5                    | Any Grade                    | Grade3-4                     | Grade5                       |
| TOTALSUBJECTSWITHANEVENT | 20(8.5)                   | 1(0.4)                    | 0                         | 17 (15.3)                    | 2(1.8）                       | 0                            |
| DTARRHOEA COLITIS        | 20(8.5) 0                 | 1 (0.4) 0                 |                           | 16(14.4) 1(0.9               | 2 (1.8) 0                    |                              |

MedIRA Version:19.0; CTC Version 4.0; Includes events reported between first dose and 30 days afterlastdose ofstucly therapy.

Soulrce:TableS.6.14

## Hepatic Events

As of the 20-Sep-2016 database lock for CA209141, hepatic select AEs (all-causality, any grade) were reported in 26 subjects (11.0%) in the nivolumab group and 12 subjects (10.8%) in the investigator's choice group.

<div style=\"page-break-after: always\"></div>

In the nivolumab group, 7 subjects (3.0%) had hepatic select AEs considered to be drug-related by the investigator (Table 41) most drug-related events were Grade 1-2; two subjects had Grade 3-4 drug-related events. The 2 Grade 3-4 drug-related events led to permanent discontinuation of nivolumab.

Table 41: Summary of Drug-related Hepatic Select Adverse Events Reported Up to 30 days After Last Dose All Treated Subjects - CA209141 (20-Sep-2016 database lock )

|                                                                     | Nivolumab3mg/kg N=236   | Nivolumab3mg/kg N=236   | Nivolumab3mg/kg N=236   | Investigator's Choice N=111   | Investigator's Choice N=111   | Investigator's Choice N=111   |
|---------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------------|-------------------------------|-------------------------------|
| Preferred Tenm($)                                                   | Any Grade               | Grade3-4                |                         | Grade5Any Grade               | Grade3-4Grade5                |                               |
| TOTAISUBJECTSWITHANEVENT                                            | 7(3.0)                  | 2(0.8)                  | 0                       | 5（4.5)                        | 1(0.9)                        | 0                             |
| ASPARTATEAMTNOTRANSFERASEINCREASED ALANINEAMTNOTRANSFERASEINCREASED | 3)                      | (0.4)                   |                         | ww #12:3                      | 01000 (0.9)                   |                               |
| BTOODAIKALINEPHOSEHATASEINCREASED TRANSAMINASESINCREASED            | 4332110 1.3) (8.0       | 0101010 (0.4)           | 0000000                 | 000                           |                               | 0000000                       |
| BIOODBILIRUBININCREASED                                             | 0.4)                    |                         |                         |                               |                               |                               |
| LIVEREUNCTIONTESTINCREASED                                          | 0.4)                    | (0.4)                   |                         | 0                             | 0                             |                               |
| GAMMA-GTUTAMYTTRANSFERASEINCREASED                                  |                         |                         |                         | 1 (0.9)                       | 1 (0.9)                       |                               |
| HEPATICENZYMEINCREASED                                              | 0                       | 0                       | 0                       | 1 0.9)                        | 0                             | 0                             |

MedDRA Version:19.0

CICVersion 4.0

Includes events reported between first dose and 30 days after last dose of studly therapy. Source:Table S.6.14

## Pulmonary Events

As of the 20-Sep-2016 database lock for CA209141, pulmonary select AEs (all-causality, any grade) were reported in 10 subjects (4.2%) in the nivolumab group and 2 subjects (1.8%) in the investigator's choice group.

In the nivolumab group, 7 subjects (3.0%) had pulmonary select AEs considered to be drug-related by the investigator (Table 42). The majority drug-related events were pneumonitis. Two subjects had Grade 3-4 events, 1 of which led to death. Two drug-related pulmonary select AEs led to permanent discontinuation (one of which led to death) of nivolumab (refer to subheading 'Deaths' for a narrative of this death).

Table 42: Summary of Drug-related Pulmonary Select Adverse Events Reported Up to 30 days After Last Dose - All Treated Subjects- CA209141 (20-Sep-2016 database lock)

|                          | Nivolumab3mg/kg N=236   | Nivolumab3mg/kg N=236   | Nivolumab3mg/kg N=236   | Investigator'sChoice N=111   | Investigator'sChoice N=111   | Investigator'sChoice N=111   |
|--------------------------|-------------------------|-------------------------|-------------------------|------------------------------|------------------------------|------------------------------|
| Preferred Term ($)       | Any Grade               | Grade3-4Grade5          |                         | Any Grade                    | Grade3-4                     | Grade5                       |
| TOTALSUBJECTSWITHANEVENT | 7(3.0)                  | 2(0.8)                  |                         | 1(0.9)                       | 0                            | 0                            |
| ENEUMONITIS              | 51 (2.1)                |                         | 00                      | 1 (0.9)                      | 00                           | 0:0                          |
| INIERSTITIALLUNG DISEASE | 0.4）                    |                         |                         | 0                            |                              |                              |

MedLRA Versicn:19.0

CIC Version 4.0

Includes events reported between first dose andl 30 days after last dose of study therapy. In the nivolumab group, 1 Grade 3 crug-related event of pneumonitis led to death (see Section 7.1). Source:TableS.6.14

## Renal Events

As  of  the  20-Sep-2016  database  lock  for  CA209141,  renal  select  AEs  (all-causality,  any  grade)  were reported in 9 subjects (3.8%) in the nivolumab group and 2 subjects (1.8%) in the investigator's choice group.

<div style=\"page-break-after: always\"></div>

In the nivolumab group, 3 (1.3%) subjects had a renal select AE (2 blood creatinine increased and one acute kidney injury) that were considered to be drug-related by the investigator (Table 43). These events were Grade 1-2 and did not lead to permanent discontinuation of nivolumab.

Table 43: Summary of Drug-related Renal Select Adverse Events Reported Up to 30 days After Last Dose - All Treated Subjects- CA209141 (20-Sep-2016 database lock)

|                          | Nivolumab3mg/kg N=236   | Nivolumab3mg/kg N=236   | Nivolumab3mg/kg N=236   | Investigator'sChoice N=111   | Investigator'sChoice N=111   | Investigator'sChoice N=111   |
|--------------------------|-------------------------|-------------------------|-------------------------|------------------------------|------------------------------|------------------------------|
| Preferred Tenm (%)       | Any Grade               |                         | Grade3-4Grade5          | Any Grade                    | Grade3-4                     | Grade5                       |
| TOTALSUBJECTSWITHANEVENT | 3(1.3)                  | 0                       | 0                       | 2(1.8)                       | 1(0.9)                       | 0                            |
| BLOODCREATININEDNCREASED | 2(0.8)                  | 0                       | 0                       | 0                            | 0                            |                              |
| ACUIEKIINEYINJURY        | 1(0.4)                  |                         |                         | 2(1.8)                       | 1(0.9)                       |                              |

MecTRA Version:19.0

CTC Version 4.0

In the nivolumab group,1 Grade 3 drug-related eventofpneumonitisled to death (see Section 7.1). Source:TableS.6.14

As of the 20-Sep-2016 database lock for CA209141, skin select AEs (all-causality, any grade) were reported in 49 subjects (20.8%) in the nivolumab group and 16 subjects (14.4%) in the investigator's choice group.

In the nivolumab group, 40 subjects (16.9%) had skin select AEs considered to be drug-related by the investigator (Table 44). The most frequently reported drug-related events were rash and pruritus. There was no event of toxic epidermal necrolysis reported. All of the drug-related events were Grade 1-2 and none led to permanent discontinuation of nivolumab.

Table 44: Summary of Drug-related Skin Select Adverse Events Reported Up to 30 days After Last Dose - All Treated Subjects CA209141 (20-Sep-2016 database lock)

|                                            | Nivolumab3mg/kg N=236   | Nivolumab3mg/kg N=236   | Investigator'sChoice N=111   | Investigator'sChoice N=111   | Investigator'sChoice N=111   | Investigator'sChoice N=111   |
|--------------------------------------------|-------------------------|-------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
| Preferred Term($)                          | Any Grace               | Grade 3-4 Grade5        | Any Grace                    | Grade3-4                     | Grade5                       |                              |
| TOTALSUBJECTSWITHANEVENT                   | 40(16.9)                | 0                       | 14 (12.6)                    | 2(1.8)                       | 0                            |                              |
| ERURITUS                                   | 19 8.1)                 | 0                       | 0510400                      | 0                            | 0                            |                              |
| RASH                                       | 8.1)                    |                         |                              | 1 (0.9)                      |                              |                              |
| RASHMACULO-PAFULAR                         | 2.1)                    | 0:0                     | 6:3                          | 0                            |                              |                              |
| ECZEMA                                     | 0.8)                    |                         |                              | D                            | 0                            |                              |
| ERYTHEMA                                   | 0.8)                    |                         | (3.6)                        | 1 (0.9)                      | 0                            |                              |
| SKINEXFOLTATION                            | 0.8)                    |                         |                              | 00                           |                              |                              |
| EXFOLTATTVERASH                            | 0.4)                    | 000                     |                              |                              | 00                           |                              |
| PAIMAR-PLANTAR ERYTHRODYSAESTHESIASYNLROME | 0.4)                    |                         | 2 (1.8)                      | 1 (0.9)                      | 0                            |                              |
| RASH MACULAR                               | 1 (0.4)                 |                         | 1 (0.9)                      | 0                            |                              |                              |
| URTICARIA                                  | (0.4)                   |                         |                              | 00                           |                              |                              |
| TERMATITIS                                 | 10                      | 00                      | 2 (1.8)                      |                              | 0                            |                              |

MecIRA Version: 19.0

CICVersion 4.0

Source:TableS.6.14

Includes events reported between first dose and 30 days after last dose of studly therapy.

## Hypersensitivity/Infusion Reactions

As of the 20-Sep-2016 database lock for CA209141, hypersensitivity/infusion reactions (all-causality, any grade)  were  reported  in  3  subjects  (1.3%)  in  the  nivolumab  group  and  2  subjects  (1.8%)  in  the investigator's choice group.

All  of  the  infusion  reaction  events  in  the  nivolumab  group  were  considered  to  be  drug-related  by  the investigator (Table 45). All drug-related events were infusion-related reactions, all were Grade 1-2, and none led to permanent discontinuation of nivolumab.

<div style=\"page-break-after: always\"></div>

Table 45: Summary of Drug-related Hypersensitivity/Infusion Reactions Reported Up to 30 days After Last Dose - All Treated Subjects (20-Sep-2016 database lock)

|                          | Nivolumab3mg/kg N=236   | Nivolumab3mg/kg N=236   | Nivolumab3mg/kg N=236   | Investigator'sChoioe N=111   | Investigator'sChoioe N=111   | Investigator'sChoioe N=111   |
|--------------------------|-------------------------|-------------------------|-------------------------|------------------------------|------------------------------|------------------------------|
| PreferredTerm(%)         | Any Grade               | Grade3-4Grade5          |                         | Any Grade                    | Grade3-4                     | Garade5                      |
| TOTALSUBJECTSWITHANEVENT | 3(1.3)                  | 0                       | 0                       | 2(1.8)                       | 1.(0.9)                      | 0                            |
| INFUSIONRELATEDREACTION  | 3(1.3)                  |                         |                         | 2(1.8)                       | 1.(0.9)                      |                              |

MedIRA Version:19.0

CTCVersion 4.0

Source:TableS.6.14

## Safety to Support the Product Information

Safety data to support Section 4.8 of the SmPC were integrated across completed studies in multiple indications using the intended dose and regimen for nivolumab monotherapy. The studies included in the analyses of nivolumab monotherapy (3 mg/kg Q2W) were as follows:

- HNSCC: CA209141

- cHL: CA209205 Cohort A+B+C + CA209039 all cHL

- RCC: CA209025

• Melanoma: CA209037, CA209066, and CA209067 (monotherapy arm)

- NSCLC: CA209057, CA209017, and CA209063

Table 46: Frequencies of Adverse Reactions included in Section 4.8 of the SmPC - Nivolumab Monotherapy Studies

| ADR a,b,c                                                                | No. of Subjects                                                          | %of subjects                                                             | Designation of frequency                                                 |
|--------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Total no. of nivolumab-monotherapy treated subjects = 2227               | Total no. of nivolumab-monotherapy treated subjects = 2227               | Total no. of nivolumab-monotherapy treated subjects = 2227               | Total no. of nivolumab-monotherapy treated subjects = 2227               |
| Infections and infestations                                              | Infections and infestations                                              | Infections and infestations                                              | Infections and infestations                                              |
| Upper respiratory tract infection                                        | 22                                                                       | (1.0)                                                                    | Common                                                                   |
| Pneumonia                                                                | 15                                                                       | (0.7)                                                                    | Uncommon                                                                 |
| Bronchitis                                                               | 4                                                                        | (0.2)                                                                    | Uncommon                                                                 |
| Neoplasms benign, malignant and unspecified (including cysts and polyps) | Neoplasms benign, malignant and unspecified (including cysts and polyps) | Neoplasms benign, malignant and unspecified (including cysts and polyps) | Neoplasms benign, malignant and unspecified (including cysts and polyps) |
| Histiocytic necrotising lymphadenitis (Kikuchi                           |                                                                          |                                                                          |                                                                          |
| lymphadenitis)                                                           | 1                                                                        | <0.1                                                                     | Rare                                                                     |
| Blood and lymphatic system disorders                                     | Blood and lymphatic system disorders                                     | Blood and lymphatic system disorders                                     | Blood and lymphatic system disorders                                     |
| Eosinophilia                                                             | 5                                                                        | (0.2)                                                                    | Uncommon                                                                 |
| Immune system disorders                                                  | Immune system disorders                                                  | Immune system disorders                                                  | Immune system disorders                                                  |
| Infusion related reaction                                                | 77                                                                       | (3.5)                                                                    | Common                                                                   |
| Anaphylactic reaction                                                    | 2                                                                        | <0.1                                                                     | Rare                                                                     |
| Hypersensitivity                                                         | 35                                                                       | (1.6)                                                                    | Common                                                                   |
| Endocrine disorders                                                      | Endocrine disorders                                                      | Endocrine disorders                                                      | Endocrine disorders                                                      |
| Hypothyroidism                                                           | 134 41                                                                   | (6.0) (1.1) (0.4) (0.3)                                                  | Common Common Common Uncommon Uncommon Uncommon Uncommon                 |
| Hyperthyroidism                                                          |                                                                          | (1.8)                                                                    |                                                                          |
| Hyperglycaemia                                                           | 25                                                                       |                                                                          |                                                                          |
| Adrenal insufficiency                                                    | 10                                                                       |                                                                          |                                                                          |
| Hypopituitarism                                                          | 5                                                                        | (0.2)                                                                    |                                                                          |
| Hypophysitis                                                             | 6                                                                        |                                                                          |                                                                          |
| Thyroiditis                                                              | 13                                                                       | (0.6)                                                                    |                                                                          |
| Diabetic ketoacidosis                                                    | 2                                                                        | <0.1                                                                     | Rare                                                                     |
| Diabetes mellitus                                                        | 1                                                                        | <0.1                                                                     | Rare                                                                     |
| Metabolism and nutrition disorders                                       | Metabolism and nutrition disorders                                       | Metabolism and nutrition disorders                                       | Metabolism and nutrition disorders                                       |
| Decreased appetite                                                       | 202                                                                      | (9.1)                                                                    | Common                                                                   |
| Dehydration                                                              | 12                                                                       | (0.5)                                                                    | Uncommon                                                                 |
| Metabolic acidosis                                                       | 3                                                                        | (0.1)                                                                    | Uncommon                                                                 |
| Hepatobiliary disorders                                                  | Hepatobiliary disorders                                                  | Hepatobiliary disorders                                                  | Hepatobiliary disorders                                                  |
| hepatitis                                                                | 5                                                                        | (0.2)                                                                    | Uncommon                                                                 |
| hyperbilirubinemia                                                       | 3                                                                        | (0.1)                                                                    | Uncommon                                                                 |
| cholestasis                                                              | 2                                                                        | <0.1                                                                     | Rare                                                                     |

<div style=\"page-break-after: always\"></div>

| ADR a,b,c                                                           | No. of Subjects                                                     | %of subjects                                                        | Designation of frequency                                            |
|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| Nervous system disorders                                            | Nervous system disorders                                            | Nervous system disorders                                            | Nervous system disorders                                            |
| Peripheral neuropathy                                               | 47                                                                  | (2.1)                                                               | Common                                                              |
| Headache                                                            | 93                                                                  | (4.2)                                                               | Common                                                              |
| Dizziness                                                           | 45                                                                  | (2.0)                                                               | Common                                                              |
| Polyneuropathy                                                      | 3                                                                   | (0.1)                                                               | Uncommon                                                            |
| Guillain-Barré                                                      |                                                                     |                                                                     |                                                                     |
| syndrome                                                            | 1                                                                   | <0.1                                                                | Rare                                                                |
| Demyelination Myasthenic                                            | 1 1                                                                 | <0.1 <0.1                                                           | Rare                                                                |
| syndrome Autoimmune neuropathy                                      |                                                                     |                                                                     | Rare                                                                |
| (including facial and abducens                                      |                                                                     |                                                                     |                                                                     |
| nerve paresis)                                                      | 2                                                                   | <0.1                                                                | Rare                                                                |
| Eye disorders                                                       |                                                                     |                                                                     |                                                                     |
| Vision blurred                                                      | 18                                                                  | (0.8)                                                               | Uncommon                                                            |
| Dry eye                                                             | 20                                                                  | (0.9)                                                               | Uncommon                                                            |
| Uveitis                                                             | 9                                                                   | (0.4)                                                               | Uncommon                                                            |
| Cardiac disorders                                                   |                                                                     |                                                                     |                                                                     |
| Tachycardia                                                         | 8                                                                   | (0.4)                                                               | Uncommon                                                            |
| Arrhythmia (including                                               |                                                                     |                                                                     | Rare                                                                |
| ventricular arrhythmia) Atrial fibrillation                         | 1 1                                                                 | <0.1 <0.1                                                           | Rare                                                                |
| Vascular disorders                                                  |                                                                     |                                                                     |                                                                     |
| Hypertension                                                        | 27                                                                  | (1.2)                                                               | Common                                                              |
| Vasculitis                                                          | 2                                                                   | <0.1                                                                | Rare                                                                |
| Respiratory, thoracic and mediastinal disorders                     | Respiratory, thoracic and mediastinal disorders                     | Respiratory, thoracic and mediastinal disorders                     | Respiratory, thoracic and mediastinal disorders                     |
| Pneumonitis                                                         | 66                                                                  | (3.0)                                                               | Common                                                              |
| Dyspnoea                                                            | 101                                                                 | (4.5)                                                               | Common                                                              |
| Cough                                                               | 108                                                                 | (4.8)                                                               | Common                                                              |
| Pleural effusion                                                    | 6                                                                   | (0.3)                                                               | Uncommon                                                            |
| Lung infiltration                                                   | 1                                                                   | <0.1                                                                | Rare                                                                |
| Gastrointestinal disorders                                          |                                                                     |                                                                     |                                                                     |
| Diarrhoea                                                           | 274                                                                 | (12.3)                                                              | Very common                                                         |
| Nausea                                                              | 278                                                                 | (12.5)                                                              | Very common                                                         |
| Colitis                                                             | 20                                                                  | (0.9)                                                               | Uncommon                                                            |
| Stomatitis                                                          | 68                                                                  | (3.1)                                                               | Common                                                              |
|                                                                     | 122                                                                 |                                                                     |                                                                     |
| Vomiting                                                            |                                                                     | (5.5)                                                               | Common                                                              |
| Abdominal pain                                                      | 81                                                                  | (3.6)                                                               | Common                                                              |
| Constipation                                                        | 108                                                                 | (4.8)                                                               | Common                                                              |
| Dry mouth                                                           | 58                                                                  | (2.6)                                                               | Common                                                              |
| Pancreatitis                                                        | 7                                                                   | (0.3)                                                               | Uncommon                                                            |
| Gastritis                                                           | 2                                                                   | <0.1                                                                | Rare                                                                |
| Duodenal                                                            | 1                                                                   | <0.1                                                                | Rare                                                                |
| ulcer Skin and subcutaneous tissue disorders                        | ulcer Skin and subcutaneous tissue disorders                        | ulcer Skin and subcutaneous tissue disorders                        | ulcer Skin and subcutaneous tissue disorders                        |
| Rash                                                                | 380                                                                 | (17.1)                                                              | Very common                                                         |
| Pruritus                                                            | 276                                                                 | (12.4)                                                              | Very common                                                         |
| Vitiligo                                                            | 69                                                                  | (3.1)                                                               | Common                                                              |
| Dry skin                                                            | 87                                                                  | (3.9)                                                               | Common                                                              |
| Erythema                                                            | 38                                                                  |                                                                     | Common                                                              |
|                                                                     |                                                                     | (1.7)                                                               |                                                                     |
| Alopecia                                                            | 25                                                                  | (1.1)                                                               | Common                                                              |
| Erythema multiforme                                                 | 3                                                                   | (0.1)                                                               | Uncommon                                                            |
| Psoriasis Rosacea                                                   | 3 3                                                                 | (0.1) (0.1)                                                         | Uncommon Uncommon                                                   |
|                                                                     |                                                                     | (0.4)                                                               |                                                                     |
| Urticaria                                                           | 9                                                                   |                                                                     | Uncommon                                                            |
| Toxic epidermal necrolysis                                          | 2                                                                   | <0.1                                                                | Rare                                                                |
| Musculoskeletal and connective tissue disorders                     | Musculoskeletal and connective tissue disorders                     | Musculoskeletal and connective tissue disorders                     | Musculoskeletal and connective tissue disorders                     |
| Musculoskeletal pain                                                | 161                                                                 | (7.2)                                                               | Common                                                              |
| Arthralgia                                                          | 128                                                                 | (5.7)                                                               | Common                                                              |
| Polymyalgia rheumatica                                              | 3                                                                   | (0.1)                                                               | Uncommon                                                            |
| Arthritis                                                           | 21                                                                  | (0.9)                                                               | Uncommon Rare                                                       |
| Myopathy 1 <0.1 disorders                                           | Myopathy 1 <0.1 disorders                                           | Myopathy 1 <0.1 disorders                                           | Myopathy 1 <0.1 disorders                                           |
| Renal and urinary Tubulointerstitial nephritis                      | 4                                                                   | (0.2)                                                               | Uncommon                                                            |
| Renal failure (including acute                                      | 15                                                                  | (0.7)                                                               | Uncommon                                                            |
| kidney injury) General disorders and administration site conditions | kidney injury) General disorders and administration site conditions | kidney injury) General disorders and administration site conditions | kidney injury) General disorders and administration site conditions |
| Fatigue                                                             | 674                                                                 | (30.3)                                                              | Very common                                                         |
| Pyrexia                                                             | 128                                                                 | (5.7)                                                               | Common                                                              |
| Oedema (including peripheral oedema)                                | 67                                                                  | (3.0)                                                               | Common                                                              |
| Pain                                                                | 18                                                                  | (0.8)                                                               | Uncommon                                                            |

<div style=\"page-break-after: always\"></div>

| ADR a,b,c                                                                                                                                                                                                                                                                                    | No. of Subjects                                                                                           | %of subjects                                                                        | Designation of frequency                                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| Chest pain                                                                                                                                                                                                                                                                                   | 18                                                                                                        | (0.8)                                                                               | Uncommon                                                                                                                                        |
| Investigations Increased AST Increased ALT Increased alkaline phosphatase Increased lipase Increased amylase Increased creatinine lymphocyte absolute (lymphopaenia) leukocyte absolute (leucopenia) platelet count (thrombocytopenia) haemoglobin (B) (anemia) Hypercalcaemia Hyperkalaemia | 570/2151 456/2160 520/2148 169/871 100/752 430/2167 881/2155 316/2175 274/2169 772/2169 227/2076 396/2112 | (26.5) (21.1) (24.2) (19.4) (13.3) (19.8) (40.9) (14.5) (12.6) (35.6) (10.9) (18.8) | Very common Very common Very common Very common Very common Very common Very common Very common Very common Very common Very common Very common |

MedDRA Version: 18.1, CTC Version 4.0

Includes events reported between first dose and 30 days after last dose of study therapy

Unless otherwise noted, some preferred terms are re-mapped or deleted based on BMS medical review.

Monotherapy  Pooled  group  consists  of  nivolumab  monotherapy  treatment  group  from  studies  CA209063,  CA209017,  CA209057, CA209037, CA209066, CA209067, CA209025, CA209039 (cHL subjects), CA209205, and CA209141

This event frequency comes from an unmapped output.

This event frequency is based on all causality output.

Includes events autoimmune neuropathy (1/2227), VIth nerve paralysis (1/2227), and VIIth nerve paralysis (0/2227)

Includes events acute kidney injury (9/2227) and renal failure (6/2227)

## Laboratory findings

Among all treated subjects, any grade shifts from baseline value were reported within 30 days of last dose for selected laboratory tests including absolute neutrophils, haemoglobin, leukocytes, lymphocytes, platelet count, ALP, total bilirubin, AST, ALT, creatinine, and thyroid stimulating hormone (TSH).

## Haematology

Abnormalities in haematology tests performed during treatment or within 30 days of last dose of study drug were primarily Grade 1-2 in the nivolumab and investigator's choice groups.

- In the nivolumab group, the only Grade 3-4 haematologic abnormalities reported in ≥5% of treated subjects with on-treatment laboratory results were decreased haemoglobin (8.4% Grade 3 only) and decreased absolute lymphocytes (30% Grade 3; 3.6% Grade 4).
- In the investigator's choice group, the only Grade 3-4 hematologic abnormalities reported in ≥5% of subjects were decreased haemoglobin (11.5% Grade 3 only), decreased leukocytes (6.7% Grade 3 only), decreased lymphocytes (41.3% Grade 3; 8.7% Grade 4), and decreased neutrophil count (5.8% Grade 3; 1.9% Grade 4).

Treated subjects who experienced a ≥2-grade shift from baseline to a Grade 3 or 4 hematologic abnormality are summarized in Table 47.

<div style=\"page-break-after: always\"></div>

Table  47:  Subjects  Who  Experienced  a  ≥  2-Grade  Shift  From  Baseline  to  a  Grade  3  or  4  Hematologic Abnormality - All Treated Subjects in CA209141

|               | Nivolumab (N=236)   | Nivolumab (N=236)    | Nivolumab (N=236)    | Investigator's Choice (N=111)   | Investigator's Choice (N=111)   | Investigator's Choice (N=111)   |
|---------------|---------------------|----------------------|----------------------|---------------------------------|---------------------------------|---------------------------------|
|               |                     | Worst Toxicity Grade | Worst Toxicity Grade |                                 | Worst Toxicity Grade            | Worst Toxicity Grade            |
|               | Baseline            | Grade 3              | Grade 4              | Baseline                        | Grade 3                         | Grade 4                         |
| Hemoglobin    | Grade 0             | 0                    | NA                   | Grade 0                         | 0                               | NA                              |
|               | Grade 1             | 13 (5.5)             | NA                   | Grade 1                         | 7 (6.3)                         | NA                              |
|               | Grade 2             |                      | NA                   | Grade 2                         |                                 | NA                              |
| Leucocytes    | Grade 0             | 2 (0.8)              | 1 (0.4)              | Grade 0                         | 7 (6.3)                         | 0                               |
|               | Grade 1             | 0                    | 0                    | Grade 1                         | 0                               | 0                               |
|               | Grade 2             |                      | 0                    | Grade 2                         |                                 | 0                               |
| Lymphocytes   | Grade 0             | 4 (1.7)              | 0                    | Grade 0                         | 0                               | 0                               |
| (Absolute)    | Grade 1             | 7 (3.0)              | 2 (0.8)              | Grade 1                         | 11 (9.9)                        | 0                               |
|               | Grade 2             |                      | 4 (1.7)              | Grade 2                         |                                 | 5 (4.5)                         |
| Neutrophils   | Grade 0             | 1 (0.4)              | 0                    | Grade 0                         | 6 (5.4)                         | 2 (1.8)                         |
|               | Grade 1             | 0                    | 0                    | Grade 1                         | 0                               | 0                               |
|               | Grade 2             |                      | 0                    | Grade 2                         |                                 | 0                               |
| PlateletCount | Grade 0             | 0                    | 0                    | Grade 0                         | 0                               | 2 (1.8)                         |
|               | Grade 1             | 0                    | 1 (0.4)              | Grade 1                         | 0                               | 0                               |
|               | Grade 2             |                      | 0                    | Grade 2                         |                                 | 0                               |

Percentages in eachgroup are out of all treatedsubjects(n=236nivolumaband n=111 investigator's choice). Per anemia criteriainCTCVersion 4.0 thereisnoGrade 4for hemoglobin.

Source:RefertoTableS.7.3-SIoftheCA209141CSR

## Serum Chemistry

## Liver parameters

Treated subjects who experienced a ≥2-grade shift from baseline to a Grade 3 or 4 laboratory abnormalities are summarized in Table 48.

Table 48: Subjects Who Experienced a ≥2-Grade Shift From Baseline to a Grade 3 or 4 Liver Test Abnormality - All Treated Subjects in CA209141

|             | Nivolumab(N=236)   | Nivolumab(N=236)   | Nivolumab(N=236)   | Investigator'sChoice(N=1l1)   | Investigator'sChoice(N=1l1)   | Investigator'sChoice(N=1l1)   |
|-------------|--------------------|--------------------|--------------------|-------------------------------|-------------------------------|-------------------------------|
|             |                    | WorstToxicityGrade | WorstToxicityGrade |                               | WorstToxicityGrade            | WorstToxicityGrade            |
|             | Bascline           | Grade 3            | Gradc 4            | Bascline                      | Gradc3                        | Gradc 4                       |
| ALT         | Grade 0            | 2 (0.8)            | 0                  | Grade 0                       | 0                             | 0                             |
|             | Grade 1            | 0                  | 0                  | Grade 1                       | 1 (0.9)                       | 0                             |
|             | Grade 2            |                    | 0                  | Grade 2                       |                               | 0                             |
| Alkaline    | Grade 0            | 2 (0.8)            | 0                  | Grade 0                       | 0                             | 0                             |
| Phosphatase | Grade 1            | 1 (0.4)            | 0                  | Grade 1                       | 0                             | 0                             |
|             | Grade 2            |                    | 0                  | Grade 2                       |                               | 0                             |
| AST         | Grade 0            | 1 (0.4)            | 1 (0.4)            | Grade 0                       | 0                             | 0                             |
|             | Grade 1            | 2 (0.8)            | 0                  | Grade 1                       | 0                             | 0                             |
|             | Grade 2            |                    | 0                  | Grade 2                       |                               | 0                             |
| Bilirubin   | Grade 0            | 1 (0.4)            | 0                  | Grade 0                       | 0                             | 1 (0.9)                       |
| (Total)     | Grade 1            | 0                  | 0                  | Grade 1                       | 0                             | 0                             |
|             | Grade 2            |                    | 0                  | Grade 2                       |                               | 0                             |

Percentagcsincachgrouparcoutofalltrcatedsubjects(n=236nivolumabandn=111invcstigator'schoice).

Source:RefertoTableS.7.3-SIoftheCA209141CSR

A summary of on-treatment laboratory abnormalities is provided in Table 49.

<div style=\"page-break-after: always\"></div>

Table 49: Summary of On-Treatment Laboratory Abnormalities in Specific Liver Tests (SI Units) - All Treated Subjects in CA209141

| Lab Test Toxicity Grade                                                  | Nivolumab 3 mg/kg (N=236)   | Imvestigator's Choice (N=111)   | Total (N=347)   |
|--------------------------------------------------------------------------|-----------------------------|---------------------------------|-----------------|
|                                                                          | N = 220                     | N=98                            | N = 318         |
| ALTORAST>3XULN                                                           | 10 (4.5)                    | 5 (5.1)                         | 15 (4.7)        |
| ALT OR AST > 5XULN                                                       | 4 (1.8)                     | 2 (2.0)                         | 6 (1.9)         |
| ALTOR AST>10XULN                                                         | 2 (0.9)                     | 0                               | 2 (0.6)         |
| ALTOR AST>20XULN                                                         | 1 (0.5)                     | 0                               | 1 (0.3)         |
|                                                                          | N = 220                     | N = 97                          | N = 317         |
| TOTALBILIRUBIN>2XULN                                                     | 3 (1.4)                     | 2 (2.1)                         | 5 (1.6)         |
|                                                                          | N = 220                     | N=98                            | N = 318         |
| CONCURRENT(WITHINONEDAY）ALTORAST ELEVATION>3XULNWITHTOTALBILIRUBIN>2XULN | 2 (0.9)                     | 0                               | 2 (0.6)         |
| CONCURRENT(WITHIN3ODAYS)ALTORAST ELEVATION>3XULNWITHTOTALBILIRUBIN>2XUIN | 2 (0.9)                     | 0                               | 2 (0.6)         |

Denominator corresponds to subjects with at least one on-treatment measurement of the corresponding laboratory parameter.

Includes laboratory results reported after the first dose and within 30 days of last dose of study therapy.

=   =    o investigator' s choice) .

## Renal parameters

In the nivolumab and investigator's choice groups, the majority of subjects with at least 1 on treatment measurement had normal creatinine values during the treatment reporting period. In both groups, reported abnormalities in creatinine (increases) were all Grade 1 or 2. No Grade 3 or 4 abnormalities were reported. In  both  groups,  no  subjects  experienced  a  ≥2-grade  shift  from  baseline  to  a  Grade  3  or  4  laboratory abnormality in creatinine.

## Thyroid function tests

The majority of subjects in both groups had normal TSH levels at baseline and throughout the treatment period (Table 50). The proportion of subjects with TSH increases (&gt; ULN) or decreases (&lt; LLN) from baseline was slightly higher in the nivolumab group than the investigator's choice group.

<div style=\"page-break-after: always\"></div>

Table 50: Summary of On-Treatment Laboratory Abnormalities in Specific Thyroid Tests - (SI Units) Treated Subjects with at Least One On-Treatment TSH in CA209141

|                                                                                                                                | Nivolumab 3 mg/kg (N=236)   | Investigator's Choice (N=111)   | Total (N=347)                |
|--------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------------------|------------------------------|
| TSH > ULN TSH > ULN                                                                                                            | 107 (45.3)                  | 39 (35.1)                       | 146 (42.1)                   |
| WITH TSH<=ULN AT BASELINE TSH > ULN                                                                                            | 43 (18.2)                   | 14 (12.6)                       | 57 (16.4)                    |
| WITH AT LEAST ONE FT3/FT4 TEST VALUE < LIN _(a) WITH ALL OTHER FT3/FT4 TEST VALUES >= LIN (a) WITH FT3/FT4 TEST MISSING (a)(b) | 67 (28.4) 33±(14.0)         | 16 (14.4) 16 (14.4) 7 (6.3)     | 83 (23.9) 49 (14.1) 14 (4.0) |
|                                                                                                                                | 7 (3.0)                     |                                 |                              |
| TSH < LIN                                                                                                                      | 39 (16.5)                   | 13 (11.7)                       | 52 (15.0)                    |
| TSH< LIN WITH TSH >= LIN AT BASELINE TSH < LIN                                                                                 | 32 (13.6)                   | 10 (9.0)                        | 42 (12.1)                    |
| WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN (a) WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN (a) WITH FT3/FT4 TEST MISSING (a)(b)  | 16 (6.8)                    | 3 (2.7) 9 8.1)                  | 19 (5.5)                     |
|                                                                                                                                | 20 ( 8.5)                   |                                 | 29 8.4)                      |
|                                                                                                                                | 3 (1.3)                     | 1 (0.9)                         | 4(1.2)                       |

investigator' s choice).

(a)Within a 2-week window after the abnormal TSH test date.

Includes laboratory results reported after the first dose and within 30 days of last dose of study therapy.

(b) Includes subjects with TSH abnormality and with no FT3/Fr4 test values in the 2-week window or with non-abnormal value(s)from only one of the two tests and no value from the other test.

## Electrolytes

In the nivolumab and investigator's choice groups, most subjects had normal electrolyte levels during the treatment reporting period. In both groups, abnormalities in electrolytes during treatment were primarily Grade 1 to 2 in severity. In both groups, the only Grade 3-4 abnormality in electrolytes reported in ≥5% of treated subjects with on-treatment laboratory results was hyponatremia (nivolumab: 10.7% Grade 3,0.9% Grade 4; investigator's choice: 14.4% Grade 3, 1.0% Grade 4).

<div style=\"page-break-after: always\"></div>

Table 51: Subjects Who Experienced a ≥2-Grade Shift From Baseline to a Grade 3 or 4 Electrolyte Abnormality - All Treated Subjects in CA209141

|                 | Nivolumab (N=236)   | Nivolumab (N=236)    | Nivolumab (N=236)    | Investigator's Choice (N=111)   | Investigator's Choice (N=111)   | Investigator's Choice (N=111)   |
|-----------------|---------------------|----------------------|----------------------|---------------------------------|---------------------------------|---------------------------------|
|                 |                     | Worst Toxicity Grade | Worst Toxicity Grade |                                 | Worst Toxicity Grade            | Worst Toxicity Grade            |
|                 | Baseline            | Grade 3              | Grade 4              | Baseline                        | Grade 3                         | Grade 4                         |
| Hypernatremia   | Grade 0             | 0                    | 1 (0.4)              | Grade 0                         | 0                               | 0                               |
|                 | Grade 1             | 0                    | 0                    | Grade 1                         | 0                               | 1 (0.9)                         |
|                 | Grade 2             |                      | 0                    | Grade 2                         |                                 | 0                               |
| Hyponatremia    | Grade 0             | 13 (5.5)             | 0                    | Grade 0                         | 8 (7.2)                         | 1 (0.9)                         |
|                 | Grade 1             | 8 (3.4)              | 2 (0.8)              | Grade 1                         | 6 (5.4)                         | 0                               |
|                 | Grade 2             |                      | 0                    | Grade 2                         |                                 | 0                               |
| Hypermagnesemia | Grade 0             | 1 (0.4)              | 0                    | Grade 0                         | 0                               | 0                               |
|                 | Grade 1             | 0                    | 0                    | Grade 1                         | 0                               | 0                               |
|                 | Grade 2             |                      | 0                    | Grade 2                         |                                 | 0                               |
| Hypomagnesemia  | Grade 0             | 0                    | 0                    | Grade 0                         | 0                               | 0                               |
|                 | Grade 1             | 1 (0.4)              | 0                    | Grade 1                         | 0                               | 0                               |
|                 | Grade 2             |                      | 0                    | Grade 2                         |                                 | 0                               |
| Hypercalcemia   | Grade 0             | 2 (0.8)              | 1 (0.4)              | Grade 0                         | 1 (0.9)                         | 0                               |
|                 | Grade 1             | 1 (0.4)              | 1(0.4)               | Grade 1                         | 0                               | 0                               |
|                 | Grade 2             | \"                    | 0                    | Grade 2                         |                                 | 0                               |
| Hypocalcemia    | Grade 0             | 0                    | 1 (0.4)              | Grade 0                         | 0                               | 0                               |
|                 | Grade 1             | 0                    | 0                    | Grade 1                         | 0                               | 0                               |
|                 | Grade 2             |                      | 0                    | Grade 2                         |                                 | 0                               |
| Hyperkalemia    | Grade 0             | 1 (0.4)              | 0                    | Grade 0                         | 0                               | 0                               |
|                 | Grade 1             | 0                    | 0                    | Grade 1                         | 0                               | 0                               |
|                 | Grade 2             |                      | 0                    | Grade 2                         |                                 | 0                               |
| Hypokalemia     | Grade 0             | 1 (0.4)              | 1 (0.4)              | Grade 0                         | 1 (0.9)                         | 0                               |
|                 | Grade 1             | 0                    | 0                    | Grade 1                         | 2 (1.8)                         | 0                               |
|                 | Grade 2             |                      | 0                    | Grade 2                         |                                 | 0                               |

Percentages in each group are out ofalltreated subjects (n= 236 nivolumab and n= 111 investigator's choice).

## Safety in special populations

In CA209141, the frequencies of all-causality and drug-related AEs in the nivolumab group for subgroups of gender, race, age, and region were similar to the AE frequencies in the overall treated population. Small numerical differences in frequencies of AEs were observed in nivolumab-treated subjects:

- Any-grade and Grade 3-4 drug-related AEs for male (60.8% and 13.9%) vs female (50.0% and 9.5%).
- No Grade 3-4 AEs were reported in the 'other' race group, and all causality and drug-related Grade 3-4 AEs ranged from 30.0% to 43.8% and 10.0% to 14.1%, respectively, in the rest of the race groups.
- A greater frequency of all causality Grade 3-4 AEs were reported in Europe (45.4%) vs. North America (39.8%) or Rest of World (30.0%). The frequency of drug-related (any grade) AEs reported was lower in Europe (51.9%) vs. North America (63.3%) or Rest of World (70.0%).
- Grade 3-4 AEs, all causality and drug-related, reported in subjects &lt; 75 years of age were greater than those &gt; 75 years of age.
- -All causality and drug-related Grade 3-4 AEs in subjects &lt; 65 years: 40.5% and 13.7%
- -All causality and drug-related Grade 3-4 AEs in subjects 65 to &lt; 75 years: 44.6% and 12.5%
- -All causality and drug-related Grade 3-4 AEs in subjects ≥75 years of age: 33.3% and 8.3%

In CA209141, the frequency of total AEs, AEs leading to discontinuation, and AEs by MedDRA High-level Group Term (HLGT)/SMQs/SOC by age group are presented in Table 52:

<div style=\"page-break-after: always\"></div>

Table 52: Summary of Safety Results by Age Group- All Treated Subjects in CA209141

|                                                                                     | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   |
|-------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| MedDRA Terms                                                                        | Age<65 years (N =168)    | Age 65-74 years (N = 56) | Age 75-84 years (N =12)  | Age 85+ years (N=0)      |
| Total AEs                                                                           | 165 (98.2)               | 54 ( 96.4)               | 10 ( 83.3)               | 0                        |
| Serious AEs -Total                                                                  | 91 (54.2)                | 32 ( 57.1)               | 4(33.3)                  | 0                        |
| Fatal                                                                               | 38 (22.6)                | 15 (26.8)                | 1 ( 8.3)                 | 0                        |
| Hospitalization/prolong existing hospitalization                                    | 79 ( 47.0)               | 25 ( 44.6)               | 4 (33.3)                 | 0                        |
| Life-threatening                                                                    | 2 ( 1.2)                 | 0                        | 0                        | 0                        |
| Cancer                                                                              | 0                        | 1( 1.8)                  | 0                        | 0                        |
| Disability/incapacity                                                               | 0                        | 0                        | 0                        | 0                        |
| AEs leading to drop-out                                                             | 34 (20.2)                | 14 (25.0)                | 3 (25.0)                 | 0                        |
| Psychiatric disorders                                                               | 31 (18.5)                | 8 ( 14.3)                | 0                        | 0                        |
| Nervous system disorders                                                            | 24 ( 33.8)               | 8 (22.2)                 | 1 (25.0)                 | 0                        |
| Accidents and Injuries                                                              | 2 ( 2.8)                 | 2 ( 5.6)                 | 0                        | 0                        |
| Cardiac disorders                                                                   | 8 (11.3)                 | 4 (11.1)                 | 2 ( 50.0)                | 0                        |
| Vascular disorders                                                                  | 8 (11.3)                 | 6 (16.7)                 | 1 (25.0)                 | 0                        |
| Central nervoussystemvascular disorders                                             | 2(1.2)                   | 1( 1.8)                  | 2 (16.7)                 | 0                        |
| Infections and infestations                                                         | 61 (36.3)                | 23 ( 41.1)               | 4 (33.3)                 | 0                        |
| Anticholinergic syndrome                                                            | 56 (33.3)                | 22 (39.3)                | 5 (41.7)                 | 0                        |
| Quality of life decreased                                                           | 0                        | 0                        | 0                        | 0                        |
| Sum of postural hypotension,falls, blackouts, syncope, dizziness, ataxia, fractures | 11 ( 6.5)                | 2 ( 3.6)                 | 0                        | 0                        |

MedDRA Version: 18.0; CTC version 4.0

Abbreviations: AE: adverse event; HLGT: MedDRA High-Level Group Term; MedDRA: Medical Dictionary for Regulatory Activities; SMQ: Standardized MedDRA Queries; SAE: serious adverse event; SOC: System Organ Class.

Includes events reported between first dose and 30 days after last dose of study therapy.

## Safety by age Across Integrated Monotherapy Studies Including CA209141

Nivolumab  monotherapy  integrated  across  indications  (SCCHN,  cHL,  RCC,  melanoma,  and  NSCLC)  is presented in Table 53. Frequencies of SAEs, AEs leading to dropout, and postural hypotension increased slightly with increasing age.

<div style=\"page-break-after: always\"></div>

Table 53: Summary of On-treatment AEs by Age Group - All Treated Subjects - Nivolumab Monotherapy Data Integrated across Indications including CA209141

|                                                                                      | Number of Subjects (%)                     | Number of Subjects (%)                     | Number of Subjects (%)                     | Number of Subjects (%)                     |
|--------------------------------------------------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
|                                                                                      | MonotherapyDataIntegratedAcrossIndications | MonotherapyDataIntegratedAcrossIndications | MonotherapyDataIntegratedAcrossIndications | MonotherapyDataIntegratedAcrossIndications |
| MedDRA Terms                                                                         | Age < 65 years (N =1469)                   | Age 65-74 years (N = 560)                  | Age 75-84 years (N =177)                   | Age 85+ years (N = 21)                     |
| Total AEs                                                                            | 1425 (97.0)                                | 546 ( 97.5)                                | 172 (97.2)                                 | 21 (100.0)                                 |
| Serious AEs -Total                                                                   | 592 ( 40.3)                                | 268 (47.9)                                 | 86 ( 48.6)                                 | 12 ( 57.1)                                 |
| Fatal                                                                                | 142 ( 9.7)                                 | 60 (10.7)                                  | 22 ( 12.4)                                 | 3 (14.3)                                   |
| Hospitalization/prolong existing hospitalization                                     | 524 (35.7)                                 | 234 (41.8)                                 | 77 ( 43.5)                                 | 8 (38.1)                                   |
| Life-threatening                                                                     | 22 ( 1.5)                                  | 7(1.3)                                     | 2( 1.1)                                    | 0                                          |
| Cancer                                                                               | 13 ( 0.9)                                  | 12 ( 2.1)                                  | 9( 5.1)                                    | 1 ( 4.8)                                   |
| Disability/incapacity                                                                | 1 (<0.1)                                   | 1 (0.2)                                    | 0                                          | 0                                          |
| AEs leading to drop-out                                                              | 187 (12.7)                                 | 91 (16.3)                                  | 41 ( 23.2)                                 | 5 (23.8)                                   |
| Psychiatric disorders                                                                | 253 (17.2)                                 | 86 ( 15.4)                                 | 26 ( 14.7)                                 | 6 (28.6)                                   |
| Nervous system disorders                                                             | 496 ( 33.8)                                | 189 ( 33.8)                                | 60 ( 33.9)                                 | 13 (61.9)                                  |
| Accidents and injuries                                                               | 95 ( 6.5)                                  | 48 ( 8.6)                                  | 16( 9.0)                                   | 3 (14.3)                                   |
| Cardiac disorders                                                                    | 125 ( 8.5)                                 | 55 ( 9.8)                                  | 14 (7.9)                                   | 5 (23.8)                                   |
| Vascular disorders                                                                   | 215 ( 14.6)                                | 101 (18.0)                                 | 28 ( 15.8)                                 | 9 (42.9)                                   |
| Central nervous system vascular disorders                                            | 19 ( 1.3)                                  | 22 ( 3.9)                                  | 5 ( 2.8)                                   | 1 ( 4.8)                                   |
| Infections and infestations                                                          | 554 ( 37.7)                                | 240 ( 42.9)                                | 66 ( 37.3)                                 | 11 ( 52.4)                                 |
| Anticholinergic syndrome                                                             | 496 ( 33.8)                                | 182 ( 32.5)                                | 61 (34.5)                                  | 9 (42.9)                                   |
| Quality of life decreased                                                            | 0                                          | 0                                          | 0                                          | 0                                          |
| Sum of postural hypotension, falls, blackouts, syncope, dizziness, ataxia, fractures | 139 ( 9.5)                                 | 70 ( 12.5)                                 | 24 ( 13.6)                                 | 4 (19.0)                                   |

Nivolumab treatment group consists of nivolumab monotherapy treatment group from studies CA209063, CA209017,CA209057, CA209037,CA209066,CA209067, CA209025, CA209039 (cHL subjects),CA209205 and CA209141.

## Mental Ability

Nivolumab has minor influence on the ability to drive and use machines. Fatigue is a very common side effect which may also impair the ability to drive and use machines. Patients should be advised not to drive or use machines if they feel tired.

## Safety related to drug-drug interactions and other interactions

No new information.

## Discontinuation due to adverse events

The overall frequency of AEs (regardless of causality) leading to a dose delay or reduction was 29.2% in the nivolumab group and 45.9% in the investigator's choice group.

The overall frequencies of all-causality AEs leading to discontinuation were similar between the treatment groups;  however,  the  frequencies  of  drug-related  AEs  leading  to  discontinuation  were  lower  in  the nivolumab group than in the investigator's choice group.

<div style=\"page-break-after: always\"></div>

Table 54: Summary of Adverse Events Leading to Discontinuation by Worst CTC Grade (Any Grade, Grade 3-4, Grade 5) - All Treated Subjects - CA209141 (20-Sep-2016 database lock)

|                                                                   | Nivolumab 3 mg/kg N=236   | Nivolumab 3 mg/kg N=236   | Nivolumab 3 mg/kg N=236   | Investigator's Choice N=111   | Investigator's Choice N=111   | Investigator's Choice N=111   |
|-------------------------------------------------------------------|---------------------------|---------------------------|---------------------------|-------------------------------|-------------------------------|-------------------------------|
| System Organ Class (%) Preferred Term (%)                         | Any Grace                 | Grade 3-4                 | Gradle 5                  | Any Grade                     | Grade 3-4                     | Grade 5                       |
| TOTALSUBJECTS WITHANEVENT                                         | 55 (23.3)                 | 37 (15.7)                 | 14 ( 5.9)                 | 25 (22.5)                     | 13 (11.7)                     | 4 ( 3.6)                      |
| NEOPLASMSBENIGN,MALIGNANTAND                                      | 20 ( 8.5)                 | 9 ( 3.8)                  | 10 ( 4.2)                 | 5 ( 4.5)                      | 2 (1.8)                       | 3 (2.7)                       |
| UNSPECIFIED (INCL CYSTS AND POLYPS) MALIGNANTNEOPLASM PROGRESSION | 18 (7.6)                  | 7 (3.0)                   | 10 ( 4.2)                 | 5 ( 4.5)                      | 2 (1.8)                       | 3 ( 2.7)                      |
| MALIGNANT PLEURALEFFUSION                                         | 1 (0.4)                   | 1 ( 0.4)                  | 0                         | 0                             | 0                             | 0                             |
| TUMOUR HAFMORRHAGE                                                | 1 (0.4)                   | 1 ( 0.4)                  | 0                         | 0                             | 0                             | 0                             |
|                                                                   | 6 (2.5)                   | 6 (2.5)                   | 0                         | 3 ( 2.7)                      | 3 ( 2.7)                      | 0                             |
| FNEUMONIA                                                         | 3 (1.3)                   | 3 (1.3)                   | 0                         | 2 ( 1.8)                      | 2 (1.8)                       | 0                             |
| RESPIRATORY TRACT INFECTION                                       | 2 (0.8)                   | 2 (0.8)                   | 0                         | 0                             | 0                             | 0                             |
| INFECTION                                                         | 1 (0.4)                   | 1 (0.4)                   | 0                         | 0                             | 0                             | 0                             |
| SEPTIC SHOCK                                                      | 1 (0.4)                   | 1 ( 0.4)                  | 0                         | 0                             | 0                             | 0                             |
| SEPSIS                                                            | 0                         | 0                         |                           | 1 (0.9)                       | 1 (0.9)                       | 0                             |
| RESPIRATORY,THORACICANDMEDIASTINAL DISORDERS                      | 6 (2.5)                   | 4 ( 1.7)                  | 0                         | 5 ( 4.5)                      | 2 (1.8)                       | 0                             |
| FNEUMONIA ASPIRATION                                              | 2 (0.8)                   | 2 (0.8)                   | 0                         | 0                             | 0                             | 0                             |
| FNEUMONITIS                                                       | 2 (0.8)                   | (0.4)                     | 0                         | 1 (0.9)                       | 0                             | 0                             |
| DYSPNOEA                                                          | 1 (0.4)                   | 0                         | 0                         | 0                             | 0                             | 0                             |
| PUIMONARY EMBOLISM                                                | 1 (0.4)                   | 1 ( 0.4)                  | 0                         | 0                             | 0                             | 0                             |
| RESPIRATORY DISTRESS                                              | 1 (0.4)                   | (0.4) 0                   | 0                         | 0 1 (0.9)                     | 0                             | 0 0                           |
| BRONCHOENEUMOPATHY                                                |                           |                           | 0                         |                               | 1 (0.9)                       |                               |
| LARYNGEAL OEDEMA                                                  | 0                         | 0                         | 0                         | 1 (0.9)                       |                               | 0                             |
| PLEURAL EFFUSION                                                  | 0                         | 0                         | 0                         | 1 ( 0.9)                      | 1 (0.9)                       | 0                             |
| PUIMONARY TOXICITY                                                | 0                         | 0                         | 0                         | 1 ( 0.9)                      | 0                             | 0                             |
| GENERALDISORDERSANDAIMINISTRATIONSITE CONDITIONS                  | 4 ( 1.7)                  | 4 ( 1.7)                  | 0                         | 3 ( 2.7)                      | 0                             | 0                             |
| ASTHENIA                                                          | 1 ( 0.4)                  | 1 ( 0.4)                  | 0                         | 0                             | 0                             |                               |

<div style=\"page-break-after: always\"></div>

Table  55  Drug-related  AEs  Leading  to  Discontinuation  by  Worst  CTC  Grade  -  All  Treated  Subjects  CA209141 (CA209141 Final CSR, 20-Sep-2016 database lock)

|                                                                                                                                | Nivolumab 3 mg/kg N=236           | Nivolumab 3 mg/kg N=236            | Nivolumab 3 mg/kg N=236   | Investigator's Choice N=111                   | Investigator's Choice N=111   | Investigator's Choice N=111   | Investigator's Choice N=111   |
|--------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|------------------------------------|---------------------------|-----------------------------------------------|-------------------------------|-------------------------------|-------------------------------|
| System Organ Class (%) Preferred Term (%)                                                                                      | Any Grade                         | Grade 3-4                          | Grade 5                   | Any Grade                                     | Grade 3-4                     | Grade 5                       | Grade 5                       |
| TOTALSUBJECTSWITHANEVENT                                                                                                       | 9 (3.8)                           | 7 (3.0)                            | 0                         | 10 (9.0)                                      | 6 (5.4)                       | 0                             | 0                             |
| INVESTIGATIONS AMYLASE INCREASED LIPASE INCREASED LIVER FUNCTION TEST INCREASED TRANSAMINASESINCREASED HEPATICENZYME INCREASED | 3 1.3) 0.4) ( 0.4) 1 0.4) (0.4)   | 3 1.3) 1 0.4) 1 0.4) 0.4) 1 0.4) 0 | 0 0 0 0 0                 | 1 (0.9) 0 0 0 0                               | 0 0 0 0 0                     | 0                             | 0                             |
| RESPIRATORY,THORACICANDMEDIASTINAL DISORDERS PUIMONARY TOXICITY                                                                | 0 2 (0.8) 2 (0.8) 0:0 (0.4) (0.4) | 1 (0.4) 1 (0.4) 0:0 1 0.4) 1 0.4)  | 0 0 0 0 0                 | 1 ( 0.9) 3 ( 2.7) 1 (0.9) 1 ( 0.9) (6.0 0:0:0 | 0 1 (0.9) 0 1 (0.9) 0 0:0     | 0 0 0 0                       | 0 0 0 0                       |
| GASTROINIESTINALDISORDERS DIARRHOEA METABOLISMANDNUIRITIONDISORDERS HYPERCAICAEMTA                                             | 1 ( 0.4) 1 18:3 1 (0.4)           | 1 ( 0.4) 00 1 (0.4) 1 ( 0.4)       | 0 0 0:0 0 0               | 0:0 0:0 0 0                                   | 0 0:0 0:0                     | 0:0                           | 0:0                           |
| SKINANDSUBCUTANEOUS TISSUEDISORDERS SKIN MASS                                                                                  |                                   | 0 0                                | 0 0 0                     | 0.9) 1 9.97 1 (6:0                            | 1 (0.9) 0:0 0                 |                               |                               |
| BLOODANDLYMPHATICSYSTEMDISORDERS ANAEMIA                                                                                       | 000 0                             | 0 0 0                              | 0 0                       | 1 0.9) 2  (1.8) 1 0.9)                        | (1.8) 0.9)                    | 0                             | 0                             |
| LEUKOFENIA                                                                                                                     | 0                                 | 0 0                                | 0                         | 1(8.9) 1 ( 0.9)                               |                               | 0                             | 0                             |
| GENERALDISORIERSANDAIMINISTRATIONSITE                                                                                          | 0                                 | 0                                  |                           |                                               | 0                             |                               |                               |
|                                                                                                                                |                                   |                                    | 0                         |                                               |                               | 0                             | 0                             |
| CONDITIONS                                                                                                                     | 0                                 | 0                                  |                           | 1 ( 0.9)                                      |                               |                               |                               |
| MALAISE                                                                                                                        | 0                                 | 0 0                                | 0 0                       |                                               | 2 ( 1.8)                      |                               |                               |
| PIEURAL EFFUSION                                                                                                               |                                   |                                    |                           |                                               | 1 (0.9)                       |                               |                               |
|                                                                                                                                | 0                                 |                                    |                           |                                               |                               |                               |                               |
| ENDOCRINE DISORIERS HYFOPHYSITIS SECONDARY HYFOTHYROIDISM                                                                      |                                   | 0                                  | 0                         | 1 (0.9)                                       |                               |                               |                               |
| IMMUNE SYSTEMDISORDERS                                                                                                         |                                   |                                    |                           |                                               |                               |                               |                               |
| ALIERGIC GRANULOMATOUSANGIITIS                                                                                                 | 1 8:4                             | 1 (9.4) 1 ( 8.4)                   |                           |                                               | 0                             |                               |                               |
|                                                                                                                                |                                   |                                    | 0 0                       |                                               | 0                             | 0                             | 0                             |
|                                                                                                                                |                                   |                                    |                           | 2                                             |                               |                               |                               |
|                                                                                                                                | 1 (0.4)                           |                                    | 0                         | (1.8)                                         |                               | 0                             | 0                             |
|                                                                                                                                | 1 (0.4)                           |                                    |                           |                                               | 0                             |                               |                               |
| ONYCHOLYSIS                                                                                                                    | 1 (0.4)                           |                                    |                           |                                               |                               |                               |                               |
|                                                                                                                                |                                   |                                    |                           |                                               | 1 (0.9)                       | 0                             | 0                             |
| ONYCHOMADESIS                                                                                                                  |                                   |                                    | 0                         |                                               |                               | 0                             | 0                             |
| RASH                                                                                                                           |                                   |                                    |                           |                                               |                               |                               |                               |
|                                                                                                                                |                                   |                                    |                           |                                               |                               | 0                             | 0                             |
| SKIN DISORIER                                                                                                                  |                                   |                                    |                           |                                               |                               |                               |                               |
|                                                                                                                                | 0                                 | 0                                  |                           |                                               |                               | 0                             | 0                             |
|                                                                                                                                |                                   |                                    |                           |                                               | 0                             | 0                             | 0                             |
|                                                                                                                                |                                   |                                    |                           | 2 (1.8)                                       | 2 (1.8)                       | 0                             | 0                             |
| INFECTIONS AND INFESTATIONS                                                                                                    |                                   |                                    |                           | 2 ( 1.8)                                      |                               | 0                             | 0                             |
| PNEUMONIA                                                                                                                      |                                   |                                    |                           |                                               |                               |                               |                               |
|                                                                                                                                |                                   |                                    |                           |                                               |                               | 0                             | 0                             |
| COMPLICATIONS                                                                                                                  |                                   |                                    |                           |                                               |                               |                               |                               |
|                                                                                                                                |                                   |                                    | 0                         |                                               | 1 ( 0.9)                      |                               |                               |
|                                                                                                                                |                                   |                                    |                           | 1 ( 0.9)                                      |                               |                               |                               |
|                                                                                                                                | 0                                 |                                    |                           |                                               |                               |                               |                               |
| INJURY，FOISONING AND PROCEDURAL                                                                                                |                                   |                                    |                           |                                               |                               |                               |                               |
|                                                                                                                                |                                   |                                    |                           |                                               |                               | 0                             | 0                             |
| INFUSION RELATED REACTION                                                                                                      |                                   |                                    |                           |                                               |                               |                               |                               |
|                                                                                                                                |                                   | 0                                  |                           |                                               |                               |                               |                               |
|                                                                                                                                | 0                                 |                                    |                           |                                               |                               |                               |                               |

MecDRA Version: 19.0

CTC Version 4.0

Source: Table S.6.89

- 3.4% of subjects in the nivolumab group had an infusion interruption. Of the subjects who required an infusion interruption, all had only 1 infusion interrupted. Infusion interruptions were more frequent with cetuximab (30.8% of subjects).

1.7% of subjects in the nivolumab group had an infusion rate reduction. Infusion rate reductions were slightly more frequent with methotrexate (6.5% of subjects).

Dose delays of nivolumab were more frequent than cetuximab and less frequent than methotrexate and docetaxel. 36.4%, 23.1%, 50.0%, and 57.7% of subjects had at least one dose delayed of nivolumab, cetuximab, methotrexate, and docetaxel, respectively. Most subjects with dose delay only experienced only 1.

In  the  investigator's  choice  group,  7.7%,  28.3%,  and  26.9%  of  subjects  required  a  dose  reduction  of cetuximab, methotrexate, or docetaxel, respectively.

## Immunogenicity

In CA209141, the incidence of nivolumab ADA was low and did not appear to have an effect on the safety of nivolumab. Of the 148 SCCHN subjects who were evaluable for ADA, 13 (8.8%) subjects were ADA positive.

<div style=\"page-break-after: always\"></div>

No subjects were persistent positive, and one subject (0.7%) was neutralizing ADA positive. Of all subjects who were evaluable for ADA, none experienced hypersensitivity/infusion reaction category events.

An integrated analysis of immunogenicity assessments was performed with data available from the following studies:  CA209037,  CA209063,  CA209066,  CA209017,  CA209067  (nivolumab  monotherapy  arm), CA209025,  CA209039,  CA209205,  and  CA209141.  No  clear  association  was  established  between  the presence of ADA and hypersensitivity or infusion reactions, suggesting nivolumab ADA does not alter the safety profile of nivolumab (see also section 2.3.3 of this AR).

## Post marketing experience

No new significant safety concerns were identified based on the postmarketing reports.

Nivolumab was first approved on 4 July 2014 in Japan for unresectable melanoma and has since been approved in multiple countries, including the US and the EU, and for other indications (e.g. metastatic NSCLC, advanced RCC). Based on pharmacovigilance activities conducted by BMS Global Pharmacovigilance and Epidemiology, review of postmarketing safety data is consistent with, and confirms the clinical trial safety data for nivolumab. The safety profile of nivolumab in the postmarketing setting remains favourable and similar to the profile established during clinical trials. To date, no new significant safety concerns have been identified based on global postmarketing reports. Postmarketing data for nivolumab are subject to continued active pharmacovigilance monitoring and are reported as per applicable post-marketing safety reporting requirements, as well as periodically to global health authorities.

## 2.5.1. Discussion on clinical safety

Study CA209141 is the main safety dataset supporting this application. Safety data in this application support the use of nivolumab at the proposed dose and schedule of 3 mg/kg administered as an IV infusion Q2W for the treatment of patients with recurrent or metastatic SCCHN relapsing or progressing on or within 6 months of the last dose of a platinum-based therapy.

The overall safety profile of nivolumab was consistent with the safety profile of nivolumab monotherapy previously observed in other tumour types, and no new safety concerns were identified in this study.

Any-grade AEs (regardless of causality) were reported in 98.3% of subjects in the nivolumab group and 98.2% of subjects in the investigator's choice group. In the nivolumab group, the most frequently reported AEs were fatigue (28.4%), nausea (21.2%), anaemia (20.3%), decreased appetite (19.5%), malignant neoplasm progression (19.5%), and constipation (15.7%). Grade 3-4 AEs (regardless of causality) were reported in 47.9% of subjects in the nivolumab group and 62.2% of subjects in the investigator's choice group. In the nivolumab group, the most frequently reported Grade 3-4 AEs were anaemia (6.4%), dyspnoea (5.5%), hyponatremia (4.7%), pneumonia (4.7%) and malignant neoplasm progression (4.7%).

The overall frequency of drug-related any-grade AEs was lower in the nivolumab group (61.9%) compared with the investigator's choice group (79.3%). In the nivolumab group, the most frequently reported drug-related AEs were nausea (9.3%), diarrhoea (8.5%), rash (8.1%), pruritus (8.1%), decreased appetite (8.1%), and anaemia (5.1%). Furthermore, grade ≥3 drug-related AEs were reported much less frequently in the nivolumab group than in the investigator's choice group (15.3% vs. 36.9%, respectively). In the nivolumab group, the most frequently reported Grade 3-4 drug-related AEs were fatigue (2.1%) and anaemia (1.3%).

Among 236 nivolumab monotherapy-treated subjects, 2 deaths (pneumonitis and hypercalcaemia) in the nivolumab group were assessed as study-drug associated by the investigator and one death attributed to study drug toxicity (pneumonia) in the investigator's choice group. Pneumonitis is a known adverse event associated with nivolumab treatment. Serious complications due to hypercalcemia have not been associated with nivolumab treatment and are most likely a consequence of tumour progression.

<div style=\"page-break-after: always\"></div>

The overall frequencies of all-causality SAEs (any grade) were similar between the treatment groups. In the nivolumab group, the most frequently reported SAEs were malignant neoplasm progression (19.5%), pneumonia (4.7%), dyspnoea (3.8%), and pneumonia aspiration (3.4%).

Drug-related SAEs were reported in 7.2% of subjects in the nivolumab group and 15.3% of subjects in the investigator's choice group. In the nivolumab group, the only drug-related SAE reported in at least 2 subjects was pneumonitis; 2 (0.8%) subjects.

Grade 3-4 drug-related SAEs were reported in 5.5% and 10.8% of subjects in the nivolumab and investigator's choice groups, respectively.

The frequencies of all types of AEs of special interest (endocrine, gastrointestinal, hepatic, pulmonary, renal, and dermatological events) showed that both all-causality and drug-related AEs of any grade were similar in patients treated with nivolumab and in patients treated with investigator's choice. The majority of select AEs reported were Grade 1-2, and most were considered drug-related by the investigator. The most frequently reported any-grade drug-related select AE categories with nivolumab treatment were skin (16.9%), endocrine (9.3%) and gastrointestinal (8.5%). Across select AE categories, the majority of events were manageable, with resolution occurring when immune-modulating medications (mostly systemic corticosteroids) were administered.  All-causality and drug-related AEs of special interest of grade ≥3 were low in frequency and occurred at similar frequencies in both treatment arms. The frequencies of select AEs are consistent with the existing safety data obtained in melanoma, NSCLC, and RCC.

As of the 20 September 2016 database lock, a lower proportion of treated subjects in the nivolumab group had died (183 subjects [77.5%]) compared with the investigator's choice group (96 subjects [86.5%]). Disease progression was the most common cause of death for both groups, including deaths occurring within 30 days of last dose and deaths occurring within 100 days of last dose.

Two (0.8 %) deaths in the nivolumab group and one death in the investigator's choice group were attributed to study drug toxicity by the investigator

In CA209141 (18 December 2015 database lock), the frequencies of all-causality and drug-related AEs in the nivolumab group for subgroups of gender, race, age, and region were similar to the AE frequencies in the overall  treated  population.  Observed  small  numerical  differences  in  frequencies  of  AEs  are  of  limited interpretability  due  to  low  sample  sizes  and  event  rates,  and  do  not  alter  the  overall  safety  profile  of nivolumab in these subgroups.

Interpretation of safety in the elderly is limited by the small number of subjects in the 75 to 84 years of age subgroup (n=12) and the fact that there were no treated subjects ≥ 85 years of age. However, in the already approved indications for nivolumab, there were no indications of worse (or better) safety in the elderly compared to younger patients. The data in patients with SCCHN &gt; 75 years of age has been included as missing information in the RMP.

Abnormalities in haematology laboratory results, liver tests, kidney function tests, and electrolytes in nivolumab subjects were primarily Grade 1 or 2.

The overall frequency of all-causality AEs leading to discontinuation were similar between the treatment groups; however, the frequencies of drug-related AEs leading to discontinuation were lower in the nivolumab group than in the investigator's choice group.

In CA209141, the incidence of nivolumab ADA was low and did not appear to have an effect on the safety of nivolumab. The results regarding immunogenicity are in line with the results obtained in previously authorised indications.

No clear association was established between the presence of ADA and hypersensitivity or infusion reactions, suggesting nivolumab ADA does not alter the safety profile of nivolumab. Overall, immunogenicity is not

<div style=\"page-break-after: always\"></div>

clinically meaningful based on low ADA titers, low persistent positive rates, low incidence of neutralising antibodies, minimal impact on nivolumab CL, and no evidence of an altered safety profile.

No meaningful differences in the safety profile were observed based on PD-L1 expression levels as compared to the overall study population, and the safety profile with nivolumab was favourable across PD-L1 expression levels as compared with investigator's choice therapy (data not shown).

## 2.5.2. Conclusions on clinical safety

In study CA209141, the safety profile of nivolumab compared favourably with that of investigator's choice in terms of the frequency of all-grade and severe (grade ≥ 3) drug-related AEs.

The observed safety profile of nivolumab is consistent with the safety profile of nivolumab monotherapy previously observed in other tumour types, and no new safety concerns were identified in study CA209141. No new risks in addition to those identified in previous studies in other indications were identified.

Clinically significant select AEs were manageable using treatment algorithms that recommend nivolumab dose delay or discontinuation and introduction of immune-modulating therapy or other targeted medical intervention (eg, hormone replacement therapy for endocrine events).

## 2.5.3. PSUR cycle

The PSUR cycle remains unchanged.

The next data lock point will be 3/07/2017.

The annex II related to the PSUR, refers to the EURD list which remains unchanged.

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 6.3 is acceptable.

The CHMP endorsed the Risk Management Plan version 6.3 with the following content:

<div style=\"page-break-after: always\"></div>

## Safety concerns

## Table 56

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                   |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-related pneumonitis Immune-related colitis Immune-related hepatitis Immune-related nephritis and renal dysfunction Immune-related endocrinopathies Immune-related skin ARs Other immune-related adverse reactions (ARs) Severe infusion reactions                                                                                     |
| Important potential risks    | Embryofetal toxicity Immunogenicity Cardiac arrhythmias (previously treated melanoma indication, only) Complications of allogeneic HSCT following nivolumab therapy                                                                                                                                                                          |
| Missing information          | Pediatric patients <18 years of age Elderly patients with: - cHL ≥ 65 years of age - SCCHN ≥ 75 years of age Patients with severe hepatic and/or renal impairment Patients with autoimmune disease Patients already receiving systemic immunosuppressants before starting nivolumab Use in patients who have undergone influenza vaccination |

Due to the limited data in SCCHN patients over 75 years of age, the summary of safety concerns for nivolumab has been updated to include 'Elderly patients with SCCHN ≥ 75 years of age' as missing information.

## Pharmacovigilance plan

## Table 57 Ongoing and planned studies in the PhV development plan

| Activity/Study title (type of activity, study title [if known] category 1-3)                   | Objectives                                                               | Safety concerns addressed                                                        | Status Planned, started   | Date for submission of interim or final reports (planned or actual)   |
|------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------|-----------------------------------------------------------------------|
| CA209835: A registry study in patients who underwent post-nivolumab allogeneic HSCT Category 3 | To assess transplant-related complications following prior nivolumab use | Postmarketing safety assessment of the outcome of post-nivolumab allogeneic HSCT | Planned                   | Final CSR submission: 4Q2022                                          |

<div style=\"page-break-after: always\"></div>

| Activity/Study title (type of activity, study title [if known] category 1-3)                              | Objectives                                                                                                                                                                                     | Safety concerns addressed                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Status Planned, started   | Date for submission of interim or final reports (planned or actual)   |
|-----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|-----------------------------------------------------------------------|
| CA209234: Pattern of Use, Safety, and Effectiveness of Nivolumab in Routine Oncology Practice. Category 3 | To assess use pattern, effectiveness, and safety of nivolumab, and management of important identified risks of nivolumab in patients with lung cancer or melanoma in routine oncology practice | Postmarketing use safety profile, management and outcome of immune-related pneumonitis, colitis, hepatitis, nephritis or renal dysfunction, endocrinopathies, rash, and other immune-related adverse reactions (uveitis, pancreatitis, demyelination, Guillain-Barre syndrome, and myasthenic syndrome, and encephalitis), and infusion reactions Guillain-Barre syndrome, myasthenic syndrome, encephalitis, myositis, myocarditis, and rhabdomyolysis, and encephalitis), and infusion reactions | Started                   | Final CSR submission: 4Q2024 (interim report annually)                |

The PRAC Rapporteur, having considered the updated data submitted, was of the opinion that the proposed post-authorisation PhV development plan remains sufficient to identify and characterise the risks of the product.

The PRAC Rapporteur also considered that routine PhV remains sufficient to monitor the effectiveness of the risk minimisation measures.

## Risk minimisation measures

Table 58 Summary table of Risk Minimisation Measures

| Safety concern                                                                                                            | Routine risk minimisation measures                                                                                                                                       | Additional risk minimisation measures                                                                                                                        |
|---------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks                                                                                                |                                                                                                                                                                          |                                                                                                                                                              |
| Immune-related pneumonitis Immune-related colitis Immune-related hepatitis Immune-related nephritis and renal dysfunction | The SmPC warns the risks of immune-related pneumonitis, immune-related colitis, immune-related hepatitis, immune-related nephritis and renal dysfunction, immune-related | To further raise awareness of HCPs on important risks and their appropriate management, additional risk minimization activity includes a Communication Plan. |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                   | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Additional risk minimisation measures                                                                                                             |
|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-related endocrinopathies Immune-related skin ARs Other immune-related ARs | endocrinopathies, immune-related rash, and other immune-related adverse reactions in Section 4.4 (Special warnings and precautions for use), and provides specific guidance on their monitoring and management, including treatment delay or discontinuation and intervention with corticosteroids in Sections 4.2, 4.4 and 4.8, as appropriate. Further ADRs are included in Section 4.8. In addition, the package leaflet also includes specific warnings and descriptions of the most important safety information in the language suitable for patients. | The Plan comprising 2 tools to be distributed to potential prescribers at launch by BMS: • Adverse Reaction Management Guide • Patient Alert Card |
| Severe infusion reactions                                                        | The SmPC warns the risk of severe infusion reactions in Section 4.4 and ADR in Section 4.8.                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | None                                                                                                                                              |
| Important Potential Risks                                                        | Important Potential Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Important Potential Risks                                                                                                                         |
| Embryofetal Toxicity                                                             | SmPC includes Embryofetal Toxicity in Section 4.6 Fertility, pregnancy and lactation, Section 5.3 Preclinical safety data The package leaflet also includes specific description on the safety information in the language suitable for patients.                                                                                                                                                                                                                                                                                                            | None                                                                                                                                              |
| Immunogenicity                                                                   | SmPC Section 4.8 Immunogenicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | None                                                                                                                                              |
| Cardiac arrhythmias (previously treated melanoma indication, only)               | SmPC Section 4.8 Undesirable effects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | None                                                                                                                                              |
| Complications of allogeneic HSCT following nivolumab therapy                     | SmPC Section 4.4 recommends case by case considerations, and close monitoring of patients undergoing allogeneic HSCT for hyperacute GVHD, Grade 3-4 acute GVHD, steroid requiring febrile syndrome, hepatic veno-occlusive disease, and other transplant related complications. Related information is found in SmPC Section 4.8 Undesirable effects.                                                                                                                                                                                                        | Adverse Reaction Management Guide                                                                                                                 |
| Missing Information                                                              | Missing Information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Missing Information                                                                                                                               |
| Pediatric patients                                                               | SmPC Section 4.2 Posology and method of administration, subsection on Pediatric population                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | None                                                                                                                                              |
| Elderly patients with: - cHL ≥ 65 years of age - SCCHN ≥ 75 years of age         | SmPC Sections 4. 2 Posology and method of administration, 4 .8 Undesirable effects, and 5.1 Pharmacodynamic properties                                                                                                                                                                                                                                                                                                                                                                                                                                       | None                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                   | Routine risk minimisation measures                                                                                                                                          | Additional risk minimisation measures   |
|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Severe hepatic and/or renal impairment                                           | SmPC Section 4.2 Posology and method of administration: Patients with hepatic or renal impairment; SmPC Section 5.2 Pharmacokinetic properties: Hepatic or renal impairment | None                                    |
| Patients with autoimmune disease                                                 | SmPC Section 4.4 provides warning and cautionary information for patients with a history of autoimmune disease                                                              | None                                    |
| Patients already receiving systemic immunosuppressants before starting nivolumab | SmPC Sections 4.4 Special populations and 4.5 Systemic Immunosuppressants                                                                                                   | None                                    |
| Use in patients who have undergone influenza vaccination                         | Safety monitoring and signal detection                                                                                                                                      | None                                    |

The PRAC Rapporteur, having considered the updated data submitted, was of the opinion that the proposed risk minimisation measures are sufficient to minimise the risks of the product in the proposed indication(s).

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated. Particularly, a new warning to recommend careful consideration before initiating treatment with nivolumab in patients excluded from the SCCHN clinical trial (patients with a baseline performance score ≥ 2, untreated brain metastasis, active autoimmune disease, medical conditions requiring systemic immunosuppression, or carcinoma of the nasopharynx or salivary gland as the primary tumour sites) has been added to the product information. In addition, physicians are also recommended to consider the delayed onset of nivolumab effect before initiating treatment in patients with poorer prognostic features and/or aggressive disease. In head and neck cancer, a higher number of deaths within 3 months was observed in nivolumab compared to docetaxel. Factors associated with early deaths were ECOG performance status, fast progressive disease on prior platinum therapy and high tumour burden.

The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the applicant and has been found acceptable as the changes introduced in the PL as part of this variation application do not have a relevant impact on the readability of the PL.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The present application is to extend the indication of nivolumab (Opdivo) in the treatment of recurrent or metastatic squamous cell cancer of the head and neck after platinum-based therapy.

<div style=\"page-break-after: always\"></div>

In SCCHN, approximately 50% of the population initially treated with curative intent will either have refractory disease or will eventually develop recurrent disease. For these patients, the 1-year survival rate is 5-33% by various estimates with a median OS (mOS) of 6 to 9 months. Patients whose disease progresses within 6 months of platinum-based therapy (for locally advanced or metastatic disease), have a poor prognosis.

## 3.1.2. Available therapies and unmet medical need

In this patient population, no OS benefit has ever been demonstrated, and thus the choice of chemotherapy is not well defined. Treatment choice is based on several factors including previous chemotherapy exposure, performance status, and comorbid conditions. In the US and the EU, recommendations include best supportive care, clinical trials, and single agents including paclitaxel, docetaxel, 5-FU, methotrexate, cetuximab, ifosfamide, bleomycin, gemcitabine, capecitabine, and vinorelbine.

## 3.1.3. Main clinical studies

The results of an open label, randomized phase 3 clinical trial of nivolumab vs therapy of investigator's choice in the recurrent or metastatic platinum-refractory SCCHN have been submitted.

## 3.2. Favourable effects

Based on a pre-specified interim analysis, with 55.4% of events in the experimental arm, nivolumab showed a gain in median OS of almost 2.5 months (HR = 0.70 [97.73% CI: 0.51, 0.96]; stratified log-rank test p-value = 0.0101).

The magnitude of the difference in survival is around 15% between groups (OS rates at 6, 9 and 12 months). Results from the two sensitivity analyses carried out (unstratified analysis and analysis based on subjects with no relevant deviations) are consistent with the main one. Furthermore, a multivariate analysis adjusted for HPV-p16 status, baseline ECOG PS, and prior chemotherapy for metastatic disease, showed similar result. When the results are analysed by individual investigator's choice therapy subgroups, the evidence for an advantage of nivolumab in terms of OS was clearer in the cetuximab (HR 0.54; 95% CI: 0.30, 0.98) and methotrexate (HR 0.60; 95% CI: 0.41, 0.86) subgroups compared to the docetaxel subgroup (HR=0.92; 95% CI: 0.66, 1.29).

In the updated analysis (20 September 2016 database lock) nivolumab continued to demonstrate statistically significant and clinically meaningful improvement in OS versus investigator's choice therapy (HR= 0.71 [95% CI: 0.55, 0.90]; stratified log-rank test p-value = 0.0048), with survival rates of 34.0% and 21.5% at 12 and 18 months, respectively.

ORR results offer better outcomes, with a significant difference in favour of nivolumab (13% vs 6% nivo and control respectively) but with only 6 complete responders. Median time to objective response was 2 months.

## 3.3. Uncertainty in the knowledge about the beneficial effects

When OS difference is analysed for the various comparators, the benefit vs docetaxel is not as clear as vs cetuximab and methotrexate. Focusing on docetaxel comparison, the same pattern of higher number of deaths soon after the start of treatment with nivolumab that has been previously noted in melanoma and lung cancer studies is observed again. There was a higher percentage of patients who died within the first 3 months in the nivolumab group vs docetaxel arm (28.3% vs 18.5% of the whole number of nivolumab and docetaxel treated patients respectively). The delay in the onset of action of nivolumab along with some prognostic factors appear the most plausible explanations. Similarly to NSCLC and melanoma, ECOG performance status, fast progressive disease and high tumour burden seem to be important factors to consider when starting a nivolumab treatment.

<div style=\"page-break-after: always\"></div>

The lack of positive results in PFS has been previously observed in other clinical developments with nivolumab (renal and non-squamous NSCLC), highlighting the discrepancy between PFS and OS. Despite some hypotheses discussed (pseudoprogression, a delay in the onset of effect, etc), there is no explanation to this phenomenon.

In the European patient population, neither OS (HR 0.91, 95%CI: 0.62, 1.33) nor ORR (10.1% vs 9.7%) showed a clear benefit for nivolumab and the control group seem to offer better results in terms of PFS (HR 1.27, 95%CI: 0.90, 1.78). Even though some imbalances in prognostic factors (time from prior platinum to progression, gender and HPV status) could partly explain this absence of benefit, no firm conclusions can be drawn. In a worst-case scenario, nivolumab would offer similar efficacy vs docetaxel, though with a priori better safety profile.

A lower activity of nivolumab vs investigator's choice therapy (ICT) has been observed in patients with low tumour PD-L1 expression (&lt;1%) compared to patients with higher tumour PD-L1 expression (≥1%).

Several exploratory, post-hoc analyses exploring the link between PD-L1 expression on tumour cells and tumour-associated immune cells (TAICs) and response to treatment with nivolumab in HNSCC showed greater benefit of nivolumab in the subgroup of patients with intratumoural PD-L1 expressing TAIC compared to ICT.

The subgroup of patients with low tumour cell PD-L1 expression (&lt;1%) without intratumoural PD-L1 expressing TAIC appears not to show greater benefit from nivolumab treatment compared to ICT. A less pronounced, but a similar pattern is observed in the subgroup of patients with tumour cell PD-L1 expression ≥1%, with the number and the localisation of the PD-L1 positive TAIC appearing to be associated with response to nivolumab. Investigated subgroups are small, and in combination with technical aspects (it was based on qualitative data collected using a non-validated assay) definitive conclusions cannot yet be drawn from this analysis. In order to further investigate the relationship between clinical outcomes to nivolumab and PD-L1 expression in immune cells and other biomarkers (PD-L2, mutational load), a biomarker investigation in SCCNH patients has been included as post authorisation measure (see Annex II).

In the updated analysis of efficacy by both baseline PD-L1 expression and p16 status, nivolumab treatment had numerically better efficacy than ICT in all subgroups, except for PD-L1&lt;1% and p16 unknown (HR 1.41 [CI95 0.72- 2.88]). Since the confidence interval encompasses 1 and it concerns a small sample size, no conclusion can be drawn on these data. With the addition of 6 p16-negative patients and the updated analyses, the HR for the PD-L1 &lt;1% and p16-negative patients decreased from 0.82 to 0.53, which is reassuring.

## 3.4. Unfavourable effects

The safety of nivolumab in SCCHN was consistent with the overall experience with nivolumab in other tumour types. No new safety concerns have been identified in patients with SCCHN compared to the other indications.

## 3.5. Uncertainty in the knowledge about the unfavourable effects

As of 20 September 2016 database lock, the number of subject who died within 30 days of last dose were higher in the nivolumab group (22.0%, 52/236 subjects) compared to the ICT group (18.9%, 21/111 subjects) and may be attributed to longer duration of study treatment in the nivolumab group compared to ICT.

Interpretation of safety in the elderly is limited by small numbers of subjects in the 75 to 84 years of age subgroup (n = 12) and the fact that there were no treated subjects ≥ 85 years of age (see missing

<div style=\"page-break-after: always\"></div>

information in the RMP). However, in other indications for which nivolumab has already been approved, there were no indications of worse (or better) safety in the elderly relative to younger patients.

Subjects with active, known or suspected autoimmune disease were excluded from the pivotal study and therefore the B/R is uncertain in this population. However, the current SmPC accurately reflects a warning regarding the potential risks associated with patients with active, known or suspected autoimmune disease.

Experience with nivolumab in SCCHN is, from a safety perspective, limited, and long-term safety is not well characterised. There is, however, a relatively large safety dataset of nivolumab monotherapy in other indications.

## 3.6. Effects Table

Table 59: Effects Table for nivolumab for the treatment of SCCHN  (data cut-off: 05-May-2016; tumour assessment; September 2016 safety/efficacy assessment)

| Effect                | Short Description                                                                            | Unit                 | Treatment            | Control              | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                                             | References           |
|-----------------------|----------------------------------------------------------------------------------------------|----------------------|----------------------|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Favourable Effects    | Favourable Effects                                                                           | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                                                                                                                                                                                                                                                                              | Favourable Effects   |
| OS                    | Time from randomization to the date of death from any cause                                  | Median (months)      | 7.72                 | 5.06                 | Lower benefit as compared to docetaxel. Higher number of deaths associated to nivo vs docetaxel in the first 3 months Uncertainty in European population Nivolumab does not show better PFS outcomes than comparators Uncertainty in European population Lower benefit as compared to docetaxel |                      |
| OS                    |                                                                                              | HR (95%CI)           | 0.71 (0.55-0.90)     | 0.71 (0.55-0.90)     | Lower benefit as compared to docetaxel. Higher number of deaths associated to nivo vs docetaxel in the first 3 months Uncertainty in European population Nivolumab does not show better PFS outcomes than comparators Uncertainty in European population Lower benefit as compared to docetaxel |                      |
| PFS                   | Time from randomization to first date of documented                                          | Median (months)      | 2.04                 | 2.33                 |                                                                                                                                                                                                                                                                                                 |                      |
| PFS                   | progression, or to death due to any cause.                                                   | HR (95% CI)          | 0.87 (0.69-1.11)     | 0.87 (0.69-1.11)     |                                                                                                                                                                                                                                                                                                 |                      |
| ORR                   | %of randomized subjects who achieved a best response of CR or PR (RECIST v1.1 investigator). | %                    | 13.3                 | 5.8                  | Uncertainty in European population                                                                                                                                                                                                                                                              |                      |
| Unfavourable Effects  | Unfavourable Effects                                                                         | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                                                                                                                                                                                                                            | Unfavourable Effects |
| All Grade 3/4 AEs     | Drug-related AEs                                                                             | %                    | 15.3                 | 36.0                 | No new safety concerns with nivolumab monotherapy treatment were identified in SCCHN                                                                                                                                                                                                            |                      |
| SAEs                  | Drug-related SAEs                                                                            | %                    | 7.2                  | 15.3                 | No new safety concerns with nivolumab monotherapy treatment were identified in SCCHN                                                                                                                                                                                                            |                      |
| Fatigue               | Most frequent drug-related AE                                                                | %                    | 15.7                 | 18.0                 | No new safety concerns with nivolumab monotherapy treatment were identified in SCCHN                                                                                                                                                                                                            |                      |
| Nausea                | Most frequent drug-related AE                                                                | %                    | 9.3                  | 20.7                 | No new safety concerns with nivolumab monotherapy treatment were identified in SCCHN                                                                                                                                                                                                            |                      |
| Anaemia               | Most frequent drug-related AE                                                                | %                    | 5.1                  | 17.1                 | No new safety concerns with nivolumab monotherapy treatment were identified in SCCHN                                                                                                                                                                                                            |                      |
| Asthenia              | Most frequent drug-related AE                                                                | %                    | 4.2                  | 15.3                 | No new safety concerns with nivolumab monotherapy treatment were identified in SCCHN                                                                                                                                                                                                            |                      |
| Mucosal inflammati on | Most frequent drug-related AE                                                                | %                    | 1.7                  | 13.5                 | No new safety concerns with nivolumab monotherapy treatment were identified in SCCHN                                                                                                                                                                                                            |                      |

<div style=\"page-break-after: always\"></div>

Abbreviations: AEs (adverse events), AR (assessment report), CR (complete response), HR (hazard ratio), PFS (progression free survival), ORR (objective response rate), OS (overall survival), PR (partial response), SCCHN (squamous cell carcinoma of the head and neck).

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The benefit in survival is considered clinically meaningful. Despite the a priori modest result in the absolute gain in terms of median OS (2.5 months), it is deemed relevant since no other therapies in the platinum refractory setting have been able to achieve such improvement.

The uncertainties related to some subgroup analysed (PD-L1&lt;1% and European population) were further explored. In the European population, where no benefit has been demonstrated, the better safety profile favours a positive B/R profile.

Further analyses have explored the relationship between PD-L1 expression in the tumour/tumour microenvironment and efficacy of nivolumab in HNSCC. While certain patient subgroups benefit less from nivolumab than others, it cannot be concluded at present that certain patient subgroups could benefit significantly less from nivolumab than from ICT. When considered in the context of a more favourable safety profile of nivolumab compared to ICT, it is concluded that the B/R is positive for the overall population.

From a safety point of view, the toxicity and tolerability of nivolumab was consistent with previously submitted pooled data of nivolumab monotherapy in melanoma, NSCLC and RCC. No new safety concerns with nivolumab monotherapy treatment were identified in SCCHN. The safety profile of nivolumab compared favourably with that of ICT in terms of the frequency of all-grade and grade ≥3 drug-related AEs. The safety profile of nivolumab was in line with that of previously authorised indications. Furthermore, comparative safety data from CA209141 demonstrate that nivolumab monotherapy has an acceptable safety profile compared to ICT group, as evidenced by the rates of drug-related AEs and drug-related AEs leading to discontinuation.

## 3.7.2. Balance of benefits and risks

The efficacy of nivolumab in the overall studied population seems undisputable. The longer survival obtained with this treatment when compared to different alternatives is clinically meaningful. The increase in life expectancy overcomes the risks associated to nivolumab, which are considered tolerable and manageable, with an overall apparently better safety profile than alternatives.

## 3.7.3. Additional considerations on the benefit-risk balance

The CHMP considers the following measures necessary to address issues related to efficacy:

The MAH should further investigate in study CA209141, the association between improved clinical outcomes to nivolumab and the presence of:

- -Higher mutational load, and as feasible, PD L1 tumour associated immune cell (TAIC) expression (30 September 2017)
- -PD-L2 expression (31 March 2018)
- -High inflamed phenotype (30 September 2018)

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of Indication to include treatment of squamous cell cancer of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy for OPDIVO as monotherapy.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, of the SmPC are updated in order to add the proposed new indication, add a warning to recommend careful consideration before initiating treatment with nivolumab in patients excluded from the SCCHN clinical trial (patients with a baseline performance score ≥ 2, untreated brain metastasis, active autoimmune disease, medical conditions requiring systemic immunosuppression, or carcinoma of the nasopharynx or salivary gland as the primary tumour sites) and update the undesirable effect and safety information. Package leaflet is updated in accordance. Moreover, the updated RMP version 6.3 has been submitted, and agreed during procedure.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

This CHMP recommendation is subject to the following new condition:

## · Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

| Description                                                                                                                                                                                                                                                                 | Due date                                                      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|
| 6. To further investigate, in CA209141, the association between improved clinical outcomes to nivolumab and the presence of: - Higher mutational load, and as feasible, PD L1 tumour associated immune cell (TAIC) expression - PD-L2 expression - High inflamed phenotype. | - 30th September 2017 - 31st March 2018 - 30th September 2018 |

These conditions do fully reflect the advice received from the PRAC.